High-throughput single-cell transcriptome libraries and methods of making and using the same

Abstract

To provide: methods for preparing a sequencing library that includes nucleic acids from a plurality of single nuclei or single cells; and methods for identifying cell state transition dynamics by labeling newly synthesized RNA.SOLUTION: A sequencing library is prepared which includes nucleic acids from a plurality of single cells. In one embodiment, the sequencing library includes nucleic acids that represent all transcriptomes from the plurality of single cells. In one embodiment, the nucleic acids include three index sequences. Also provided herein are compositions, such as compositions that include the nucleic acids having three index sequences.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 680,259, filed June 4, 2018, and U.S. Provisional Application No. 62 / 821,678, filed March 21, 2019, each of which is incorporated herein by reference.

[0002] Government funding This invention was made with Government support under Grant No. DP1 HG007811 awarded by the National Institutes of Health. The Government has certain rights in the invention.

[0003] Technical Field Aspects of the present disclosure relate to nucleic acid sequencing. In particular, aspects of the methods and compositions provided herein relate to producing indexed single-cell transcriptome libraries and obtaining sequence data therefrom. [Background technology]

[0004] Cells undergo transitions between distinct functional and molecular states during various processes, such as during the development of multicellular organisms, and in response to various conditions, such as exposure to therapeutic agents. Characterizing the pathways of cell state transitions or cell fates is useful in understanding pathways involving cellular development and molecular responses to changes in the environment. For example, regulators of developmental abnormalities can be identified, and we can better understand how therapeutic agents affect cells.

[0005] Single-cell combinatorial indexing ("sci-") is a methodological framework that uses split-pool barcoding to uniquely label the nucleic acid content of large numbers of single cells or nuclei. However, current single-cell genomic techniques lack the throughput and resolution to obtain a complete picture of the molecular state and trajectory of the rapidly diversifying and expanding number of cell types typically present during the development of multicellular organisms. Current single-cell genomic techniques capture only a snapshot of the state of the cell and therefore cannot provide information on cell transition dynamics that are regulated by intrinsic factors (e.g., the cell's intrinsic cell cycle program) and extrinsic factors (e.g., the cell's response to external stimuli such as therapeutic agents). Summary of the Invention

[0006] Herein, we provide a method to identify cell state transition dynamics by labeling newly synthesized RNA. Both the total transcriptome and newly synthesized RNA transcriptome are captured, allowing characterization of transcriptome dynamics between several time points at the single cell level. Herein, we also provide a method to focus single cell sequencing on the mRNA of interest, thereby dealing with limited power to detect changes in abundance of any given transcript. Furthermore, we provide a method to overcome the rate of cell loss and limited reaction efficiency, resulting in profiling a larger number of single cells than previously possible.

[0007] In one embodiment, a method includes providing a plurality of nuclei or cells to a first plurality of compartments, each compartment containing a subset of nuclei or cells, and labeling the newly synthesized RNA in the subset of cells or a subset of nuclei obtained from the cells. The RNA molecules of each subset of nuclei or cells are processed to generate indexed nuclei or cells, in which the RNA nucleic acids present in each subset of nuclei or cells are added with index sequences unique to the first compartment to obtain indexed DNA nucleic acids present in the indexed nuclei or cells, and then the indexed nuclei or cells are combined to generate pooled indexed nuclei or cells.

[0008] In another embodiment, a method includes providing a plurality of nuclei or cells in a first plurality of compartments, each compartment comprising a subset of nuclei or cells. Each subset is contacted with a reverse transcriptase and a primer annealing to a predetermined RNA nucleic acid to obtain a double-stranded DNA nucleic acid having a corresponding DNA nucleotide sequence of the primer and the template RNA nucleic acid. The DNA molecules of each subset of nuclei or cells are processed to produce indexed nuclei or cells, in which the DNA nucleic acid present in each subset of nuclei or cells is added with an index sequence unique to the first compartment to obtain indexed DNA nucleic acid present in the indexed nuclei or cells, and then the indexed nuclei or cells are combined to produce pooled indexed nuclei or cells.

[0009] In another embodiment, a method includes providing a plurality of nuclei or cells in a first plurality of compartments, each compartment comprising a subset of nuclei or cells. Each subset is contacted with a reverse transcriptase and a primer annealing to a given RNA nucleic acid to obtain a double-stranded DNA nucleic acid having a corresponding DNA nucleotide sequence of the primer and the template RNA nucleic acid. The DNA molecules of each subset of nuclei or cells are processed to produce indexed nuclei or cells, in which the DNA nucleic acid present in each subset of nuclei or cells is added with an index sequence unique to the first compartment to obtain indexed DNA nucleic acid present in the indexed nuclei or cells, and the indexed nuclei or cells are then combined to produce pooled indexed nuclei or cells. The pooled indexed nuclei or cells are split, then further processed to add an index unique to the second compartment to the DNA molecule, combined, split, and further processed to add an index unique to the third compartment to the DNA molecule.

[0010] definition Terms used herein shall be understood to take their ordinary meaning in the relevant art unless otherwise specified. Some terms used herein and their meanings are set forth below.

[0011] As used herein, the terms "organism" and "subject" are used interchangeably and refer to microorganisms (e.g., prokaryotes or eukaryotes), animals, and plants. One example of an animal is a mammal, such as a human.

[0012] As used herein, the term "cell type" is intended to distinguish cells based on morphology, phenotype, developmental origin, or other known or recognizable distinguishing cellular characteristics. A variety of different cell types can be obtained from a single organism (or from organisms of the same species). Exemplary cell types include gametes (including female gametes, such as eggs or egg cells, and male gametes, such as sperm), ovarian epithelium, ovarian fibroblasts, testis, bladder, immune cells, B cells, T cells, natural killer cells, dendritic cells, cancer cells, eukaryotic cells, stem cells, blood cells, muscle cells, adipocytes, skin cells, nerve cells, bone cells, pancreatic cells, endothelial cells, pancreatic epithelium, pancreatic alpha, pancreatic beta, pancreatic endothelium, bone marrow lymphoblasts, bone marrow B lymphoblasts, bone marrow macrophages, bone marrow erythroblasts, bone marrow dendrites, bone marrow adipocytes, bone marrow osteocytes, bone marrow chondrocytes, promyeloblasts, bone marrow megakaryoblasts, bladder, brain B lymphocytes, brain glia, neurons, brain astrocytes, neuroectoderm, brain macrophages, brain microglia, brain epithelium, cortical neurons, brain fibroblasts, breast Epithelium, colonic epithelium, colonic B lymphocyte, mammary epithelium, mammary myoepithelium, mammary fibroblast, colonic enterocyte, cervical epithelium, mammary ductal epithelium, tongue epithelium, tonsillar dendrite, tonsillar B lymphocyte, peripheral blood lymphoblast, peripheral blood T lymphoblast, peripheral blood skin T lymphocyte, peripheral blood natural killer, peripheral blood B lymphoblast, peripheral blood monocyte, peripheral blood myeloblast, peripheral blood monoblast, peripheral blood promyeloblast, peripheral blood macro These include, but are not limited to, phage, peripheral blood basophils, liver endothelium, liver mast, liver epithelium, liver B lymphocytes, splenic endothelium, splenic epithelium, splenic B lymphocytes, liver hepatocytes, liver, fibroblasts, lung epithelium, bronchial epithelium, lung fibroblasts, lung B lymphocytes, lung Schwann, lung squamous epithelium, lung macrophages, lung osteoblasts, neuroendocrine, lung alveolar, gastric epithelium, and gastric fibroblasts.

[0013] As used herein, the term "tissue" is intended to mean a collection or aggregate of cells that act together to perform one or more specific functions in an organism. The cells can be of similar morphology in some cases. Exemplary tissues include, but are not limited to, embryo, epididymis, eye, muscle, skin, tendon, vein, artery, blood, heart, spleen, lymph node, bone, bone marrow, lung, bronchus, trachea, digestive tract, small intestine, large intestine, colon, rectum, salivary gland, tongue, gallbladder, appendix, liver, pancreas, brain, stomach, skin, kidney, ureter, bladder, urethra, gonads, testes, ovaries, uterus, fallopian tubes, thymus, pituitary gland, thyroid gland, adrenal gland, or parathyroid gland. The tissue can be derived from any of a variety of organs of a human or other organism. The tissue can be healthy or diseased tissue. Examples of pathological tissues include, but are not limited to, malignant tumors in reproductive tissues, lung, breast, colorectum, prostate, nasopharynx, stomach, testes, skin, nervous system, bone, ovaries, liver, blood tissue, pancreas, uterus, kidney, lymphatic tissue, etc. Malignant tumors can be of various histological subtypes, e.g., carcinoma, adenocarcinoma, sarcoma, fibroadenocarcinoma, neuroendocrine, or undifferentiated.

[0014] As used herein, the term "compartment" is intended to mean an area or volume that separates or isolates something from another. Exemplary compartments include, but are not limited to, vials, tubes, wells, droplets, boluses, beads, containers, surface features, or areas or volumes separated by physical forces such as fluid flow, magnetism, electric current, etc. In one embodiment, the compartment is a well of a multi-well plate, such as a 96-well plate or a 384-well plate. As used herein, a droplet may include hydrogel beads, which are beads for encapsulating one or more nuclei or cells, and includes a hydrogel composition. In some embodiments, the droplet is a uniform droplet of hydrogel material or a hollow droplet with a polymer hydrogel shell. Whether uniform or hollow, the droplet can encapsulate one or more nuclei or cells. In some embodiments, the droplet is a surfactant-stabilized droplet.

[0015] As used herein, a "transposome complex" refers to a nucleic acid that includes an integrase and an integration recognition site. A "transposome complex" is a functional complex formed by a transposase and a transposase recognition site that can catalyze a transposition reaction (see, for example, Gunderson et al., International Publication No. WO 2016 / 130704). Examples of integrases include, but are not limited to, integrases and transposases. Examples of integration recognition sites include, but are not limited to, transposase recognition sites.

[0016] As used herein, the term "nucleic acid" shall be consistent with its use in the art and includes naturally occurring nucleic acids or functional analogs thereof. Particularly useful functional analogs can hybridize to nucleic acids in a sequence-specific manner or can be used as templates for replicating a particular nucleotide sequence. Naturally occurring nucleic acids generally have a backbone that includes phosphodiester bonds. Analog structures can have alternative backbone bonds, including any of a variety known in the art. Naturally occurring nucleic acids generally have a deoxyribose sugar (e.g., found in deoxyribonucleic acid (DNA)) or a ribose sugar (e.g., found in ribonucleic acid (RNA)). Nucleic acids can include any of a variety of analogs of these sugar moieties known in the art. Nucleic acids can include natural or non-natural bases. In this regard, natural deoxyribonucleic acids can have one or more bases selected from the group consisting of adenine, thymine, cytosine, or guanine, and ribonucleic acids can have one or more bases selected from the group consisting of adenine, uracil, cytosine, or guanine. Useful non-natural bases that can be included in nucleic acids are known in the art. Examples of non-natural bases include locked nucleic acid (LNA), bridged nucleic acid (BNA), and pseudo-complementary bases (Trilink Biotechnologies, San Diego, CA). LNA and BNA bases can be incorporated into DNA oligonucleotides to increase the strength and specificity of oligonucleotide hybridization. LNA and BNA bases and the use of such bases are known and routine to those skilled in the art. Unless otherwise specified, the term "nucleic acid" includes natural and non-natural mRNA, non-coding RNA, such as RNA that does not contain polyA at the 3' end, nucleic acid derived from RNA, such as cDNA, and DNA.

[0017] As used herein, the term "target", when used in reference to a nucleic acid, shall have its meaning as a semantic identifier for the nucleic acid in the context of the methods or compositions described herein and shall not necessarily limit the structure or function of the nucleic acid beyond that otherwise specified. A target nucleic acid may be essentially any nucleic acid of known or unknown sequence. A target nucleic acid may be, for example, a fragment of genomic DNA (e.g., chromosomal DNA), extrachromosomal DNA such as a plasmid, cell-free DNA, RNA (e.g., RNA or non-coding RNA), a protein (e.g., a cellular or cell surface protein), or a cDNA. Sequencing may lead to the determination of the sequence of all or part of the target molecule. Targets may be derived from a primary nucleic acid sample, such as a nucleus. In one embodiment, targets may be processed into a template suitable for amplification by placing a universal sequence at one or both ends of each target fragment. Targets may also be derived from a primary RNA sample by reverse transcription into cDNA. In one embodiment, target is used in reference to a subset of DNA, RNA, or proteins present in a cell. Targeted sequencing typically uses the selection and isolation of genes or regions or proteins of interest, either by PCR amplification (e.g., region-specific primers) or hybridization-based capture methods or antibodies. Targeted enrichment can be performed at various stages of the method. For example, targeted RNAs can be displayed using target-specific primers at the reverse transcription stage or hybridization-based enrichment of subsets from more complex libraries. One example is exome sequencing or the L1000 assay (Subramanian et al., 2017, Cell, 171;1437-1452). Targeted sequencing can include any of the enrichment methods known to those skilled in the art.

[0018] The term "universal" as used herein, when used to describe a nucleotide sequence, refers to a region of sequence common to two or more nucleic acid molecules, where the molecules also have regions of sequence that differ from each other. A universal sequence present in different members of a collection of molecules can allow the capture of multiple different nucleic acids using a population of universal capture nucleic acids, such as a capture oligonucleotide that is complementary to a portion of the universal sequence, such as a universal capture sequence. Non-limiting examples of universal capture sequences include sequences that are identical to or complementary to a P5 primer and a P7 primer. Similarly, a universal sequence present in different members of a collection of molecules can allow the replication (e.g., sequencing) or amplification of multiple different nucleic acids using a population of universal primers that are complementary to a portion of the universal sequence, such as a universal anchor sequence. In one embodiment, the universal anchor sequence is used as a site to which the universal primer (e.g., sequencing primer for read 1 or read 2) anneals for sequencing. Thus, the capture oligonucleotide or universal primer comprises a sequence that can specifically hybridize to the universal sequence.

[0019] The terms "P5" and "P7" may be used to refer to a universal capture sequence or capture oligonucleotide. The terms "P5'" (P5 prime) and "P7'" (P7 prime) refer to the complement of P5 and P7, respectively. It will be understood that any suitable universal capture sequence or capture oligonucleotide can be used in the methods presented herein, and the use of P5 and P7 is merely an exemplary embodiment. The use of capture oligonucleotides such as P5 and P7 or their complements on a flow cell is known in the art, as exemplified by the disclosures of WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO 1998 / 044151 and WO 2000 / 018957. For example, suitable forward amplification primers can be used in the methods presented herein for hybridizing to complementary sequences and amplifying sequences, whether immobilized or dissolved.Similarly, suitable reverse amplification primers can be used in the methods presented herein for hybridizing to complementary sequences and amplifying sequences, whether immobilized or dissolved.Those skilled in the art should be able to understand how to design and use suitable primer sequences for capturing and / or amplifying nucleic acid as presented herein.

[0020] As used herein, the term "primer" and its derivatives generally encompass any nucleic acid that can hybridize to a target sequence of interest. Typically, a primer serves as a substrate onto which nucleotides can be polymerized by a polymerase or onto which a nucleotide sequence, such as an index, can be ligated; however, in some embodiments, a primer can be incorporated into a synthesized nucleic acid strand to provide a site to which another primer can hybridize to prime the synthesis of a new strand complementary to the synthesized nucleic acid molecule. A primer can comprise any combination of nucleotides or their analogs. In some embodiments, a primer is a single-stranded oligonucleotide or polynucleotide. The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein and refer to polymeric forms of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. These terms should be understood to encompass, as equivalents, any analog of DNA, RNA, cDNA, or antibody-oligoconjugates made from nucleotide analogs, and are applicable to single-stranded (such as sense or antisense) polynucleotides and double-stranded polynucleotides. The term used herein also includes cDNA, which is the complementary DNA or copy DNA produced from an RNA template, for example, by the action of reverse transcriptase.The term refers only to the primary structure of the molecule.Thus, the term includes triple-stranded, double-stranded and single-stranded deoxyribonucleic acid ("DNA"), as well as triple-stranded, double-stranded and single-stranded ribonucleic acid ("RNA").

[0021] As used herein, the term "adapter" and its derivatives, such as universal adaptor, generally refers to any linear oligonucleotide that can be attached to a nucleic acid molecule of the present disclosure. In some embodiments, the adaptor is substantially non-complementary to the 3' or 5' end of any target sequence present in a sample. In some embodiments, suitable adaptor lengths range from about 10-100 nucleotides, about 12-60 nucleotides, or about 15-50 nucleotides in length. In general, an adaptor can include any combination of nucleotides and / or nucleic acids. In some embodiments, an adaptor can include one or more cleavable groups at one or more locations. In other embodiments, an adaptor can include a sequence that is substantially identical or substantially complementary to at least a portion of a primer, such as a universal primer. In some embodiments, an adaptor can include a barcode (also referred to herein as a tag or index) to aid in downstream error correction, identification, or sequencing. The terms "adaptor" and "adapter" are used interchangeably.

[0022] As used herein, the term "each," when used in reference to a group of items, is intended to identify each individual item in the group, but does not necessarily refer to every item in the group, unless the context clearly dictates otherwise.

[0023] As used herein, the term "transport" refers to the movement of molecules through a fluid. The term can include passive transport, such as the movement of molecules along a concentration gradient (such as passive diffusion). The term can also include active transport, in which molecules can move along or against a concentration gradient. Thus, transport can include the application of energy to move one or more molecules in a desired direction or to a desired location, such as an amplification site.

[0024] As used herein, "amplify", "amplifying" or "amplification reaction" and their derivatives generally refer to any act or process in which at least a portion of a nucleic acid molecule is replicated or copied to at least one additional nucleic acid molecule. The additional nucleic acid molecule may optionally comprise a sequence that is substantially identical or substantially complementary to at least a portion of the template nucleic acid molecule. The template nucleic acid molecule may be single-stranded or double-stranded, and the additional nucleic acid molecule may be independently single-stranded or double-stranded. The amplification may optionally comprise linear or exponential replication of the nucleic acid molecule. In some embodiments, such amplification may be performed using isothermal conditions; in other embodiments, such amplification may include temperature cycling. In some embodiments, the amplification is a multiplex amplification that includes simultaneous amplification of multiple target sequences in a single amplification reaction. In some embodiments, "amplification" includes amplification of at least a portion of DNA and RNA-based nucleic acids, alone or in combination. The amplification reaction may include any of the amplification processes known to those of skill in the art. In some embodiments, the amplification reaction includes polymerase chain reaction (PCR).

[0025] As used herein, "amplification conditions" and its derivatives generally refer to conditions suitable for amplifying one or more nucleic acid sequences. Such amplification can be linear or exponential. In some embodiments, amplification conditions can include isothermal conditions, or alternatively can include temperature cycling conditions, or a combination of isothermal and temperature cycling conditions. In some embodiments, conditions suitable for amplifying one or more nucleic acid sequences include polymerase chain reaction (PCR) conditions. Typically, amplification conditions refer to a reaction mixture that is sufficient to amplify a nucleic acid, such as one or more target sequences adjacent to a universal sequence, or amplify an amplified target sequence ligated to one or more adapters. Generally, amplification conditions include a catalyst for amplification or nucleic acid synthesis, such as a polymerase; a primer that has a degree of complementarity to the nucleic acid to be amplified; and nucleotides such as deoxyribonucleotide triphosphates (dNTPs), which facilitate extension of the primer once hybridized to the nucleic acid. Amplification conditions can require hybridization or annealing of a primer to a nucleic acid, extension of the primer, and a denaturation step in which the extended primer is separated from the nucleic acid sequence being amplified. Typically, but not necessarily, amplification conditions can include temperature cycling; in some embodiments, amplification conditions include multiple cycles in which the annealing, extension and separation steps are repeated. Typically, amplification conditions include, but are not limited to, Mg 2+ Or Mn 2+ and various modifiers of ionic strength.

[0026] As used herein, "reamplification" and its derivatives generally refer to any process in which at least a portion of an amplified nucleic acid molecule is further amplified via any suitable amplification process (in some embodiments referred to as a "secondary" amplification), thereby producing a re-amplified nucleic acid molecule. The secondary amplification need not be identical to the original amplification process in which the amplified nucleic acid molecule was produced; nor does the re-amplified nucleic acid molecule need to be completely identical or completely complementary to the amplified nucleic acid molecule; all that is required is that the re-amplified nucleic acid molecule contains at least a portion of the amplified nucleic acid molecule or its complement. For example, re-amplification can involve the use of different amplification conditions and / or different primers, including different target-specific primers than the primary amplification.

[0027] As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of Mullis, U.S. Pat. Nos. 4,683,195 and 4,683,202, which reports a method for increasing the concentration of a segment of a polynucleotide of interest in a mixture of genomic DNA without cloning or purification. This process for amplifying a polynucleotide of interest consists of introducing a large excess of two oligonucleotide primers to a DNA mixture containing the desired polynucleotide of interest, followed by a series of temperature cycling in the presence of a DNA polymerase. The two primers are complementary to each strand of the double-stranded polynucleotide of interest. The mixture is first denatured at a higher temperature, after which the primers are annealed to complementary sequences within the polynucleotide of the molecule of interest. Following annealing, the primers are extended with a polymerase to form a new pair of complementary strands. The denaturation, primer annealing, and polymerase extension steps can be repeated many times (referred to as temperature cycling) to obtain a highly concentrated amplified segment of the desired polynucleotide of interest. The length of the amplified segment of the desired polynucleotide of interest (amplicon) is determined by the relative positions of the primers with respect to each other, and therefore is a controllable parameter. Because this process is repeated, the method is called PCR. The desired amplified segment of the polynucleotide of interest is said to be "PCR amplified" because it becomes the predominant nucleic acid sequence (in terms of concentration) in the mixture. In a modification of the method discussed above, the target nucleic acid molecule can be PCR amplified using multiple different primer pairs, possibly more than one primer pair per target nucleic acid molecule of interest, thereby forming a multiplex PCR reaction.

[0028] As defined herein, "multiplex amplification" refers to the selective and non-random amplification of two or more target sequences in a sample using at least one target-specific primer. In some embodiments, multiplex amplification is performed such that some or all of the target sequences are amplified in a single reaction vessel. The "plexy" or "plex" of a given multiplex amplification generally refers to the number of different target-specific sequences amplified during that single multiplex amplification. In some embodiments, the plex can be about 12-plex, 24-plex, 48-plex, 96-plex, 192-plex, 384-plex, 768-plex, 1536-plex, 3072-plex, 6144-plex or more. It is also possible to detect the amplified target sequence by several different methods (e.g., gel electrophoresis followed by concentration measurement, quantification by bioanalyzer or quantitative PCR, hybridization with a labeled probe; incorporation of a biotinylated primer followed by avidin-enzyme conjugate detection; detection of the amplified target sequence by hybridization with a labeled probe; 32 (incorporation of P-labeled deoxynucleotide triphosphates).

[0029] As used herein, "amplified target sequence" and its derivatives generally refer to a nucleic acid sequence produced by amplifying a target sequence using target-specific primers and the methods provided herein. The amplified target sequence may be either of the same sense (i.e., the positive strand) or of the antisense (i.e., the negative strand) with respect to the target sequence.

[0030] As used herein, the terms "ligating", "ligation" and their derivatives generally refer to the process of covalently linking two or more molecules together, e.g., the process of covalently linking two or more nucleic acid molecules together. In some embodiments, ligation involves joining nicks between adjacent nucleotides of a nucleic acid. In some embodiments, ligation involves forming a covalent bond between an end of a first nucleic acid molecule and an end of a second nucleic acid molecule. In some embodiments, ligation involves forming a covalent bond between a 5' phosphate group of one nucleic acid and a 3' hydroxyl group of a second nucleic acid, thereby forming a ligated nucleic acid molecule. Generally, for purposes of this disclosure, an amplified target sequence can be ligated to an adaptor to generate an adaptor-ligated amplified target sequence.

[0031] As used herein, "ligase" and its derivatives generally encompass agents capable of catalyzing the ligation of two substrate molecules. In some embodiments, a ligase comprises an enzyme capable of catalyzing the joining of nicks between adjacent nucleotides of a nucleic acid. In some embodiments, a ligase comprises an enzyme capable of catalyzing the formation of a covalent bond between the 5' phosphate of one nucleic acid molecule and the 3' hydroxyl of another nucleic acid molecule, thereby forming a ligated nucleic acid molecule. Suitable ligases may include, but are not limited to, T4 DNA ligase, T4 RNA ligase, and E. coli DNA ligase.

[0032] As used herein, "ligation conditions" and its derivatives generally refer to conditions suitable for ligating two molecules together. In some embodiments, the ligation conditions are suitable for sealing a nick or gap between nucleic acids. As used herein, the term nick or gap is consistent with the use of the term in the art. Typically, a nick or gap can be ligated in the presence of an enzyme such as a ligase at an appropriate temperature and pH. In some embodiments, T4 DNA ligase can ligate a nick between nucleic acids at a temperature of about 70-72°C.

[0033] The term "flow cell" as used herein refers to a chamber that includes a solid surface through which one or more fluidic reagents can flow.Examples of flow cells and related fluidic systems and detection platforms that can be easily used in the method of the present disclosure are described in, for example, Bentley et al., Nature 456:53-59 (2008), WO 04 / 018497; U.S. Patent No. 7,057,026; WO 91 / 06678; WO 07 / 123744; U.S. Patent No. 7,329,492; U.S. Patent No. 7,211,414; U.S. Patent No. 7,315,019; U.S. Patent No. 7,405,281, and U.S. Patent Application Publication No. 2008 / 0108082.

[0034] As used herein, the term "amplicon" refers to a product of nucleic acid replication, said product having a nucleotide sequence that is identical or complementary to at least a portion of the nucleotide sequence of said nucleic acid. An amplicon can be produced by any of a variety of amplification methods using a nucleic acid or its amplicon as a template, including, for example, polymerase extension, polymerase chain reaction (PCR), rolling circle amplification (RCA), ligation extension or ligation chain reaction. An amplicon can be a nucleic acid molecule having a single copy of a particular nucleotide sequence (e.g., a PCR product) or multiple copies of said nucleotide sequence (e.g., a concatemer product of RCA). The initial amplicon of a target nucleic acid is typically a complementary copy. Subsequent amplicons are copies generated from the target nucleic acid or the initial amplicon after the generation of the initial amplicon. Subsequent amplicons can have a sequence that is substantially complementary to the target nucleic acid or substantially identical to the target nucleic acid.

[0035] As used herein, the term "amplification site" refers to a site within or on an array at which one or more amplicons can be generated. Further, an amplification site can be configured to contain, hold, or attach at least one amplicon generated at that site.

[0036] As used herein, the term "array" refers to a collection of sites that can be distinguished from one another by their relative positions. Different molecules at different sites of an array can be distinguished from one another depending on the site's position in the array. Each site of an array can contain one or more molecules of a particular type. For example, a site can contain a single target nucleic acid molecule with a particular sequence, or a site can contain several nucleic acid molecules with the same sequence (and / or its complementary sequence). The sites of an array can be different features on the same substrate. Exemplary features include, but are not limited to, wells in a substrate, beads (or other particles) in or on a substrate, protrusions from a substrate, bumps on a substrate, or channels in a substrate. The sites of an array can be separate substrates, each holding a different molecule. Different molecules attached to separate substrates can be identified by the position of the substrate on a surface that is bound to the substrate, or by the position of the substrate in a liquid or gel. Exemplary arrays with separate substrates on a surface include, but are not limited to, arrays with beads in wells.

[0037] The term "capacity" as used herein, when used in relation to a site and nucleic acid material, refers to the maximum amount of nucleic acid material that can occupy the site.For example, this term can refer to the total number of nucleic acid molecules that can occupy the site in a particular state.Other measures can also be used, such as the total mass of nucleic acid material, or the total number of copies of a particular nucleotide sequence that can occupy the site in a particular state.Typically, the volume of a site with respect to a target nucleic acid will be substantially equivalent to the volume of the site with respect to an amplicon of the target nucleic acid.

[0038] As used herein, the term "capture agent" refers to a material, chemical, molecule, or portion thereof, that can attach to, hold, or bind to a target molecule (e.g., a target nucleic acid). Exemplary capture agents include, but are not limited to, a capture nucleic acid (also referred to herein as a capture oligonucleotide) that is complementary to at least a portion of a target nucleic acid, a member of a receptor-ligand binding pair (e.g., avidin, streptavidin, biotin, lectins, carbohydrates, nucleic acid binding proteins, epitopes, antibodies, etc.) that can bind to a target nucleic acid (or a linking moiety attached thereto), or a chemical reagent that can form a covalent bond with a target nucleic acid.

[0039] As used herein, the term "reporter moiety" can refer to an identifiable tag, label, index, barcode, or group that allows for determining the composition, identity, and / or source of the analyte being investigated. In some embodiments, the reporter moiety can comprise an antibody that specifically binds to a protein. In some embodiments, the antibody can comprise a detectable label. In some embodiments, the reporter can comprise an antibody or affinity reagent labeled with a nucleic acid tag. The nucleic acid tag can be detectable, for example, by proximity ligation assay (PLA) or proximity extension assay (PEA) or sequencing-based readout (Shahi et al., Scientific Reports volume 7, Article number:44447, 2017) or CITE-seq (Stoeckius et al., Nature Methods 14:865-868, 2017).

[0040] As used herein, the term "clonal population" refers to a population of nucleic acids that are homogeneous with respect to a particular nucleotide sequence. A homogeneous sequence is typically at least 10 nucleotides in length, but can be longer, including, for example, at least 50 nucleotides, 100 nucleotides, 250 nucleotides, 500 nucleotides, or 1000 nucleotides in length. A clonal population can be derived from a single target or template nucleic acid. Typically, all nucleic acids in a clonal population will have the same nucleotide sequence. It will be understood that a small number of mutations (e.g., due to amplification artifacts) can occur in a clonal population without departing from clonality.

[0041] As used herein, the term "unique molecular identifier" or "UMI" refers to a random, non-random, or semi-random molecular tag that may be attached to a nucleic acid. When incorporated into a nucleic acid, the UMI can be used to correct for subsequent amplification bias by directly counting unique molecular identifiers (UMIs) that are sequenced after amplification.

[0042] As used herein, an "exogenous" compound, such as an exogenous enzyme, refers to a compound that is not normally or naturally found in a particular composition. For example, if a particular composition includes a cell lysate, an exogenous enzyme is an enzyme that is not normally or naturally found in the cell lysate.

[0043] As used herein, "providing" in the context of a composition, article, nucleic acid, or nucleus means making the composition, article, nucleic acid, or nucleus, purchasing the composition, article, nucleic acid, or nucleus, or otherwise obtaining the compound, composition, article, or nucleus.

[0044] The term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements.

[0045] The words "preferred" and "preferably" refer to embodiments of the present disclosure that may provide certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the description of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present disclosure.

[0046] The terms "comprises" and variations thereof do not have a limiting meaning where these terms appear in the description and claims.

[0047] Whenever an embodiment is described in this specification using words such as "include," "includes," or "including," it will be understood that other similar embodiments described using the terms "consisting of" and / or "consisting essentially of" are also provided.

[0048] Unless otherwise stated, "a," "an," "the," and "at least one" are used interchangeably and mean one or more.

[0049] Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0050] For any method disclosed herein that includes distinct steps, those steps may be performed in any order practicable, and, where appropriate, any combination of two or more steps may be performed simultaneously.

[0051] References throughout this specification to "one embodiment," "an embodiment," "particular embodiment," "some embodiments," or the like, mean that the particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosure. Thus, the appearance of such phrases in various places throughout this specification does not necessarily refer to the same embodiment of the disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments. [Brief description of the drawings]

[0052] The following detailed description of illustrative embodiments of the disclosure may be best understood when read in conjunction with the following drawings.

[0053] [Figure 1] FIG. 1 shows a general block diagram of a general illustrative method for single-cell combinatorial indexing according to the present disclosure. [Diagram 2] FIG. 2 shows a general block diagram of a general illustrative method for single-cell combinatorial indexing according to the present disclosure. [Diagram 3] FIG. 3 shows a general block diagram of a general illustrative method for single-cell combinatorial indexing according to the present disclosure. [Figure 4]Figure 4 shows that sci-RNA-seq3 can profile ~2 million cells from 61 mouse embryos across five developmental stages in a single experiment. (A) sci-RNA-seq3 workflow and experimental scheme. (B) Comparison of our throughput per experiment with that of recent reports. (C) Scatter plot of mouse UMI counts vs. human UMI counts from HEK293T and NIH / 3T3 cells. (D) Bar graph showing the number of cells profiled from each of the 61 mouse embryos. (E) Box plot showing the number of genes and UMIs detected per cell. (F) Scatter plot of unique reads aligning to the Xist (chr X) gene vs. chrY gene per mouse embryo. (G) Pseudo-time trajectories of pseudo-bulk RNA-seq profiles of mouse embryos. (H) Heat map of changes in marker gene expression E9.5 to E13.5 from pseudo-bulk RNA-seq profiles of mouse embryos.

[0054] [Diagram 5] Figure 5 shows the performance and QC-related analyses of sci-RNA-seq3. (A) Bar graph showing the number of RT wells used for each of 61 mouse embryos. (B) Histogram showing the distribution of raw sequencing read data from each PCR well of sci-RNA-seq3. (C) Box plot showing the number of UMIs per cell from HEK293T and NIH / 3T3 cells. (D) Box plot showing the percentage of reads mapping to predicted species for HEK293T (human) and NIH / 3T3 (mouse) cells. (E) Box plot comparing the number of UMIs per cell (downsampled to 20,000 raw reads per cell) for sci-RNA-seq3 vs. sci-RNA-seq. (F) Correlation of gene expression measurements in aggregate profiles of HEK293T cells from sci-RNA-seq3 vs. sci-RNA-seq. [Figure 6]Figure 6 shows further performance and QC related analyses for sci-RNA-seq3. (A) Scatter plot showing correlation between number of RT wells used and number of cells harvested per embryo. (B-D) Bar graphs comparing number of raw sequencing reads (B), genes detected (C) and UMIs (D) per cell between sci-RNA-seq3 and other methods. (E) Box plot showing number of UMIs detected per cell from embryos across five developmental stages. (F) Bar graph showing number of male and female embryos profiled at each developmental stage. [Figure 7] Figure 7 shows that pseudobulk RNA-seq profiles of mouse embryos are readily separated by developmental stage. (A) t-SNE of aggregate transcriptomes of single cells derived from each of 61 mouse embryos results in five highly clustered groups that perfectly match developmental stages. (B) Pseudotime trajectories of pseudobulk RNA-seq profiles of mouse embryos, same as in Figure 4G but colored by pseudotime. (C) The 61 profiled embryos are aligned in pseudotime sequence. The earliest three E10.5 embryos and the most recent (in pseudotime) three E10.5 embryos are pictured, which appear morphologically distinct. [Figure 8] Figure 8 shows the identification of major cell types of mouse organogenesis. (A) t-SNE visualization of 2,026,641 mouse embryonic cells colored by cluster ID from Louvain clustering and annotated based on marker genes. The same t-SNE is plotted below, showing only cells from each developmental stage. Primitive erythroid (transient) and definitive erythroid (expanding) clusters are boxed to show their proliferation kinetics. (B) Dot plot showing the expression of one selected marker gene per cell type. The size of the dot encodes the percentage of cells within a cell type, while its color encodes the average expression level.

[0055] [Figure 9]Figure 9 shows the identification of major cell types of mouse organogenesis and the corresponding set of cell type-specific marker genes. (A) t-SNE visualization of cell state transitions from E9.5 to E13.5, colored by developmental stage. This is the same t-SNE shown in Figure 8A, but in each plot, only cells from a single time point are shown. (B) Heatmap showing relative expression of genes across the major cell types identified. (C) Bar graph showing the number of marker genes in each cell type that show more than 2-fold expression when compared to the second highest expressing cell type (5% FDR). [Figure 10] Figure 10 shows that cells derived from replicate embryos at the same time point exhibit no obvious batch effect. (A-E) t-SNE visualization of mouse embryonic cells at different developmental stages: E9.5 (A), E10.5 (B), E11.5 (C), E12.5 (D), E13.5 (E), color-coded by embryo ID at each stage. [Figure 11] FIG. 11 shows the dynamics of cell type numbers during mouse organogenesis. (A) Bar graph showing the number of cells profiled for each cell type split by developmental stage. (B) Heatmap showing the relative cell numbers of each cell type (rows) in 61 mouse embryos (columns). Estimates of absolute cell numbers per cell type per embryo were calculated by multiplying the proportion that a cell type contributes to a given embryo by the estimated total number of cells at that developmental stage. For display, these estimates are normalized in each row by the maximum estimated cell number of a given cell type across all 61 embryos. Embryos are sorted from left to right by developmental pseudotime. (C) Line graph showing the change in relative cell numbers for primitive and definitive erythroid lineages, calculated as in panel B. Dashed lines show the relative expression of marker genes for primitive erythroid (Hbb-bh1) and definitive erythroid (Hbb-bs). Data points for individual embryos were sorted by developmental pseudotime series and smoothed with the loess method.

[0056] [Figure 12]Figure 12 shows the Louvain clustering and t-SNE visualization of the subclusters for each of the 38 major cell types. Because cell type heterogeneity was readily apparent among many of the 38 clusters shown in Figure 8A, we employed an iterative strategy in which we repeated the Louvain clustering on each major cell type to identify subclusters. After removing subclusters dominated by one or two embryos and merging highly similar subclusters, we ended up with a total of 655 subclusters (also called "subtypes" to distinguish them from the 38 major cell types identified in the initial clustering). [Figure 13] Figure 13 shows the Louvain clustering and t-SNE visualization of subclusters for each of the 38 major cell types across all developmental stages. Same as Figure 12, but cells are colored by developmental stage instead of subcluster ID. [Figure 14] Figure 14 shows that the sensitivity of detecting cell types is a function of cell coverage. (A) t-SNE visualization of all cells (left plot, n=2,026,641) and the downsampled subset (right plot, n=50,000), colored by the Leuven cluster ID from Figure 8A. (B) t-SNE visualization of all endothelial cells (left plot, n=35,878) and those from the downsampled subset (right plot, n=1,173), colored by the Leuven cluster ID calculated based on 35,878 endothelial cells. (C) t-SNE visualization of 1,173 endothelial cells, colored by the Leuven cluster ID calculated based on 1,173 endothelial cells.

[0057] [Figure 15]Figure 15 shows 655 cell subtypes derived from multiple embryos and defined by a set of markers. (A) Histogram showing distribution of subclusters with respect to cell number (median 1,869; range 51-65,894). (B) Histogram showing distribution of subclusters with respect to number of contributing embryos (more than 5 cells to be considered as contributing). (C) Histogram showing distribution of subclusters with respect to proportion of cells derived from the highest contributing embryo. (D) Histogram showing distribution of subclusters with respect to number of marker genes (at least 1.5-fold higher expression when compared to the second highest expressing cell subtype within the same major cluster; 5% FDR). [Figure 16] Figure 16 shows the dynamics of cell subtype numbers during mouse organogenesis. (A) Heatmap showing relative expression of genes across 655 identified subclusters. (B) Heatmap showing relative cell numbers of each cell subtype (rows) in 61 mouse embryos (columns). Estimates of absolute cell numbers per cell subtype per embryo were calculated as in Figure 11B. (C) t-SNE visualization of all 61 mouse embryos based solely on the proportion of 655 cell subtypes in each embryo. [Figure 17] Figure 17 shows identification and characterization of epithelial cell subtypes and the apical ectodermal ridge of the limb (AER). (A) t-SNE visualization and marker-based annotation of epithelial cell subtypes. (B) t-SNE visualization of all epithelial cells colored by expression levels of Fgf8. (C) In situ hybridization images of Fgf8 in E10.5 (left) and E11.5 (right) embryos. (D) t-SNE visualization of all epithelial cells colored by expression levels of Fndc3a. (E) In situ hybridization images of Fndc3a in E10.5 embryos. Arrows: sites of gene expression. (F) Box plots showing the percentage of AER cells per embryo at different developmental stages. (G) Pseudotime trajectories of AER single-cell transcriptomes, colored by developmental stage. (H) Line graphs showing relative expression of AER marker genes across developmental pseudotime.

[0058] [Figure 18] Figure 18 shows the discrimination of mouse epithelial subtypes. Dot plots showing the expression of one selected marker gene per epithelial subtype. The size of the dot encodes the percentage of cells within a cell type, and its color encodes the average expression level. [Figure 19] Figure 19 shows the dynamics of gene expression in limb ectodermal apical ridge (AER) cells over pseudotime. (A) Heatmap showing smoothed pseudotime-dependent differential gene expression in AER cells generated by negative binomial regression and scaled as percent of maximum gene expression (FDR at 1%). Each row shows a different gene, splitting these into subsets that exhibit activation kinetics (top), repression kinetics (middle), or transient kinetics (bottom) between E9.5 and E13.5. (B-C) Plots showing -log10 transformed q-values ​​and enrichR-based combined scores of enriched Reactome terms (B) and transcription factors (C) for genes whose expression is significantly decreased in developing AER. Top enriched pathway terms (Reactome2016) for significantly decreased genes include cell cycle progression (mitotic cell cycle, qval=0.0002) and glucose metabolism (carbohydrate metabolism, qval=0.0002). Top enriched TFs with targets from decreasing genes include pluripotency factors such as Isl1 (qval<10-5), Pou5f1 (qval=0.002), and Nanog (qval=0.003). [Figure 20]Figure 20 shows characterization of cell trajectories during limb mesenchymal differentiation. (A) UMAP 3D visualization of limb mesenchymal cells colored by developmental stage (left and right represent views from two directions). (B) Scatter plot showing normalized expression of Pitx1 and Tbx5 in limb mesenchymal cells. Only cells in which Pitx1 and / or Tbx5 were detected are displayed. (C) Volcano plot showing differentially expressed genes (5% FDR, colored in red) between forelimbs and hindlimbs. Top differentially expressed genes are labeled. X-axis: log2-transformed fold change between forelimbs and hindlimbs for each gene. Y-axis: -log10-transformed qval from differentiation study. (D) Same visualization as in panel A, colored by normalized gene expression of proximal / chondrocyte (Sox6, Sox9), distal (Hoxd13, Tfap2b), anterior (Pax9, Alx4), or posterior (Hand2, Shh) markers. (F) In situ hybridization images of Hoxd13 in E10.5 to E13.5 embryos. (G) Same visualization as in panels A and D, colored by normalized gene expression of Cpa2. Its expression pattern within this trajectory led us to predict that Cpa2 is a distal marker of developing limb mesenchyme, like Hoxd13. (H) In situ hybridization images of Cpa2 in E10.5 and E11.5 embryos. (I) Overview of combined results for AER and limb mesenchyme trajectories.

[0059] [Figure 21] FIG. 21 shows characterization of cell fate trajectories during limb mesenchyme development. (A) Heatmap showing top differentially expressed genes between different developmental stages of limb mesenchyme cells. (B) Bar graph showing -log10 transformed enriched transcription factor adjusted p-values ​​for genes significantly upregulated during limb mesenchyme development. (C) t-SNE visualization of limb mesenchymal cells colored by forelimb (Tbx5+) and hindlimb (Pitx1+). Cells with no or both expression in Tbx5 and Pitx1 are not shown. [Figure 22]Figure 22 shows spatially restricted expression of markers in the limbs. Each panel shows a different marker gene. Colors indicate UMI counts that were scaled to library size, log transformed, and then mapped to Z-scores to allow comparisons between genes. Cells not expressing a given marker are excluded to prevent overplotting. (A) Hindlimb marker Pitx1 and forelimb marker Tbx5. (B) 1st row: proximal limb markers Sox6 (also marks chondrocytes) and Sox9. 2nd row: distal limb markers Hoxd13 and Tfap2b. 3rd row: forelimb markers 68 Pax9 and Alx4. 4th row: hindlimb markers Shh and Hand2. [Diagram 23] Figure 23 shows modules of spatially restricted genes in the limb. A total of 1,191 genes were clustered by hierarchical clustering. Using the cutree function in R, the dendrogram was cut into 8 modules and the aggregate expression of genes in each module was calculated. Colors indicate aggregate UMI counts for each module that are scaled to library size, log transformed, and then mapped to Z-scores to allow comparison between modules. Cells with no expression of a given module are excluded to prevent overplotting.

[0060] [Figure 24] Figure 24 shows the characterization of the eight major developmental trajectories present during mouse organogenesis. (A) UMAP 3D visualization of the entire dataset. Top: Views from two directions. Bottom: Zoomed-in views of the mesenchymal (left) and neural tube / notochord (right) trajectories, colored by developmental stage. (B) Heatmap showing the percentage of cells from each of the 38 major cell types assigned to each of the eight major trajectories. Vertical columns represent the eight major lineages, labeled by the color of the top bar (see key for panel A). (C) UMAP 3D visualization of the epithelial sub-trajectories, colored by developmental stage. [Diagram 25]Figure 25 shows characterization of the eight major developmental trajectories present during mouse organogenesis. (A) Same as Figure 24A, but with colors corresponding to the 38 major cell clusters. (B-C) Area plots showing the estimated percentage (B) and estimated absolute cell numbers (C) of cells per embryo derived from each of the eight major cell trajectories from E9.5 to E13.5. [Figure 26] FIG. 26 shows a UMAP visualization of the eight major cell trajectories color-coded by major cell cluster ID. [Figure 27] FIG. 27 shows a UMAP visualization of the eight major cell trajectories color-coded by developmental stage.

[0061] [Figure 28] Figure 28 shows a UMAP visualization of epithelial cell subtypes, colored according to the 29 epithelial subtypes shown in Figure 17A. [Figure 29] Figure 29 shows the resolution of cell trajectories in myogenesis. The edges of the main graph that define the trajectories reported by Monocle 3 are displayed as light blue line segments. (A) Cells putatively involved in myogenesis were isolated in silico from the mesenchymal cell trajectory and then used to construct a myocyte sub-trajectory (Methods). (B) Cells in the myocyte sub-trajectory colored by developmental stage. (C) Cells in the myocyte trajectory colored by expression of selected transcriptional regulators of myogenesis. Cells with no detectable expression of a given gene are omitted from the plot. (D) Cells classified by developmental stage according to the markers shown in panel C (Methods). [Diagram 30]Figure 30 shows Sci-Fate co-profiling of the total and newly synthesized transcriptomes. (A) Sci-fate workflow with major steps outlined in the text. (B) Experimental scheme. A549 cells were treated with dexamethasone in a time-dependent manner. Cells from all treatment conditions were labeled with S4U 2 h before harvesting for sci-fate. (C) Violin plots showing the ratio of S4U-labeled reads per cell at six treatment times. (D) Violin plots showing the ratio of S4U-labeled reads in exonic and intronic reads. All box plots: thick horizontal line, median; top and bottom of box, first and third quartiles, respectively; whiskers, 1.5 times interquartile range; circles, outliers. (E) UMAP visualization of A549 cells with the total transcriptome (left), newly synthesized transcriptome (middle), and both (right). (F) As in (E), colored by cluster ID identified in the whole transcriptome. (G) UMAP visualization of A549 cells with combined information, colored by normalized expression of G2 / M marker genes by RNA levels (left) and newly synthesized RNA levels (right). UMI counts for these genes were scaled by library size, log-transformed, aggregated, and mapped to Z-scores.

[0062] [Diagram 31]Figure 31 shows performance and QC-related analyses for sci-fate. (A) Scatter plot of UMI counts per cell for mouse (NIH / 3T3) vs. human (HEK293T) in sci-fate condition. (B-D) Box plots showing the ratio of S4U-labeled reads per cell, number of UMIs, and purity (percentage of reads mapping to expected species) from HEK293T cells (n=932 cells) and NIH / 3T3 cells (n=438 cells). All box plots: thick horizontal line, median; top and bottom of box, first and third quartiles, respectively; whiskers, 1.5 times interquartile range; circles, outliers. (E–F) Correlation (Spearman's correlation) between gene expression measurements in aggregate profiles of HEK293T cells (E) and NIH / 3T3 cells (F) from sci-fate (y-axis) versus sci-RNA-seq cells (x-axis). [Diagram 32] Figure 32 shows the performance of sci-fate in dexamethasone-treated A549 cells. (A,B) Violin plots showing the number of UMIs (A) and genes (B) per cell in the six treatment conditions. All boxplots: thick horizontal line, median; top and bottom of box, 1st and 3rd quartiles, respectively; whiskers, 1.5 times the interquartile range; circles, outliers. (C) Correlation plot showing the Pearson correlation coefficient between different treatment conditions for the aggregated total transcriptome (top right) and the de novo synthesized transcriptome (bottom left). (D) UMAP visualization of A549 cells with de novo synthesized transcriptome, colored by cluster ID identified by the de novo synthesized transcriptome. (E) Heatmap showing the percentage of cells from each cluster defined by the total transcriptome, classified into each cell cluster by the de novo synthesized transcriptome. (F-G) UMAP visualization of A549 cells with both total and newly synthesized transcriptomes, colored by normalized expression of S-phase marker genes by total RNA expression (F) and newly synthesized RNA (G). UMI counts for these genes are scaled to library size, log-transformed, aggregated, and then mapped to Z-scores.

[0063] [Diagram 33] Figure 33 shows characterization of TF modules driving cell state transitions. (A) Links (blue) identified between transcription factors (orange) and regulatory genes (grey). TF modules related to cell cycle progression or GR response are labeled. (B) UMAP visualization of A549 cells ordered by cell cycle TF modules, colored by newly synthesized mRNAs of S-phase and G2 / M-phase markers (top), three cell cycle phases (bottom left) and nine cell cycle states (bottom right) from unsupervised clustering analysis. (C) UMAP visualization of A549 cells ordered by GR response TF modules, colored by DEX treatment time (left), CEBPB and FOXO1 activity (middle), and cluster ids (right) from unsupervised clustering analysis. To calculate TF activity, newly synthesized UMI counts for these genes are scaled by library size, log-transformed, aggregated, and mapped to Z-scores. (D) Table showing the observed proportions (in black) of cell states according to the combined state of cell cycle modules (x-axis) and GR response modules (y-axis). Red numbers are the expected proportions assuming independent assortments. (E) Heatmap showing the proportions of cell states specified by the combined state of TF modules in each major cluster identified by clustering analysis based on both the whole transcriptome and de novo synthesized transcriptome. [Diagram 34]Figure 34 shows TF modules driving cell state transitions in DEX-treated A549 cells. (A) Identified gene targets (gray) of CEBPB (orange). Only links with normalized correlation coefficients from LASSO>0.6 are shown. (B) UMAP visualization of A549 cells with whole transcriptome and de novo synthetic transcriptome colored by CEBPB expression (left) and activity (right). (C) As in (B), but colored by YOD1 expression (left) and YOD1 activity (right). (D) As in (B), but colored by GTF2IRD1 expression (left) and GTF2IRD1 activity (right). (E) As in (B), but colored by E2F1 expression (left), E2F1 activity (center), and whole transcriptome aggregated expression of E2F1-bound genes (right). (F) Heatmap showing absolute values ​​of Pearson's correlation coefficients between TF modules. The 29 TF modules were grouped into five groups by hierarchical clustering analysis.

[0064] [Diagram 35] Figure 35 shows cellular states characterized by the combinatorial state of functional TF modules. (A) Scheme showing the strategy to characterize cellular states by the combinatorial state of functional TF modules. (B) Umap visualization of whole cells with both total and de novo synthesis transcriptomes, colored by major cluster ids identified by a density peak clustering algorithm on the UMAP space. [Diagram 36]Figure 36 shows the characterization of state transition trajectories of over 6,000 single cells. (A) Scheme showing memory correction and cell linkage analysis to construct single cell transition trajectories with details outlined in the text and methods. (B) 3D plot of cells colored by DEX treatment time (also as z coordinate). x and y coordinates correspond to UMAP space with whole transcriptome and de novo synthesized transcriptome in Figure 30E (left). Grey lines connect linked parent and child cells. (C) As in (B) but x and y coordinates correspond to UMAP space with single cell transcriptome dynamics across six time points. (D) Line graphs showing cell state dynamics of different GR response states (top) and cell cycle states (bottom) in each cell trajectory cluster (left) or whole cells (right), independent of cell linkage analysis. (E) Cell state transition network. Nodes are the 27 cell states characterized in Figure 33D, and links are identified transition pathways between cell states. Links with low transition probability (<0.1) are excluded. Dashed boxes show examples of states with reversible transition kinetics. (F) Correlation plot showing correlation of cell state proportions between treatment conditions. Positive correlations are shown in blue and negative correlations in red. The shape of the ellipse correlates with the correlation coefficient (on the ellipse). (G) Scatter plot showing correlation between observed and predicted cell state proportions between 10 h DEX-treated groups. Predictions are based on cell state transition probability and cell state proportions in the no-DEX-treated group. The blue line represents the linear regression line. (H) Scatter plot showing correlation of cell state transition probability calculated with complete data (0–10 h) or partial data (0–6 h) along with the linear regression line. [Figure 37]Figure 37 shows the estimation of new RNA detection rate and RNA degradation rate. (A) Scatter plot showing the correlation of x-axis: normalized total transcriptome difference between no DEX treated cells and 2 hr DEX treated cells, and y-axis: normalized newly synthesized transcriptome difference between no DEX treated cells and 2 hr DEX treated cells. The blue line is the linear regression line. Both the total transcriptome and the newly synthesized transcriptome for each time point are normalized by the library size of the total transcriptome at that time point. (B) Correlation plot showing the correlation of estimated gene degradation rates between treatment conditions. Positive correlations are displayed in blue and negative correlations in red. The shape of the ellipse correlates with the correlation coefficient (above ellipse).

[0065] [Figure 38] Figure 38 shows a cell state transition network for cell state prediction. (A) Scatter plot showing the correlation between the observed cell states at each treatment and the cell states predicted by the cell state transition probability and the proportion of cell states in the DEX-free treatment group. The blue line represents the linear regression line. (B) Scatter plot showing the correlation between the observed proportion of cell states among the 10-hour DEX treatment group and the predicted value. The predicted value is based on the cell state transition probability estimated by partial data (0-6 hours) and the proportion of cell states in the DEX-free treatment group. The blue line represents the linear regression line. [Figure 39]Figure 39 shows that cell state transition probability is regulated by nearby state stability landscape. (A) Scatter plot showing transition distance (Pearson's distance) vs. transition probability between cell states with red LOESS smooth line in ggplot2. (B) 3D plot showing cell state instability landscape. X-axis represents GR response states (no response to low-high response states). Y-axis represents cell cycle states ordered from G0 / G1 to G2 / M states. Z-axis represents cell state instability, determined by the probability of cells in each cell state jumping to other cell states after 2 hours. (C) Scatter plot showing cell state instability vs. change in cell proportion before and after 10 hours of DEX treatment with red LOESS smooth line in ggplot2. (D) Scatter plot showing correlation between state instability and state transition entropy with linear regression line (blue). (E) Boxplot showing cross-validated r-squared for predicting state-to-state transition probability by densely connected neural networks using transition distance alone or a combination of transition distance and state instability landscape. [Diagram 40] Figure 40 shows a browser shot of targeted exons in the LMO2 gene. The exons targeted are shown in the "Targeted Exons" track. Note that the 12 RT primers that passed the filter are spread as evenly as possible across the exons. The bottom two tracks "Primers_plus / minus" and "Captured_plus / minus" show the reads mapping to the RT primers and the corresponding captured transcripts. The difference in read counts indicates the number of off-target priming events.

[0066] [Diagram 41]Figure 41 shows a table comparing the ranks of genes in the ENCODE total nuclear RNA-seq dataset and the in situ multiplex RT capture library. Targeted genes are shown in bold. Of the 12 most abundant genes in the targeted library, 8 were targeted genes. The last two columns are "Rank" i.e. rank in our dataset, and "ENCODE" i.e. rank in the ENCODE dataset. Abundant non-targeted RNAs include mitochondrial ribosomal RNAs RNR2 and RNR1, and highly abundant nuclear lncRNA MALAT1. Of note, the LMO2 gene goes from being the 4,627th most frequently detected gene (out of 26,281 genes) in the ENCODE dataset to being the 3rd most detected gene in the library. [Diagram 42] Figure 42 shows enrichment of transcripts captured across total RNA. Scatter plot of reads in targeted library vs. reads in ENCODE nuclear RNA. RT targeted genes are shown in red. Note that they generally fall off the diagonal, indicating that they are enriched above levels expected given their expression in the reference dataset. The abundant nuclear lncRNAs MALAT1 and XIST are shown in blue: they fall above the diagonal, indicating that enrichment for these RNAs is valid. Targeted eRNAs are not enriched (orange). The median enrichment above expected levels for the nine genes targeted in this experiment is 45.3-fold. Overall, reads from targeted genes account for 31% of all reads mapped to genes in this dataset.

[0067] The schematic diagrams are not necessarily drawn to scale. Like numbers used in the drawings refer to like components, steps, etc. However, it should be understood that the use of a number to refer to a component in a given drawing is not intended to limit that component in another drawing labeled with the same number. Furthermore, the use of different numbers to refer to multiple components is not intended to indicate that the differently numbered components cannot be the same or similar to the other numbered components. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0068] In one embodiment, the methods provided herein can be used to generate single-cell combinatorial indexing (sci) sequencing libraries that contain the transcriptomes of multiple single cells. For example, the methods can be used to obtain sequence information for whole-cell transcriptomes, newly synthesized RNA transcriptomes, or a combination thereof. In another embodiment, the methods provided herein can be used to generate sci sequencing libraries that contain sequence information for a subpopulation of RNA nucleic acids. For example, when non-coding regulatory regions are targeted for perturbation, coding regions in cis to the regulatory regions can be tested for changes in expression. In another example, cell atlas experiments can be performed with readouts restricted to a limited number of highly informative mRNAs.

[0069] The method may include one or more of providing isolated nuclei or cells, distributing a subset of isolated nuclei or cells into compartments, processing the isolated nuclei or cells to include nucleic acid fragments, and adding compartment-specific indexes to the nucleic acid fragments. Optionally, the method may include exposing the cells to a predetermined condition and / or labeling newly synthesized RNA in the cells. The method may be directed to obtaining information including a subpopulation of transcriptome or RNA nucleic acids of the cells. These steps may be performed in essentially any order and may be combined in various ways. If necessary, the cells may be exposed to a predetermined condition and the newly synthesized RNA may be labeled, after which the nuclei may be isolated from the cells.

[0070] Provision of isolated nuclei or cells The methods provided herein can include providing a cell or nuclei isolated from a plurality of cells (FIG. 1, block 10; FIG. 2, block 22). The cells can be from any organism, any cell type, or any tissue of an organism. In one embodiment, the cells can be embryonic cells, e.g., cells obtained from an embryo. In one embodiment, the cells or nuclei can be from cancer or diseased tissue. The method can further include dissociating the cells and / or isolating the nuclei. The number of nuclei or cells can be at least two. The upper limit is subject to practical limitations of the equipment used in other steps of the methods described herein (e.g., multi-well plates, number of indexes). The number of nuclei or cells that can be used is not intended to be limiting and can number in the billions. For example, in one embodiment, the number of nuclei or cells can be 100,000,000 or less, 10,000,000 or less, 1,000,000,000 or less, 100,000,000 or less, 10,000,000 or less, 1,000,000 or less, 100,000 or less, 10,000 or less, 1,000 or less, 500 or less, or 50 or less. One of skill in the art will recognize that in some embodiments, the nucleic acid molecule of each nucleus represents the entire transcriptome of that nucleus, e.g., the total transcriptome, the newly synthesized transcriptome, or both.

[0071] In those embodiments that use isolated nuclei, the nuclei can be obtained by extraction and fixation. Optionally and preferably, the method of obtaining isolated nuclei does not include enzymatic treatment. In those embodiments that produce newly synthesized transcriptomes, the nuclei are not isolated until the cells are exposed to conditions suitable for labeling the newly synthesized transcriptome.

[0072] In one embodiment, nuclei are isolated from individual cells that are adherent or in suspension. Methods for isolating nuclei from individual cells are known to those skilled in the art. Nuclei are usually isolated from cells present in tissue. Methods for obtaining isolated nuclei typically include preparing tissue, isolating nuclei from the prepared tissue, and then fixing the nuclei. In one embodiment, all steps are performed on ice.

[0073] Tissue preparation involves flash freezing the tissue in liquid nitrogen and then reducing the size of the tissue to fragments no larger than 1 mm in diameter. Tissues can be reduced in size by either comminuting the tissue or by subjecting it to blunt force. Comminution can be accomplished using a blade to cut the tissue into small pieces. Applying blunt force can be accomplished by crushing the tissue with a hammer or similar object, and the resulting composition of the comminuted tissue is called a powder.

[0074] Isolation of nuclei can be accomplished by incubating the fragments or powder in a cell lysis buffer for at least 1-20 minutes, such as 5 minutes, 10 minutes, or 15 minutes. Useful buffers are those that promote cell lysis but preserve the integrity of the nuclei. One example of a cell lysis buffer includes 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, ±0.1% IGEPAL CA-630, 1% SUPERase In RNase Inhibitor (20 U / μL, Ambion) and 1% BSA (20 mg / ml, NEB). Standard nuclear isolation methods often use one or more exogenous compounds, such as exogenous enzymes, to aid in the isolation. Examples of useful enzymes that can be present in the cell lysis buffer include, but are not limited to, protease inhibitors, deoxyribonucleases, lysozymes, proteinase K, detergents, lysostaphins, zymolases, celluloses, proteases or glycanases, etc. (Islam et al., Micromachines (Basel), 2017, 8(3):83; www.sigmaaldrich.com / life-science / biochemicals / biochemical-products.html?TablePage=14573107). In one embodiment, one or more exogenous enzymes are not present in the cell lysis buffer useful for the methods described herein. For example, the exogenous enzymes are (i) not added to the cells prior to mixing the cells with the lysis buffer, (ii) not present in the cell lysis buffer prior to mixing with the cells, (iii) not added to the mixture of cells and the cell lysis buffer, or a combination thereof. Those skilled in the art will recognize that the levels of these components can be somewhat altered without reducing the usefulness of the cell lysis buffer for isolating nuclei. The extracted nuclei are then purified by one or more washes with nuclear buffer. An example of nuclear buffer includes 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1% SUPERase In RNase Inhibitor (20 U / μL, Ambion) and 1% BSA (20 mg / ml, NEB). Like the cell lysis buffer, exogenous enzymes may also be absent in the nuclear buffer used in the method of the present disclosure.Those skilled in the art will recognize that these levels of components can be altered somewhat without diminishing the usefulness of the nuclear buffer for isolating nuclei. Those skilled in the art will recognize that BSA and / or detergents can be useful in buffers used for isolating nuclei.

[0075] The isolated nuclei are fixed by exposure to a cross-linking agent. Useful examples of cross-linking agents include, but are not limited to, paraformaldehyde. Paraformaldehyde can be at a concentration of 1% to 8%, for example, 4%. Treatment of nuclei with paraformaldehyde can include adding paraformaldehyde to a suspension of nuclei and incubating at 0°C. Optionally and preferably, fixation is followed by washing with a nuclear buffer.

[0076] Isolated fixed nuclei can be used immediately or aliquoted and flash frozen in liquid nitrogen for later use. In preparation for subsequent use, thawed nuclei can be permeabilized, e.g., with 0.2% tritonX-100 for 3 minutes on ice and sonicated briefly to reduce nuclear clumping.

[0077] Conventional tissue nuclei extraction techniques typically involve incubating tissues with tissue-specific enzymes (e.g., trypsin) at high temperatures (e.g., 37°C) for 30 min to several hours, and then lysing the cells with cell lysis buffer for nuclear extraction. The nuclear isolation method described herein has several advantages: (1) no artificial enzymes are introduced, and all steps are performed on ice. This reduces potential perturbations to the cellular state (e.g., transcriptomic state). (2) the novel method has been validated with most tissue types, including disease samples such as brain, lung, kidney, spleen, heart, cerebellum, and tumor tissues. Compared with conventional tissue nuclei extraction techniques that use different enzymes for different tissue types, the novel technique can potentially reduce bias when comparing cellular states of different tissues. (3) the novel method also reduces costs and increases efficiency by removing the enzyme treatment step. (4) Compared to other nuclear extraction techniques (e.g., Dounce homogenizers), the novel technique is more robust to different tissue types (e.g., the Dounce method requires optimizing the Dounce cycle for different tissues) and allows processing large pieces of samples at high throughput (e.g., the Dounce method is limited by the size of the homogenizer).

[0078] Optionally, the isolated nuclei are free of nucleosomes or can be exposed to conditions that deplete the nucleosomes, thereby generating nucleosome-depleted nuclei.

[0079] Subset Distribution The methods provided herein include distributing a subset of isolated nuclei or cells into multiple compartments (Figure 1, block 11; Figure 2, block 23; Figure 3, block 32). The methods can include multiple partitioning steps of splitting a population of isolated nuclei or cells (also referred to herein as a pool) into subsets. Typically, the subsets of isolated nuclei or cells, e.g., those present in multiple compartments, are indexed with an index unique to the compartment and then pooled. Thus, the methods typically include at least one "split and pool" step of taking pooled isolated nuclei or isolated cells, distributing them, and adding an index unique to the compartment, and the number of "split and pool" steps can depend on the number of different indexes added to the nucleic acid fragments. Each initial subset of nuclei or cells before indexing can be different from the other subsets. For example, each initial subset can be obtained from a unique sample or exposed to unique conditions. After indexing, the subsets can be pooled after indexing, split into subsets, indexed, and pooled again if necessary, until a sufficient number of indexes are added to the nucleic acid fragments. This process assigns a unique index or combination of indexes to each single cell or nucleus. After indexing is completed, for example, after one, two, three, or more indexes are added, the isolated nuclei or cells can be lysed. In some embodiments, indexing and lysis can be performed simultaneously.

[0080] The number of nuclei or cells present in a subset, and therefore in each compartment, can be at least 1. In one embodiment, the number of nuclei or cells present in a subset is 100,000,000 or less, 10,000,000 or less, 1,000,000 or less, 100,000 or less, 10,000 or less, 4,000 or less, 3,000 or less, 2,000 or less, 1,000 or less, 500 or less, or 50 or less. In one embodiment, the number of nuclei or cells present in a subset can be 1 to 1,000, 1,000 to 10,000, 10,000 to 100,000, 100,000 to 1,000,000, 1,000,000 to 10,000,000, or 10,000,000 to 100,000,000. In one embodiment, the number of nuclei or cells present in each subset is approximately equal. The number of nuclei present in a subset, and therefore in each compartment, is based in part on the desire to reduce index collisions, which is the presence of two nuclei or cells with the same index combination that end up in the same compartment at this stage of the method. Methods for distributing nuclei or cells into subsets are known and routine to those of skill in the art. Fluorescence-activated cell sorting (FACS) cytometry can be used, although in some embodiments the use of simple dilution is preferred. In one embodiment, FACS cytometry is not used. Optionally, staining, such as DAPI (4',6-diamidino-2-phenylindole) staining, can be used to gate and enrich for nuclei of different ploidy. Staining can also be used to distinguish single cells from doublets during sorting.

[0081] The number of compartments in the partitioning step (and subsequent addition of index) can vary depending on the format used. For example, the number of compartments can be 2 to 96 compartments (when using 96-well plates), 2 to 384 compartments (when using 384-well plates), or 2 to 1536 compartments (when using 1536-well plates). In one embodiment, multiple plates can be used. In one embodiment, each compartment can be a droplet. When the type of compartment used is a droplet containing two or more nuclei or cells, any number of droplets can be used, such as at least 10,000, at least 100,000, at least 1,000,000, or at least 10,000,000 droplets. The isolated subsets of nuclei or cells are usually indexed in the compartments before pooling.

[0082] In some embodiments, the compartment is a droplet or well. The transcriptome of a cell or nucleus, the newly synthesized transcriptome, or a subpopulation thereof can be labeled with a unique index or combination of indexes in a droplet or well. The indexed library derived from droplet or well division can be pooled for further processing and sequencing. Examples of such methods include, but are not limited to, the single cell analysis system from 10X Genomics (Pleasanton, CA), Bio-Rad (Hercules, CA), and Celsi (Ann Arbor, MI).

[0083] Exposure to a given condition In any embodiment, each subset of cells is exposed to an agent or perturbation (FIG. 1, block 12). The agent can be essentially anything that causes a change in the cell. For example, the agent can alter the transcriptome of the cell, alter the chromatin structure of the cell, alter the activity of a protein in the cell, alter the DNA of the cell, alter the methylation state, alter the DNA editing of the cell, or induce other changes. Examples of agents include, but are not limited to, compounds such as proteins (including antibodies), non-ribosomal proteins, polyketides, organic molecules (including organic molecules of 900 daltons or less), inorganic molecules, RNA or RNAi molecules, carbohydrates, glycoproteins, nucleic acids, or combinations thereof. In one embodiment, the agent induces a genetic perturbation, such as, for example, a DNA editing protein such as CRISPR or talen. In one embodiment, the agent is a therapeutic agent. In one embodiment, the cells can be wild-type cells, and in another embodiment, the cells can be genetically modified to include genetic perturbations, such as gene knock-ins or gene knock-outs (Szlachta et al., Nat Commun., 2018, 9:4275). Subsets of cells can be exposed to the same agent, but different variables can be altered across compartments, allowing multiple variables to be tested in a single experiment. For example, different doses, different exposure times, and different cell types can be tested in a single multi-well plate. In one embodiment, the cells can express a protein with a known activity, and the effect of the agent on the activity can be evaluated under different conditions. The use of index sequences to label nucleic acid fragments allows for subsequent identification of nucleic acids derived from unique subsets of nuclei or cells, for example from one well of a multi-well plate.

[0084] Nucleic acid labeling In an optional embodiment, nucleic acids such as RNA, cDNA, or DNA produced by a cell are labeled (FIG. 1, block 13). Current methods for single cell genomics capture snapshots of cell states and therefore do not provide information on cell transition kinetics. The inventors have discovered that by labeling newly synthesized RNA, both the total transcriptome and newly synthesized transcriptome can be captured at the single cell level using split and pool indexing, combinatorial indexing, or any single cell indexing method. The total transcriptome and newly synthesized RNA receive the same unique index or combination of indexes, allowing the current state (e.g., existing) and newly synthesized nucleic acids to be assigned to the same cell. This allows characterization of cell state transition kinetics regulated by intrinsic (e.g., the cell's intrinsic cell cycle program) and extrinsic (e.g., the cell's response to an external stimulus such as a therapeutic agent) factors. Furthermore, in some embodiments, capture of both the total transcriptome and newly synthesized transcriptome at the single cell level, along with degraded transcriptome information from its past states (memory of past states), is possible. The memory of each cell's past state can be characterized for each cell by its transcriptome dynamics between two or more time points, and can be corrected for by mRNA decay rates (memory correction).

[0085] A variety of methods exist for labeling newly synthesized nucleic acids so that they can be distinguished from existing nucleic acids, and essentially any method can be used. Typically, a label is incorporated into the nucleic acid as it is synthesized. One type of method involves the incorporation of a nucleoside analog that adds a distinguishable mutation. For example, the addition of the nucleoside analog 4-thiouridine (S4U) to an RNA molecule creates a point mutation during the reverse transcription step, resulting in a mutated first strand cDNA with a thymine to cytosine conversion (Sun and Chen, 2018, Metabolic Labeling of Newly Synthesized RNA with 4sU to in Parallel Assess RNA Transcription and Decay. In: Lamandee S. (ed.) mRNA Decay. Methods in Molecular Biology, vol. 1720. Humana Press, New York, NY). This point mutation can be identified during the sequencing and analysis steps by comparing the sequence to a reference. Another type of method includes the incorporation of hapten-labeled nucleotides that can be used to purify the RNA containing hapten. Examples include biotinylated nucleotides (Luo et al., 2011, Nucl.Acids Res., 39(19):8559-8571) and digoxigenin-modified nucleotides (available from Jena Bioscience GmbH). The third type of method includes the incorporation of nucleotides that can be modified by chemical reaction, such as click-functionalized nucleotides, and the addition of haptens (Bharmal et al., 2010, J Biomol Tech., 21(3 Suppl.):S43, and available from Jena Bioscience GmbH, and available from Thermo Fisher Scientific). Another type of method includes the incorporation of mutagenic nucleotides, such as, but not limited to, 8-oxo-dGTP and dPTP (available from Jena Bioscience GmbH).

[0086] Typically, the conditions given are used in cells rather than isolated nuclei; however, labeling of nucleic acids during synthesis can be performed using cells or nuclei isolated from cells.

[0087] In some embodiments, the label can include newly synthesized cDNA or DNA. The label can be used as an identifier for the unique state or subset of a cell or nucleus. For example, different amounts of labels, such as nucleoside analogs, hapten-labeled nucleotides, click-functionalized nucleotides and / or mutagenic nucleotides, and / or different ratios between labels, can be used to specifically label the RNA, cDNA or DNA of a compartment. In another embodiment, the labels can be added at different times to capture the time dimension. Different labels or different ratios of labels can be added to differentially label the RNA at different times. In some embodiments, the labeling can be part of an indexing scheme to resolve individual cells. For example, the extension step can include a unique set of nucleotides for each compartment. The labeling can be done at the reverse transcription step, the extension step, the hybridization, or the amplification step such as PCR. In some embodiments, this allows the detection of doublets or multiplexed cells or collisions between cells.

[0088] Processing to generate nucleic acid fragments In one embodiment, processing of isolated nuclei or cells can be used to fragment DNA nucleic acids in isolated nuclei or cells into nucleic acid fragments (Figure 1, block 14). Fragmentation of nucleic acids can be useful to obtain molecules with lengths suitable for sequencing using the methods described herein. Processing can be necessary if the target nucleic acid to be sequenced is derived from DNA present in the nucleus or cell; however, processing is optional in some embodiments if the target nucleic acid to be sequenced is derived from RNA (e.g., mRNA and / or non-coding RNA) present in the nucleus or cell, since in some embodiments RNA molecules do not need to be fragmented. In other embodiments, nucleic acids derived from RNA molecules are fragmented. Fragmentation can occur at any stage of the method. For example, the exemplary method shown in Figure 2 includes fragmentation after adding two indexes to the nucleic acid molecule.

[0089] Processing of nucleic acid in a nucleus or cell typically results in the addition of a nucleotide sequence to one or both ends of the nucleic acid fragments produced by the processing, which can and typically includes one or more universal sequences. The universal sequence can be used as a "landing pad" in a subsequent step to anneal a nucleotide sequence that can be used as a primer to add another nucleotide sequence, such as an index, to the nucleic acid fragment. The nucleotide sequence of such a primer can optionally include an index sequence. Processing of nucleic acid in a nucleus or cell can result in the addition of one or more unique molecular identifiers to one or both ends of the nucleic acid fragments produced by the processing.

[0090] Various methods are known for processing nuclear or intracellular nucleic acids into nucleic acid fragments. Examples include CRISPR and Talen-like enzymes, as well as enzymes that unwind DNA (e.g., helicases) that can create single-stranded regions to which DNA fragments can hybridize and initiate extension or amplification. For example, helicase-based amplification can be used (Vincent et al., 2004, EMBO Rep., 5(8):795-800). In one embodiment, extension or amplification is initiated with random primers. In one embodiment, transposome complexes are used.

[0091] The transposome complex is a transposase bound to a transposase recognition site, which can insert the transposase recognition site into a target nucleic acid in the nucleus in a process sometimes referred to as "tagmentation." In some of the above insertion events, one strand of the transposase recognition site may be introduced into the target nucleic acid. The above strand is referred to as the "introduced strand." In one embodiment, the transposome complex comprises a dimeric transposase having two subunits and two non-contiguous transposon sequences. In another embodiment, the transposase comprises a dimeric transposase having two subunits and a contiguous transposon sequence. In one embodiment, the 5' end of one or both strands of the transposase recognition site may be phosphorylated.

[0092] Some embodiments can include the use of hyperactive Tn5 transposase and Tn5-type transposase recognition sites (Goryshin and Reznikoff, J.Biol.Chem., 273:7367 (1998)), or MuA transposase and Mu transposase recognition sites including R1 and R2 end sequences. (Mizuuchi, K., Cell, 35:785, 1983; Savilahti, H et al., EMBO J., 14:4893, 1995). Tn5 mosaic end (ME) sequences can also be used as optimized by those skilled in the art.

[0093] Further examples of transposition systems that can be used in certain embodiments of the compositions and methods provided herein include Staphylococcus aureus Tn552 (Colegio et al., J. Bacteriol., 183:2384-8, 2001; Kirby C et al., Mol. Microbiol., 43:173-86, 2002), Ty1 (Devine and Boeke, Nucleic Acids Res., 22:3765-72, 1994 and International Publication WO 95 / 23875), transposon Tn7 (Craig, NL, Science. 271:1512, 1996; Craig, NL, Review in: Curr Top Microbiol Immunol., 204:27-48, 1996), Tn / O and IS10 (Kleckner N. et al., Curr Top Microbiol Immunol., 204:27-48, 1996). Immunol., 204:49-82, 1996), Mariner transposase (Lampe DJ et al., EMBO J., 15:5470-9, 1996), Tc1 (Plasterk RH, Curr. Topics Microbiol. Immunol., 204:125-43, 1996), P Element (Gloor, GB, Methods Mol. Bio., 260:97-114, 2004), Tn3 (Ichikawa and Ohtsubo, J Biol. Chem. 265:18829-32, 1990), bacterial insertion sequences (Ohtsubo and Sekine, Curr. Top. Microbiol. Immunol. 204:1-26, 1996), retroviruses (Brown et al., Proc Natl Acad Sci USA 86:2525-9, 1989), and yeast retrotransposons (Boeke and Corces, Annu Rev Microbiol. 43:403-34, 1989). Further examples include IS5, Tn10, Tn903, IS911, and engineered versions of transposase family enzymes (Zhang et al. (2009) PLoS Genet. 5:e1000689. Epub 2009 Oct. 16; Wilson C et al. (2007) J. Microbiol. Methods 71:332-5).

[0094] Other examples of integrases that may be used with the methods and compositions provided herein include retroviral integrases, such as integrases from HIV-1, HIV-2, SIV, PFV-1, RSV, and integrase recognition sequences for such retroviral integrases.

[0095] Transposon sequences useful for the methods and compositions described herein are provided in US Patent Application Publication No. 2012 / 0208705, US Patent Application Publication No. 2012 / 0208724 and International Patent Application Publication No. WO2012 / 061832. In some embodiments, the transposon sequence comprises a first transposase recognition site and a second transposase recognition site. In these embodiments that use transposome complexes to introduce index sequence, index sequence can be present between transposase recognition sites or within the transposon.

[0096] Some transposome complexes useful herein include a transposase with two transposon sequences.In some embodiments above, the two transposon sequences are not connected to each other, in other words, the transposon sequences are not adjacent to each other.Examples of such transposomes are known in the art (see, for example, US Patent Application Publication No. 2010 / 0120098).

[0097] Typically, tagmentation is used to produce nucleic acid fragments that contain different nucleotide sequences at each end (e.g., an N5 primer sequence at one end and an N7 primer sequence at the other end). This can be achieved by using two types of transposome complexes, each of which contains a different nucleotide sequence that is part of the incoming strand. In some embodiments, tagmentation as used herein inserts a nucleotide sequence into a nucleic acid fragment. The insertion of the nucleotide sequence results in a nucleic acid fragment that has a hairpin ligation duplex at one end and a transposome complex-inserted nucleotide sequence at the other end. The nucleotide sequence inserted by the transposome complex includes a universal sequence. The universal sequence serves as a complementary sequence for hybridization in the amplification step described herein to introduce another index.

[0098] In some embodiments, the transposome complex comprises a transposon sequence nucleic acid that binds to two transposase subunits to form a "looped complex" or "looped transposome". In one example, the transposome comprises a dimeric transposase and a transposon sequence. The looped complex can ensure that the transposon is inserted into the target DNA without fragmenting the target DNA while maintaining the sequence information of the original target DNA. As is evident from the above, the looped structure may insert a desired nucleic acid sequence, such as an index, into the target nucleic acid while maintaining the physical connectivity of the target nucleic acid. In some embodiments, the transposon sequence of the looped transposome complex may comprise a fragmentation site such that the transposon sequence can be fragmented to create a transposome complex containing two transposon sequences. Such a transposome complex is useful to ensure that adjacent target DNA fragments into which the transposon is inserted receive a combination of barcodes that can be uniquely assembled at a later stage of the assay.

[0099] In one embodiment, fragmentation of the nucleic acid is achieved by using a fragmentation site present in the nucleic acid. Typically, the fragmentation site is introduced into the target nucleic acid by using a transposome complex. In one embodiment, after the nucleic acid is fragmented, the transposase remains attached to the nucleic acid fragments, so that the nucleic acid fragments originating from the same genomic DNA molecule remain physically associated (Adey et al., 2014, Genome Res., 24:2041-2049). For example, a looped transposome complex can include a fragmentation site. The fragmentation site can be used to sever the physical association, but not the informational association, between the index sequences inserted into the target nucleic acid. The cleavage can be by biochemical, chemical, or other means. In some embodiments, the fragmentation site can include nucleotides or nucleotide sequences that can be fragmented by various means. Examples of fragmentation sites include, but are not limited to, restriction endonuclease sites, at least one ribonucleotide cleavable with a ribonuclease, a nucleotide analogue cleavable in the presence of a particular chemical, a diol bond cleavable by treatment with periodate, a disulfide group cleavable with a chemical reducing agent, a cleavable moiety that may undergo photochemical cleavage, and a peptide cleavable by a peptidase enzyme or other suitable means (see, e.g., U.S. Patent Application Publication No. 2012 / 0208705, U.S. Patent Application Publication No. 2012 / 0208724, and International Publication WO 2012 / 061832).

[0100] The transposome complex can optionally include an index sequence, also called a transposase index. The index sequence is present as part of the transposon sequence. In one embodiment, the index sequence can be present on the incoming strand, which is the strand of the transposase recognition site that is transferred to the target nucleic acid.

[0101] Following the tagmentation of nuclei and processing of nucleic acid fragments, a clean-up process can be carried out to increase the purity of the molecules. Any suitable clean-up process can be used, such as electrophoresis, size-exclusion chromatography, etc. In some embodiments, solid-phase reversibly immobilized paramagnetic beads can be used to separate the desired DNA molecules from, for example, unincorporated primers, and select nucleic acids based on size. Solid-phase reversibly immobilized paramagnetic beads are commercially available from Beckman Coulter (Agencourt AMPure XP), Thermofisher (MagJet), Omega Biotek (Mag-Bind), Promega Beads (Promega), and Kapa Biosystems (Kapa Pure Beads).

[0102] Adding unique indexes to parcels The index sequence, also called a tag or barcode, is useful as a marker characteristic of the compartment in which a particular nucleic acid was present. Thus, an index is a nucleic acid sequence tag that is bound to each target nucleic acid present in a particular compartment, the presence of which indicates or is used to identify the compartment in which the isolated nuclei or cell population was present at a particular stage of the method. The addition of indexes to nucleic acid fragments is achieved in a subset of isolated nuclei or cells distributed in different compartments (Figure 1, block 15; Figure 2, blocks 24, 26, and 30; Figure 3, blocks 33 and 37).

[0103] Index sequences can be any suitable number of nucleotides in length, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more. Using 4-nucleotide tags allows for multiplexing of 256 samples on the same array, and using 6-base tags allows for 4096 samples to be processed on the same array.

[0104] In one embodiment, the addition of the index is achieved during processing of the nucleic acid into nucleic acid fragments. For example, a transposome complex containing an index can be used. In some embodiments, the index is added after processing produces nucleic acid fragments that contain nucleotide sequences at one or both ends. In other embodiments, no processing is required to add the index. For example, an index can be added directly to an RNA nucleic acid without fragmenting the RNA nucleic acid. Thus, the term "nucleic acid fragment" encompasses nucleic acids resulting from processing and RNA nucleic acids, as well as nucleic acids derived from these nucleic acids.

[0105] Methods for adding an index include, but are not limited to, ligation, extension (including extension using reverse transcriptase), hybridization, adsorption, specific or non-specific interaction of primers, amplification, or translocation. The nucleotide sequence added to one or both ends of the nucleic acid fragment can also include one or more universal sequences and / or unique molecular identifiers. The universal sequence can be used as a "landing pad" in a subsequent step of annealing a nucleotide sequence that can be used as a primer for adding another nucleotide sequence, such as another index and / or another universal sequence, to the nucleic acid fragment. Thus, incorporation of an index sequence can be a process that includes one, two, or more steps, using essentially any combination of ligation, extension, hybridization, adsorption, specific or non-specific interaction of primers, amplification, or translocation.

[0106] For example, in embodiments involving the use of nucleic acid fragments derived from mRNA, the index can be added to the mRNA in one or two steps using a variety of methods. For example, the index can be added using the type of methods used to produce cDNA. A primer containing a poly-T sequence at the 3' end can be annealed to the mRNA molecule and extended using reverse transcriptase. When isolated nuclei or cells are exposed to these components under conditions suitable for reverse transcription, the index is added in one step, resulting in a population of indexed nuclei or cells, each of which contains an indexed nucleic acid fragment. Alternatively, the primer with the poly-T sequence contains a universal sequence instead of an index, and the index is added by a subsequent step of ligation, primer extension, amplification, hybridization, or a combination thereof. In some embodiments, the barcode is added without the use of a universal sequence. The indexed nucleic acid fragment can, and usually does, contain an index sequence that indicates a particular section on the synthesized strand.

[0107] In embodiments involving the use of nucleic acid fragments derived from non-coding RNA, various methods can be used to add an index to the non-coding RNA in one or two steps. For example, an index can be added using a first primer that includes a random sequence and a template switch primer, where both primers can include an index. A reverse transcriptase with terminal transferase activity can be used to add non-template nucleotides to the 3' end of the synthetic strand, and the template switch primer includes nucleotides that anneal with the non-template nucleotides added by the reverse transcriptase. One example of a useful reverse transcriptase is Moloney Murine Leukemia Virus Reverse Transcriptase. In certain embodiments, SMARTer RT-PCR, available from Takara Bio USA, Inc. (catalog number 634926), can be used. TMThe reagent is used to use template switching to add an index to non-coding RNA and optionally mRNA. Alternatively, the first primer and / or template switch primer can contain a universal sequence instead of an index, and the index is added by a subsequent step of ligation, primer extension, amplification, hybridization, or a combination thereof. The indexed nucleic acid fragment can, and usually does, contain an index sequence that indicates a specific section on the synthetic strand. Other embodiments include 5' or 3' profiling of RNA or full-length RNA profiling.

[0108] In another embodiment, specific mRNAs and / or non-coding RNAs can be targeted for amplification. Targeting allows for the creation of sequencing libraries enriched for sequences that are more likely to yield useful information, significantly reducing sequencing depth and associated costs, and improving the ability to detect subtle differences between cells. RNA molecules, including one or more mRNAs and / or one or more non-coding RNAs, can be selected as likely to generate useful information, and primers can be used to selectively anneal to a given RNA nucleic acid and amplify a subpopulation of the total RNA molecules present in a cell or nucleus. Those skilled in the art will recognize that the appropriate RNA molecules to select will vary from experiment to experiment. For example, in the evaluation of non-coding perturbations, only coding regions in cis to the disrupted regulatory element can be tested for changes in expression. This method may reduce the background of ribosomal reads over the use of random hexamer or poly-T primers. This method also allows for the targeting of exons due to splice junctions and alternative transcription start site events, providing isoform information not easily detected by conventional Sci methods.

[0109] Targeted amplification of RNA molecules can be carried out at several stages during library construction.In one embodiment, targeted amplification of multiple targets is carried out during reverse transcription of RNA molecules.Experiments can include multiple different primers that target different RNA molecules.In one embodiment, multiple primers that target different regions of the same RNA molecule can be used.The use of multiple primers that are directed to different regions of the same RNA molecule allows multiple opportunities for the RNA molecule to be reverse transcribed into cDNA, increasing the possibility of detection of the RNA molecule.

[0110] In one embodiment, the primers used for targeted amplification do not contain index.If no index is added during the amplification reaction, there is no need to divide cells or nuclei into different compartments, and amplification can be performed as a single reaction with all the RNA molecules and all the primers present.In the embodiment where index is added during the amplification reaction, the division of cells or nuclei is useful, and amplification can be performed as a single reaction in each compartment with all the RNA molecules and all the primers present, but each primer in a compartment has a unique index for the same compartment.

[0111] In one embodiment, the design of primers for multiplex target capture can include one or more of the following considerations. After RNA is selected for targeted amplification, the sequence of the RNA can be collected and all possible reverse transcriptase primers (candidate primers) can be determined. The length of any primer must be long enough to function in reverse transcription reaction, and can be, for example, 20 to 30 nucleotides long.

[0112] Candidate primers can be filtered by a variety of criteria, including but not limited to GC content, position of GC bases in the primer, potential for off-site targeting, and mappability. A useful GC content is 40-60%, corresponding to a melting temperature of approximately 55-70°C. It is preferable to have two guanine or cytosine bases in the last five nucleotides of the 3' end of the primer to increase the likelihood that the annealed primer will be a good substrate for extension by reverse transcriptase.

[0113] Regarding the possibility of off-target priming, we found that while the target RNA was highly enriched, the majority of reads still originated from other RNAs that were abundant in the cell. Most of these off-target priming events were the result of approximately 5-8 base pairs of complementarity between the 3' end of the primer and the off-target RNA. We found it useful to consider the abundance of the final hexamer of the candidate primer in total cellular RNA. Useful primers were identified that contained a final hexamer that was either (i) not present in ribosomal RNA or (ii) represented at low levels in total cellular RNA.

[0114] Examples of hexamers that are not present in ribosomal RNA have been reported ("Not So Random" or NSR hexamers in Armor et al., 2009, Nature Methods, 6(9):647-49). Primers with this characteristic have been found to be much less likely to have off-target priming in ribosomal RNA. One method for determining whether hexamers are represented at low levels in total cellular RNA can include identifying the abundance of each hexamer in RNA molecules in a cell, for example, all nascent transcripts, including ribosomal transcripts, in the cell type analyzed according to the methods described herein. The use of candidate primers with low levels of abundance, for example, in the lowest quartile of abundance, can reduce off-site targeting.

[0115] Candidate primers can also be evaluated by their mappability. For example, a bowtie-type algorithm can be used to align each candidate to the target, allowing for three mismatches. This step helps ensure that each primer has a unique target site in the genome.

[0116] In some embodiments, the amplification of multiple targets in the same reaction, also called multiple target capture, controlling the annealing temperature of the reverse transcriptase primer helps maintain specific reverse transcription and amplification of the desired target RNA. For example, a typical reverse transcription protocol denatures the mixture of RNA and reverse transcription primer and cools it to 4°C to allow annealing. A lower annealing temperature is too permissive and causes undesirable off-target annealing events. A high temperature is maintained throughout the process of reverse transcription to increase the likelihood that the only annealing event that extends is the event in which the entire reverse transcription primer of the target anneals to the correct target. In one embodiment, the components at 65°C (e.g., fixed cells, reverse transcription primer pool, and dNTP mixture) are annealed at 53°C and added to the annealing reaction pre-equilibrated at 53°C reverse transcriptase / buffer mixture and extended at 53°C for 20 minutes. Thus, the possibility of reverse transcription primer annealing at low temperature during the denaturation and extension steps is reduced. Those skilled in the art will recognize that some modifications can be made, for example, changing the temperature or time, without reducing the specificity of the reverse transcription.

[0117] Other methods can also be used to add an index to a nucleic acid fragment, and the method of adding an index is not intended to be limited. For example, in one embodiment, the incorporation of an index sequence includes ligating a primer to one or both ends of a nucleic acid fragment. Ligation of a ligation primer can be facilitated by the presence of a universal sequence at the end of a nucleic acid fragment. One example of a primer is a hairpin ligation duplex. The ligation duplex can be ligated to one or preferably both ends of a nucleic acid fragment.

[0118] In another embodiment, the incorporation of the index sequence includes the use of a single-stranded nucleic acid fragment and the synthesis of a second DNA strand. In one embodiment, the second DNA strand is produced using a primer that contains a sequence complementary to the nucleotides present at the end of the single-stranded nucleic acid fragment.

[0119] In another embodiment, incorporation of indexes is performed by one, two, three or more rounds of split and pool barcoding, resulting in single, double, triple or multiplex (e.g., four or more) indexed single-cell libraries.

[0120] In another embodiment, the incorporation of indexes and amplification mediators (e.g., universal sequences) is beneficial and allows for the preparation of targeted single-cell sequencing libraries and / or targeted single-cell sequencing libraries.

[0121] Addition of universal sequences for immobilization In one embodiment, the addition of nucleotides during the processing and / or indexing step adds universal sequences useful for immobilizing and sequencing the fragments. In another embodiment, the indexed nucleic acid fragments can be further processed to add universal sequences useful for immobilizing and sequencing the nucleic acid fragments. Those skilled in the art will recognize that in embodiments where the compartments are droplets, the sequence for immobilizing the nucleic acid fragments is optional. In one embodiment, the incorporation of universal sequences useful for immobilizing and sequencing the fragments includes ligating identical universal adaptors (also called "mismatch adaptors", the general characteristics of which are described in Gormley et al., U.S. Pat. No. 7,741,463 and Bignell et al., U.S. Pat. No. 8,053,192) to the 5' and 3' ends of the indexed nucleic acid fragments. In one embodiment, the universal adaptors include all sequences required for sequencing, including sequences for immobilizing the indexed nucleic acid fragments on the array.

[0122] In one embodiment, blunt-end ligation can be used. In another embodiment, the nucleic acid fragments are prepared with a single overhanging nucleotide, for example, by the activity of a specific type of DNA polymerase, such as Taq polymerase or Klenow exo minus polymerase, which has a non-template-dependent terminal transferase activity that adds one or more deoxynucleotides, such as deoxyadenosine (A), to the 3' end of the indexed nucleic acid fragment. In some cases, the overhanging nucleotide is multiple bases. Such enzymes can be used to add a single nucleotide "A" to the blunt 3' end of each strand of the nucleic acid fragment. Thus, by reaction with Taq polymerase or Klenow exo minus polymerase, an "A" can be added to the 3' end of each strand of the double-stranded target fragment, but the additional sequence added to each end of the nucleic acid fragment can include a compatible "T" overhang present at the 3' end of each region of the double-stranded nucleic acid to be added. This end modification also prevents self-ligation of the nucleic acid, such that there is a bias in the formation of indexed nucleic acid fragments flanked by sequences added in this manner.

[0123] In another embodiment, if the universal adaptors ligated to the indexed nucleic acid fragments do not contain all the sequences required for sequencing, an amplification step such as PCR can be used to further modify the universal adaptors present in each indexed nucleic acid fragment prior to immobilization and sequencing. For example, an initial primer extension reaction can be performed using a universal anchor sequence that is complementary to the universal sequence present in the indexed nucleic acid fragments, forming extension products that are complementary to both strands of each indexed nucleic acid fragment. Typically, PCR adds a universal sequence, such as a universal capture sequence.

[0124] The final index fragment will contain a universal capture sequence and an anchor sequence, either by a single step of adding universal adaptors followed by ligation or hybridization of universal adaptors that contain all the sequences required for sequencing, or by a two step method of ligating universal adaptors and then amplifying to further modify the universal adaptors. By adding universal adaptors to each end, a plurality or library of indexed nucleic acid fragments is generated.

[0125] The resulting indexed fragments collectively provide a library of nucleic acids that can be immobilized and then sequenced. The term library, also referred to herein as a sequencing library, refers to a collection of nucleic acid fragments from a single nucleus or cell that contain known universal sequences at the 3' and 5' ends. The library contains nucleic acids from the entire transcriptome, from newly synthesized RNA molecules, or a combination of both, and can be used to sequence the entire transcriptome, the transcriptome of newly synthesized RNA, or a combination of both.

[0126] The indexed nucleic acid fragments can be subjected to conditions that select for a predetermined size range, such as 150-400 nucleotides in length, such as 150-300 nucleotides. The resulting indexed nucleic acid fragments can be pooled and optionally subjected to a clean-up process to increase the purity of the DNA molecules by removing at least a portion of the unincorporated universal adaptors or primers. Any suitable clean-up process, such as electrophoresis, size-exclusion chromatography, etc., may be used. In some embodiments, solid-phase reversibly immobilized paramagnetic beads may be used to separate the desired DNA molecules from unattached universal adaptors or primers and select nucleic acids based on size. Solid-phase reversibly immobilized paramagnetic beads are commercially available from Beckman Coulter (Agencourt AMPure XP), Thermofisher (MagJet), Omega Biotek (Mag-Bind), Promega Beads (Promega), and Kapa Biosystems (Kapa Pure Beads).

[0127] A non-limiting exemplary embodiment of the present disclosure is shown in Figure 1. In this embodiment, the method includes providing a plurality of cells (Figure 1, block 10). The method further includes distributing a subset of cells into a plurality of compartments (Figure 1, block 11), and exposing the cells to a predetermined condition (Figure 1, block 12). The predetermined condition can, and usually does, vary between different compartments. For example, different compartments can include different agent doses, different perturbations, different exposure periods, different cell types, etc. The newly synthesized RNA is then labeled (Figure 1, block 13). Labeling can be performed in the cell, or the nucleus can be isolated from the cell and labeling can be performed in the nucleus. In some embodiments, the cellular RNA is processed to obtain fragments (Figure 1, block 14). The RNA present in the cell or nucleus is then indexed (Figure 1, block 15). Various embodiments for indexing the RNA are possible. For example, in one embodiment, all mRNA present in the cell is indexed by using a primer that includes a poly-T region. In another embodiment, a specific RNA nucleic acid can be indexed.

[0128] Another non-limiting exemplary embodiment of the present disclosure is shown in Figure 2 and described in Example 1. In this embodiment, the method includes providing isolated nuclei from a plurality of cells (Figure 2, block 22). The method further includes distributing a subset of the isolated nuclei into a first plurality of compartments (Figure 2, block 23). The number of compartments in the first distribution step (Figure 2, block 23) can vary depending on the format used. For example, the number of compartments can be 2 compartments to 96 compartments (if a 96-well plate is used), 2 compartments to 384 compartments (if a 384-well plate is used), or 2 compartments to 1536 compartments (if a 1536-well plate is used). Alternatively, other compartments, such as droplets, can be used.

[0129] The method also includes generating indexed nuclei (FIG. 2, block 24). In one embodiment, generating indexed nuclei includes the use of reverse transcriptase with an oligo-dT primer to add an index, a random nucleotide sequence, and a universal sequence. The index of each compartment is unique, e.g., each index is compartment-specific. The random sequence is used as a unique molecular identifier (UMI) to label unique nucleic acid fragments. The random sequence can also be used to facilitate removal of duplicates in downstream processing. The universal sequence serves as a complementary sequence for hybridization in the ligation step described herein. In another embodiment, generating indexed nuclei includes the use of reverse transcriptase with a specific primer that targets a given RNA molecule. Reverse transcription can result in the addition of an index, a random nucleotide sequence, and a universal sequence to the target RNA molecule. Exposing the nuclei to these components under conditions suitable for reverse transcription results in a population of indexed nuclei, each nuclei containing an indexed nucleic acid fragment. The indexed nucleic acid fragments can, and usually do, contain an index sequence that indicates a particular compartment on the synthetic strand. An example of an indexed nucleic acid fragment is shown in FIG. 1A of Example 1 (see "Indexed Reverse Transcription").

[0130] The indexed nuclei from the multiple compartments can be combined (Figure 2, block 25). A subset of these combined indexed nuclei, referred to herein as pooled indexed nuclei, are then distributed to a second multiple compartments (Figure 2, block 25). Following distribution to the subsets of nuclei, the indexed nucleic acid fragments in each compartment are incorporated with a second index sequence to generate dual-indexed fragments. This allows for further indexing of the indexed nucleic acid fragments (Figure 2, block 26).

[0131] In this exemplary embodiment, the incorporation of the second index sequence comprises ligating a hairpin ligation duplex to the indexed nucleic acid fragment in each section. When using a hairpin ligation duplex to introduce a universal sequence, an index, or a combination thereof to the end of a target nucleic acid fragment, typically, one end of the duplex is used as a primer for subsequent amplification. In contrast, the hairpin ligation duplex used in this embodiment does not act as a primer. The advantage of using the hairpin ligation duplex described herein is the reduction of self-self ligation observed in many hairpin ligation duplexes reported in the art. In one embodiment, the ligation duplex comprises five elements: 1) a universal sequence that is the complement of the universal sequence present on the oligo dT primer, 2) a second index, 3) ideoxy U, 4) a nucleotide sequence that can form a hairpin, and 5) the reverse complement of the second index. The second index sequence is unique to each compartment into which the distributed indexed nuclei are placed after the first index is added by reverse transcription (Figure 2, block 25). An example of a dual-indexed nucleic acid fragment is shown in Figure 1A of Example 1 (see "Indexed Hairpin Ligation").

[0132] Removal of ideoxy U present in the hairpin region of the hairpin ligation duplex incorporated into the nucleic acid fragment can be performed before, during, or after cleanup. Removal of uracil residues can be accomplished by any available method, in the Cohn embodiment, Uracil-Specific Excision Reagent (USER) available from NEB is used.

[0133] A subset of these combined dual-indexed nuclei, referred to herein as pooled dual-indexed nuclei, are then distributed into a third plurality of compartments (FIG. 2, block 27). In one embodiment, between 100 and 30,000 nuclei are distributed into each well. In one embodiment, the number of nuclei in a well is at least 100, at least 500, at least 1,000, or at least 5,000. In one embodiment, the number of nuclei in a well is 30,000 or less, 25,000 or less, 20,000 or less, or 15,000 or less. In one embodiment, the number of nuclei present in a subset can be 100-1,000, 1,000-10,000, 10,000-20,000, or 20,000-30,000. In one embodiment, 2,500 nuclei are distributed into each well. In one embodiment, the number of nuclei present in each subset is approximately equal.

[0134] Following distribution to a subset of dual-indexed nuclei, a second DNA strand is synthesized (Figure 2, block 28). The nucleic acids in the nuclei are processed by subjecting them to tagmentation (Figure 2, block 29). Each compartment containing a dual-indexed nucleus contains a transposome complex. In this embodiment, tagmentation is used to produce nucleic acid fragments that contain different nucleotide sequences at each end (e.g., an N5 primer sequence at one end and an N7 primer at the other end).

[0135] Following tagmentation of the nuclei, a third index sequence is incorporated into the dual-indexed nucleic acid fragments in each compartment to generate triple-indexed fragments, where the third index sequence in each compartment is different from the first and second index sequences in that compartment. This results in further indexing of the indexed nucleic acid fragments prior to immobilization and sequencing (FIG. 2, block 30; see also FIG. 1A ("USER Processing, Indexed PCR") in the Examples). In one embodiment, the universal sequences present at the ends of the dual-indexed nucleic acid fragments (e.g., a hairpin ligation double-stranded insertion nucleotide sequence at one end and a transposome complex insertion nucleotide sequence at the other end) can be used for primer binding and extension in an amplification reaction. Typically, two different primers are used. One primer hybridizes to the universal sequence at the 3' end of one strand of the dual-indexed nucleic acid fragment, and a second primer hybridizes to the universal sequence at the 3' end of the other strand of the dual-indexed nucleic acid fragment. Thus, the anchor sequence present on each primer (e.g., the site to which a universal primer, such as a sequencing primer for lead 1 or lead 2, anneals for sequencing) can be different. Each suitable primer can include an additional universal sequence, such as a universal capture sequence (e.g., the site to which a capture oligonucleotide hybridizes, allowing the capture oligonucleotide to be immobilized to the surface of a solid substrate). Since each primer contains an index, this step results in the addition of another index sequence, one at each end of the nucleic acid fragment, thereby forming triple-indexed fragments. In one embodiment, a third index can be added using indexed primers, such as indexed P5 primer and indexed P7 primer. The triple-indexed fragments can be pooled and subjected to a clean-up step as described herein.

[0136] Multiple triple-indexed fragments can be prepared for sequencing: The triple-indexed fragments are pooled and subjected to cleanup to enrich them, typically by immobilization and / or amplification, prior to sequencing (Figure 2, block 31).

[0137] Another non-limiting exemplary embodiment of the present disclosure is shown in FIG. 3 and described in Example 4. In this embodiment, the method includes providing isolated nuclei or cells (FIG. 3, block 30). The nuclei or cells can be exposed to reverse transcriptase and specific primers to target and enrich for a given RNA molecule (FIG. 3, block 31). Exposing the nuclei or cells to these components under conditions suitable for reverse transcription results in a population of nuclei or cells, each nucleus containing a nucleic acid fragment enriched for a sequence present in the given RNA molecule. The method further includes distributing the subset of nuclei or cells into a first plurality of compartments (FIG. 3, block 32). The number of compartments in the first distribution step (FIG. 3, block 32) can vary depending on the format used. For example, the number of compartments can be 2 compartments to 96 compartments (if a 96-well plate is used), 2 compartments to 384 compartments (if a 384-well plate is used), or 2 compartments to 1536 compartments (if a 1536-well plate is used). Alternatively, other compartments, such as droplets, can be used.

[0138] The method also includes creating indexed nuclei or cells by incorporating index sequences into the nucleic acid fragments in each compartment to generate indexed fragments (Figure 3, block 33).

[0139] In one embodiment, incorporation of the index sequence comprises ligating a hairpin ligation duplex to the indexed nucleic acid fragment in each compartment. Nuclei or cells containing the indexed fragments are pooled, and then a subset of these combined indexed nuclei or cells are distributed into a second plurality of compartments (Figure 3, block 34).

[0140] After the indexed nuclei or cells are distributed into subsets, synthesis of the second DNA strand can be performed (Figure 3, block 35). The nucleic acids in the nuclei or cells are processed by tagmenting them (Figure 3, block 36). Each compartment containing an indexed nucleus contains a transposome complex. In this embodiment, tagmentation is used to produce nucleic acid fragments that contain different nucleotide sequences at each end (e.g., an N5 primer sequence at one end and an N7 primer at the other end).

[0141] Following tagmentation of the nuclei, the indexed nucleic acid fragments in each compartment can be incorporated with a second index sequence to generate dual-indexed fragments, where the second index sequence in each compartment is different from the first index sequence in that compartment, resulting in further indexing of the indexed nucleic acid fragments prior to immobilization and sequencing (Figure 3, block 37).

[0142] Multiple dual-indexed fragments can be prepared for sequencing, provided that the sequencing data is enriched for sequences present in a given RNA molecule. The dual-indexed fragments are pooled and subjected to cleanup, typically by immobilization and / or amplification to enrich them prior to sequencing (Figure 3, block 38).

[0143] Preparation of immobilized samples for sequencing Methods for attaching indexed fragments from one or more sources to a substrate are known in the art. In one embodiment, indexed fragments can be enriched using multiple capture oligonucleotides with specificity for the indexed fragments, and the capture oligonucleotides can be immobilized on the surface of a solid substrate. For example, the capture oligonucleotides can include a first member of a universal binding pair, and a second member of the binding pair is immobilized on the surface of a solid substrate. Similarly, methods for amplifying immobilized dual-indexed fragments include, but are not limited to, bridge amplification and kinetic exclusion. Methods for immobilization and amplification prior to sequencing are described, for example, in Bignell et al. (US Pat. No. 8,053,192), Gunderson et al. (WO 2016 / 130704), Shen et al. (US Pat. No. 8,895,249), and Pipenburg et al. (US Pat. No. 9,309,502).

[0144] The pooled samples can be immobilized in preparation for sequencing. Sequencing can be performed as an array of single molecules or can be amplified prior to sequencing. Amplification can be performed using one or more immobilized primers. The immobilized primer (or immobilized multiple primers) can be, for example, a lawn on a plane, or a lawn on a pool of beads. The pool of beads can be isolated in an emulsion with a single bead in each "compartment" of the emulsion. At a concentration of only one template per "compartment", only one template is amplified on each bead.

[0145] The term "solid-phase amplification" as used herein refers to any nucleic acid amplification reaction carried out on or with a solid support, such that all or part of the amplification product is immobilized on the solid support as it is formed. In particular, this term includes solid-phase polymerase chain reaction (solid-phase PCR) and solid-phase isothermal amplification, which are reactions similar to standard liquid-phase amplification, except that one or both of the forward and reverse amplification primers are immobilized on a solid support. Solid-phase PCR includes systems such as emulsions, where one primer is immobilized on a bead and the other is in free solution, and colony formation in solid-phase gel matrices, where one primer is immobilized on a surface and one primer is in free solution.

[0146] In some embodiments, the solid support comprises a patterned surface. "Patterned surface" refers to an arrangement of different regions in or on an exposed layer of a solid support. For example, one or more regions can be features in which one or more amplification primers are present. The features can be separated by gap regions in which no amplification primers are present. In some embodiments, the pattern can be an x-y format of features in rows and columns. In some embodiments, the pattern can be a repeating arrangement of features and / or gap regions. In some embodiments, the pattern can be a random arrangement of features and / or gap regions. Exemplary patterned surfaces that can be used in the methods and compositions described herein are described in U.S. Patent Nos. 5,047,029, 8,778,848, 8,778,849 and 9,079,148, and U.S. Patent Application Publication No. 2014 / 0243224.

[0147] In some embodiments, the solid support comprises an array of wells or depressions on its surface. This may be manufactured using a variety of techniques, including but not limited to photolithography, stamping techniques, molding techniques, and microetching techniques, as is commonly known in the art. As will be understood by those skilled in the art, the technique used will vary depending on the composition and shape of the array substrate.

[0148] The features in the patterned surface can be wells (e.g., microwells or nanowells) in an array of wells on glass, silicon, plastic or other suitable solid support with a patterned covalently bonded gel such as poly(N-(5-azidoacetamidylpentyl)acrylamide-co-acrylamide) (PAZAM, see, e.g., U.S. Patent Application Publication No. 2013 / 184796, WO 2016 / 066586, and WO 2015 / 002813). This process creates a gel pad used for sequencing that can be stable throughout the sequencing run process for many cycles. Covalent attachment of the polymer to the wells is useful to maintain the gel in the structured features throughout the life of the structured substrate during various applications. However, in many embodiments, the gel does not need to be covalently bonded to the wells. For example, in some conditions, silane-free acrylamide (SFA, see, e.g., U.S. Patent Application Publication No. 8,563,477) that is not covalently bonded to any part of the structured substrate can be used as the gel material.

[0149] In certain embodiments, a structured substrate can be made by patterning a solid support material with wells (e.g., microwells or nanowells), coating the patterned support with a gel material (e.g., PAZAM, SFA, or a chemically modified variant thereof, e.g., an azido-form of SFA (azido-SFA)), and polishing the gel-coated support, e.g., by chemical or mechanical polishing, so as to retain the gel in the wells but remove or inactivate substantially all of the gel from the interstitial regions of the surface of the structured substrate between the wells. Primer nucleic acids can then be attached to the gel material. A solution of indexed fragments can then be contacted with the polished substrate such that individual indexed fragments seed individual wells through interaction with primers attached to the gel material; however, because the gel material is absent or inactive, target nucleic acids do not occupy the interstitial regions. The absence or inactivity of gel in the interstitial regions prevents outward migration of growing nucleic acid colonies, so that amplification of the indexed fragments is restricted to the wells. This process is scalable and can be conveniently manufactured utilizing conventional micro- or nano-fabrication techniques.

[0150] Although the present disclosure encompasses "solid-phase" amplification methods in which only one amplification primer is immobilized (the other primer is usually present in a free soluble state), in one embodiment, it is preferred that both immobilized forward and reverse primers are provided on the solid support. In practice, since the amplification process requires an excess of primers to maintain amplification, there will be "multiple" identical forward primers and / or "multiple" identical reverse primers immobilized on the solid support. When referring to forward and reverse primers in this specification, they should be appropriately interpreted as including "multiple" such primers, unless the context indicates otherwise.

[0151] As those skilled in the art understand, a given amplification reaction requires at least one type of forward primer and at least one type of reverse primer, both specific to the template to be amplified.However, in certain embodiments, the forward primer and reverse primer may contain the same sequence of template-specific portions, and may have completely identical nucleotide sequences and structures (including any non-nucleotide modifications).In other words, it is possible to carry out solid-phase amplification using only one type of primer, and such single primer methods are within the scope of the present disclosure.Other embodiments may use forward and reverse primers that contain the same template-specific sequence, but differ in some other structural features.For example, one type of primer may contain non-nucleotide modifications that are not present in the other.

[0152] In all embodiments of the present disclosure, primers for solid-phase amplification are preferably immobilized by a single-point covalent attachment to the solid support at or near the 5' end of the primer, leaving the template-specific portion of the primer free to anneal with its cognate template and the 3' hydroxyl group free for primer extension. Any suitable covalent attachment means known in the art may be used for this purpose. The attachment chemistry selected will depend on the nature of the solid support and any derivatization or functionalization applied to it. The primer itself may contain a moiety, which may be a non-nucleotidic chemical modification, to facilitate attachment. In certain embodiments, the primer may contain a sulfur-containing nucleophilic group at the 5' end, such as a phosphorothioate or thiophosphate. In the case of a solid-supported polyacrylamide hydrogel, this nucleophilic group will bind to a bromoacetamide group present in the hydrogel. A more specific means of attaching primers and templates to a solid support is by 5' phosphorothioate linkages to a hydrogel composed of polymerized acrylamide and N-(5-bromoacetamidylpentyl)acrylamide (BRAPA), as described in WO 05 / 065814.

[0153] Certain embodiments of the present disclosure may utilize solid supports that include an inert substrate or matrix (e.g., glass slides, polymeric beads, etc.) that have been "functionalized" by application of a layer or coating of an intermediate material that includes reactive groups that allow for covalent attachment to a biomolecule, such as a polynucleotide. Examples of such supports include, but are not limited to, polyacrylamide hydrogels supported on an inert substrate such as glass. In such embodiments, the biomolecule (e.g., polynucleotide) may be covalently attached directly to the intermediate material (e.g., hydrogel), although the intermediate material itself may be non-covalently attached to the substrate or matrix (e.g., glass substrate). The term "covalent attachment to a solid support" shall be interpreted accordingly to encompass this type of arrangement.

[0154] Pooled samples may be amplified on beads, each bead containing a forward amplification primer and a reverse amplification primer. In certain embodiments, the library of indexed fragments is used to prepare clustered arrays of nucleic acid colonies, similar to those described in US Patent Application Publication No. 2005 / 0100900, US Patent No. 7,115,400, WO 00 / 18957 and WO 98 / 44151, by solid-phase amplification, more specifically solid-phase isothermal amplification. The terms "cluster" and "colony" are used interchangeably herein to refer to distinct sites on a solid support that contain a plurality of identical immobilized nucleic acid strands and a plurality of identical immobilized complementary nucleic acid strands. The term "clustered array" refers to an array formed from such clusters or colonies. In this context, the term "array" should not be understood as requiring an ordered arrangement of clusters.

[0155] The terms "solid phase" or "surface" are used to refer to a planar array in which primers are attached to a flat surface, such as a glass, silica or plastic microscope slide or similar flow cell device; to beads, in which one or two primers are attached to the beads and the beads are amplified; or to an array of beads on a surface after the beads have been amplified.

[0156] Clustered arrays can be prepared using either the process of temperature cycling described in WO 98 / 44151, or by keeping the temperature constant and using reagent changes to perform cycles of extension and denaturation. The above isothermal amplification methods are described in WO 02 / 46456 and US 2008 / 0009420. Lower temperatures are useful in isothermal processes, which are particularly preferred in some embodiments.

[0157] It will be understood that any of the amplification methodologies described herein or generally known in the art may be used with universal or target-specific primers to amplify the immobilized DNA fragments. Methods suitable for amplification include, but are not limited to, polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription amplification (TMA) and nucleic acid sequence-based amplification (NASBA), as described in U.S. Pat. No. 8,003,354. The above amplification methods may be used to amplify one or more nucleic acids of interest. For example, PCR, including multiplex PCR, SDA, TMA, NASBA, etc. may be used to amplify the immobilized DNA fragments. In some embodiments, a primer specifically directed to the polynucleotide of interest is included in the amplification reaction.

[0158] Other methods suitable for amplifying polynucleotides may include oligonucleotide extension and ligation, rolling circle amplification (RCA) (Lizardi et al., Nat. Genet. 19:225-232 (1998)) and oligonucleotide ligation assay (OLA) (see, inclusive, U.S. Pat. Nos. 7,582,420, 5,185,243, 5,679,524 and 5,573,907, European Patent Nos. 0 320 308 B1, 0 336 731 B1, 0 439 182 B1, WO 90 / 01069, WO 89 / 12696 and WO 89 / 09835). It will be understood that these amplification methodologies may be designed to amplify immobilized DNA fragments. For example, in some embodiments, the amplification method may include a ligation probe amplification reaction or an oligonucleotide ligation assay (OLA) reaction that includes a primer specifically directed to the nucleic acid of interest. In some embodiments, the amplification method may include a primer extension-ligation reaction that includes a primer specifically directed to the nucleic acid of interest. As a non-limiting example of primer extension and ligation primers that may be specifically designed to amplify the nucleic acid of interest, the amplification may include primers used in the GoldenGate assay (Illumina, Inc., San Diego, CA), which is more specifically illustrated in U.S. Patent Nos. 7,582,420 and 7,611,869.

[0159] DNA nanoballs can also be used in combination with the methods and compositions described herein.The method of making and using DNA nanoballs for genome sequencing can be found in, for example, U.S. patents and publications, U.S. Patent No. 7,910,354, U.S. Patent Application Publication No. 2009 / 0264299, U.S. Patent Application Publication No. 2009 / 0011943, U.S. Patent Application Publication No. 2009 / 0005252, U.S. Patent Application Publication No. 2009 / 0155781, U.S. Patent Application Publication No. 2009 / 0118488, and is also described, for example, in Drmanac et al., 2010, Science 327(5961):78-81. Briefly, genomic library DNA fragmentation adapters are ligated to the fragments, and then the adapter-ligated fragments are circularized by ligation with circle ligase and rolling circle amplification is performed (Lizardi et al., 1998, Nat. Genet. 19:225-232 and US Patent Application Publication No. 2007 / 0099208 A1). The extended concatemeric structure of the amplicons promotes coiling, thereby creating compact DNA nanoballs. The DNA nanoballs are captured on a substrate, and preferably regular or patterned arrays can be created such that the distance between each nanoball is maintained, thereby allowing sequencing of individual DNA nanoballs. In some embodiments, such as those used by Complete Genomics (Mountain View, CA), successive rounds of adapter ligation, amplification, and digestion are performed prior to circularization to produce head-to-tail constructs with several genomic DNA fragments separated by adapter sequences.

[0160] Exemplary isothermal amplification methods that may be used in the methods of the present disclosure include, but are not limited to, multiple displacement amplification (MDA), as exemplified by, for example, Dean et al., Proc.Natl.Acad.Sci.USA 99:5261-66 (2002), or isothermal strand displacement nucleic acid amplification, as exemplified by, for example, U.S. Patent No. 6,214,587.Other non-PCR-based methods that may be used in the present disclosure include, for example, strand displacement amplification (SDA), as described in, for example, Walker et al., Molecular Methods for Virus Detection, Academic Press, Inc., 1995; U.S. Patent Nos. 5,455,166 and 5,130,238, and Walker et al., Nucl.Acids Res.20:1691-96 (1992), or hyperbranched strand displacement amplification, as exemplified by, for example, Lage et al., Genome Res.13:294-307 (2003). Isothermal amplification methods may be used, for example, with strand-displacing Phi 29 polymerase or large fragments of Bst DNA polymerase, 5'->3' exo-, for random-primed amplification of genomic DNA. The use of these polymerases takes advantage of their high processivity and strand-displacing activity. High processivity allows the polymerases to produce fragments of 10-20 kb in length. As noted above, polymerases with lower processivity and strand-displacing activity, such as Klenow polymerase, may be used to produce smaller fragments under isothermal conditions. Further description of the amplification reaction, conditions and components are described in detail in the disclosure of U.S. Pat. No. 7,670,810.

[0161] Another polynucleotide amplification method that is useful in the present disclosure is tagged PCR, which uses a population of two-domain primers with a constant 5' region followed by a random 3' region, as described, for example, in Grothues et al., Nucleic Acids Res. 21(5):1321-2 (1993). A first round of amplification is carried out to allow multiple initiations on heat-denatured DNA based on individual hybridization from the randomly synthesized 3' region. Due to the nature of the 3' region, the initiation sites are believed to be random throughout the genome. Unbound primers can then be removed, and further replication can be carried out using primers complementary to the constant 5' region.

[0162] In some embodiments, isothermal amplification can be performed using kinetic exclusion amplification (KEA), also known as exclusion amplification (ExAmp). The nucleic acid library of the present disclosure can be made using a method that includes reacting amplification reagents to generate a plurality of amplification sites, each of which contains a substantial clonal population of amplicons from an individual target nucleic acid seeded at the amplification site. In some embodiments, the amplification reaction proceeds until a sufficient number of amplicons are generated to fill the capacity of each amplification site. Thus, filling already seeded sites to capacity inhibits target nucleic acids from landing and amplifying at the site, thereby generating a clonal population of amplicons at the site. In some embodiments, apparent clonality can be achieved even if the amplification site is not filled to capacity before a second target nucleic acid reaches the site. Under certain conditions, amplification of a first target nucleic acid can proceed to a point where a sufficient number of copies are made to effectively outcompete or overwhelm the production of copies from a second target nucleic acid transported to the site. For example, in embodiments using a bridge amplification process with circular features smaller than 500 nm in diameter, it was determined that after 14 cycles of exponential amplification for a first target nucleic acid, contamination from a second target nucleic acid at the same site would result in an insufficient number of contaminating amplicons that would adversely affect sequencing by synthesis on Illumina's sequencing platform.

[0163] In some embodiments, the amplification sites in the array can be, but need not be, completely clonal. Rather, depending on the application, each amplification site can be dominated by amplicons from the first indexed fragment, and each amplification site can also have low levels of contaminating amplicons from the second target nucleic acid. An array can have one or more amplification sites with low levels of contaminating amplicons, as long as the level of contamination does not unacceptably affect the subsequent use of the array. For example, if the array is to be used in a detection application, an acceptable level of contamination will be one that does not affect the signal-to-noise or resolution of the detection technique in an unacceptable manner. Thus, apparent clonality will generally be related to the particular use or application of the array made by the methods described herein. Exemplary levels of contamination that may be acceptable in an individual amplification site for a particular application include, but are not limited to, up to 0.1%, 0.5%, 1%, 5%, 10% or 25% contaminating amplicons. An array can include one or more amplification sites with these exemplary levels of contaminating amplicons. For example, even up to 5%, 10%, 25%, 50%, 75%, or 100% of the amplification sites in an array may have some degree of contaminating amplicons. It will be understood that in an array or other collection of sites, at least 50%, 75%, 80%, 85%, 90%, 95%, or 99% or more of the sites may be clonal or apparently clonal.

[0164] In some embodiments, kinetic exclusion can occur when a process is performed at a rate fast enough to effectively exclude the occurrence of another event or process.For example, consider the creation of a nucleic acid array in which the array sites are randomly seeded with indexed fragments from a solution, and the amplification process generates copies of the indexed fragments to fill each seeded site to its maximum capacity.According to the kinetic exclusion method of the present disclosure, the seeding and amplification processes can proceed simultaneously under conditions in which the amplification rate exceeds the seeding rate.Therefore, the relatively fast rate at which copies are generated at the seeded site by the first target nucleic acid effectively excludes the second nucleic acid from seeding the site for amplification.The kinetic exclusion amplification method can be carried out as described in detail in the disclosure of US Patent Application Publication No. 2013 / 0338042.

[0165] Kinetic exclusion can take advantage of the relatively slow rate of initiating amplification (e.g., slow rate of generating the first copy of the indexed fragment) relative to the relatively fast rate of generating subsequent copies of the indexed fragment (or of the first copy of the indexed fragment). In the example of the previous paragraph, kinetic exclusion occurs because the rate of indexed fragment seeding is relatively slow (e.g., relatively slow diffusion or transport) relative to the relatively fast rate of amplification to fill the site with seeded copies of the indexed fragment. In another specific embodiment, kinetic exclusion can occur because the formation of the first copy of the indexed fragment that seeded the site lags behind (e.g., delayed or slow activation) the relatively fast rate at which subsequent copies are generated to fill the site. In this example, several different indexed fragments may be seeded at individual sites (e.g., several indexed fragments may be present at each site prior to amplification). However, the first copy formation of any given indexed fragment can be randomly activated such that the average rate of first copy formation is relatively slow compared to the rate at which subsequent copies are generated. In this case, an individual site may be seeded with several different indexed fragments, but kinetic exclusion ensures that only one of the indexed fragments can be amplified. More specifically, when the first indexed fragment is activated for amplification, the site is rapidly filled to capacity with copies of that fragment, thereby preventing copies of the second indexed fragment from being generated at that site.

[0166] In one embodiment, the method is carried out to (i) transport the indexed fragments to the amplification site at an average transport rate and simultaneously (ii) amplify the indexed fragments at the amplification site at an average amplification rate, where the average amplification rate is greater than the average transport rate (US Pat. No. 9,169,513). Thus, in such an embodiment, kinetic exclusion can be achieved by using a relatively slow transport rate. For example, a sufficiently low concentration of indexed fragments is selected to achieve a desired average transport rate, with lower concentrations resulting in slower average transport rates. Alternatively, or additionally, high viscosity solutions and / or the presence of molecular crowding agents in the solution can be used to reduce the transport rate. Examples of useful molecular crowding agents include, but are not limited to, polyethylene glycol (PEG), ficoll, dextran, or polyvinyl alcohol. Exemplary molecular crowding agents and formulations are described in US Pat. No. 7,399,590, which is incorporated herein by reference. Another factor that can be adjusted to achieve a desired transport rate is the average size of the target nucleic acid.

[0167] Amplification reagents can include further components that facilitate amplicon formation and in some cases increase the rate of amplicon formation. One example is recombinase. Recombinase can facilitate amplicon formation by allowing repeated invasion / extension. More specifically, recombinase can facilitate the invasion of indexed fragments by polymerase and extension of primers by polymerase using the indexed fragments as templates for amplicon formation. This process can be repeated as a chain reaction in which the amplicons generated from each round of invasion / extension serve as templates in subsequent rounds. This process can be performed more quickly than standard PCR because no denaturation cycles (e.g., by heating or chemical denaturation) are required. Thus, recombinase-facilitated amplification can be performed isothermally. It is generally desirable to include ATP or other nucleotides (or in some cases non-hydrolyzable analogs thereof) in the recombinase-facilitated amplification reagent to facilitate amplification. A mixture of recombinase and single-stranded binding (SSB) proteins is particularly useful because SSB can further facilitate amplification. Exemplary recombinase-facilitated amplification formulations include those sold as TwistAmp kits by TwistDx (Cambridge, UK). Useful components and reaction conditions for recombinase-facilitated amplification reagents are described in U.S. Patent Nos. 5,223,414 and 7,399,590.

[0168] Another example of a component that can be included in an amplification reagent to promote amplicon formation and possibly increase the rate of amplicon formation is a helicase. Helicase can promote amplicon formation by driving a chain reaction of amplicon formation. This process can be faster than standard PCR because no denaturation cycles (e.g., by heating or chemical denaturation) are required. Thus, helicase-promoted amplification can be carried out isothermally. A mixture of helicase and single-stranded binding (SSB) protein is particularly useful because SSB can further promote amplification. Exemplary helicase-promoted amplification formulations include those commercially available as IsoAmp kits from Biohelix (Beverly, Massachusetts). Further examples of useful formulations that include helicase proteins are described in U.S. Pat. No. 7,399,590 and U.S. Pat. No. 7,829,284.

[0169] Yet another example of a component that can be included in an amplification reagent to facilitate and potentially increase the rate of amplicon formation is an origin binding protein.

[0170] Sequencing Uses / Sequencing Methods Following the attachment of indexed fragments to the surface, the sequence of the immobilized and amplified indexed fragments is determined.Sequencing can be carried out using any suitable sequencing technology, and the method of determining the sequence of the immobilized and amplified indexed fragments, including strand resynthesis, is known in the art, and is described, for example, in Bignell et al. (U.S. Pat. No. 8,053,192), Gunderson et al. (WO 2016 / 130704), Shen et al. (U.S. Pat. No. 8,895,249), and Pipenburg et al. (U.S. Pat. No. 9,309,502).

[0171] The methods described herein can be used in combination with various nucleic acid sequencing techniques. Particularly applicable techniques are those in which the nucleic acids are attached to fixed positions in an array such that the relative positions of the nucleic acids do not change, and the array is imaged repeatedly. Particularly applicable are those embodiments in which images are acquired in different color channels, e.g., corresponding to different labels used to distinguish one nucleotide base type from another. In some embodiments, the process of determining the nucleotide sequence of the indexed fragments can be an automated process. A preferred embodiment includes sequencing-by-synthesis ("SBS") technology.

[0172] SBS technology generally involves the enzymatic extension of nascent nucleic acid strand through the repeated addition of nucleotides to template strand.In the conventional method of SBS, a single nucleotide monomer may be provided to target nucleic acid in the presence of polymerase in each delivery.However, in the method described herein, multiple types of nucleotide monomers can be provided to target nucleic acid in the presence of polymerase during delivery.

[0173] In one embodiment, the nucleotide monomer comprises a locked nucleic acid (LNA) or a bridged nucleic acid (BNA). The use of an LNA or BNA in the nucleotide monomer increases the hybridization strength between the nucleotide monomer and the sequencing primer sequence present on the immobilized indexed fragment.

[0174] SBS can use nucleotide monomers with or without terminator moieties. Methods using nucleotide monomers without terminators include, for example, pyrosequencing and sequencing methods using γ-phosphate-labeled nucleotides, as described in more detail herein. In methods using nucleotide monomers without terminators, the number of nucleotides added in each cycle is generally variable and depends on the template sequence and nucleotide delivery method. In the case of SBS techniques using nucleotide monomers with terminator moieties, the terminator can be effectively irreversible under the sequencing conditions used, as in the case of conventional Sanger sequencing methods using dideoxynucleotides, or the terminator can be reversible, as in the case of the sequencing method developed by Solexa (now Illumina, Inc.).

[0175] SBS techniques can use nucleotide monomers with or without a label moiety. Thus, incorporation events can be detected based on the characteristics of the label, such as the fluorescence of the label; the characteristics of the nucleotide monomer, such as molecular weight and charge; the by-products of incorporation of the nucleotide, such as the release of pyrophosphate, and the like. In embodiments in which two or more different nucleotides are present in the sequencing reagent, the different nucleotides can be distinguishable from each other, or alternatively, the two or more different labels can be indistinguishable under the detection technique being used. For example, the different nucleotides present in the sequencing reagent can have different labels, which can be distinguished using appropriate optics, as demonstrated by the sequencing method developed by Solexa (now Illumina, Inc.).

[0176] A preferred embodiment involves pyrosequencing technology. Pyrosequencing detects the release of inorganic pyrophosphate (PPi) when a specific nucleotide is incorporated into the nascent strand. (Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M. and Nyren, P. (1996) “Real-time DNA sequencing using detection of pyrophosphate release.” Analytical Biochemistry 242(1), 84-9; Ronaghi, M. (2001) “Pyrosequencing sheds light on DNA sequencing.” Genome Res. 11(1), 3-11; Ronaghi, M., Uhlen, M. and Nyren, P. (1998) “A sequencing method based on real-time pyrophosphate.” Science 281(5375), 363; U.S. Patent Nos. 6,210,891; 6,258,568 and 6,274,320). In pyrosequencing, the released PPi can be detected by being immediately converted to adenosine triphosphate (ATP) by ATP sulfurase, and the level of ATP generated is detected through photons generated by luciferase. The nucleic acid to be sequenced can be attached to a feature in an array, and the array can be imaged to capture the chemiluminescent signal generated by the incorporation of nucleotides at the feature of the array. The array can be treated with a specific nucleotide type (e.g., A, T, C, or G) and then an image can be obtained. The images obtained after the addition of each nucleotide type will differ in terms of which features in the array are detected. These differences in the images reflect the different sequence content of the features on the array. However, the relative position of each feature remains unchanged in the image. The images can be stored, processed, and analyzed using the methods described herein.For example, images obtained after processing the array with each different nucleotide type can be treated in the same manner as demonstrated herein for images obtained from different detection channels for reversible terminator-based sequencing methods.

[0177] In another typical type of SBS, cycle sequencing is achieved by stepwise addition of reversible terminator nucleotides, e.g., containing cleavable or photobleachable dye labels, as described, e.g., in WO 04 / 018497 and U.S. Pat. No. 7,057,026. This approach has been commercialized by Solexa (now Illumina Inc.) and is also described in WO 91 / 06678 and WO 07 / 123,744. The availability of fluorescently labeled terminators, whose termination can be reversed and whose fluorescent labels can be cleaved, facilitates efficient cyclic reversible termination (CRT) sequencing. Polymerases can also be engineered together to efficiently incorporate and extend from these modified nucleotides.

[0178] In some reversible terminator-based sequencing embodiments, the label does not substantially inhibit extension under SBS reaction conditions. However, the detection label can be removable, for example, by cleavage or degradation. After incorporating the label into the arrayed nucleic acid features, an image can be captured. In certain embodiments, each cycle involves the simultaneous delivery of four different nucleotide types to the array, each nucleotide type having a spectrally distinct label. Four images can then be acquired, each using a detection channel that selects one of the four different labels. Alternatively, different nucleotide types can be added sequentially, and images of the array can be acquired between each addition step. In such embodiments, each image will show nucleic acid features that incorporate a particular type of nucleotide. Different features will be present or absent in different images, since the sequence content of each feature will be different. However, the relative positions of the features within the image will not be altered. Images obtained from the reversible terminator-SBS method described above can be stored, processed, and analyzed as described herein. Following the image capture step, the label can be removed and the reversible terminator moiety can be removed for subsequent cycles of nucleotide addition and detection. Once a label is detected in a particular cycle, removal of the label prior to the subsequent cycle can provide the advantage of reducing background signal and crosstalk between cycles. Examples of useful labeling and removal methods are described herein.

[0179] In certain embodiments, some or all of the nucleotide monomers can include a reversible terminator. In such embodiments, the reversible terminator / cleavable fluorophore can include a fluorophore linked to the ribose moiety via a 3' ester bond (Metzker, Genome Res. 15:1767-1776 (2005)). Other approaches have separated the chemistry of the terminator from the cleavage of the fluorescent label (Ruparel et al., Proc Natl Acad Sci USA 102:5932-7 (2005)). Ruparel et al. described the development of a reversible terminator that uses a small 3' allyl group to block extension, but can be easily unblocked by brief treatment with a palladium catalyst. The fluorophore was attached to the base via a photocleavable linker that can be easily cleaved by 30 seconds of exposure to long wavelength UV light. Thus, either disulfide reduction or photocleavage can be used as the cleavable linker. Another approach to reversible termination is the use of natural termination that occurs after placing a bulky dye on dNTP. The presence of a charged bulky dye on dNTP can act as an effective terminator through steric and / or electrostatic hindrance. The presence of one incorporation event prevents further incorporation unless the dye is removed. Cleavage of the dye removes the fluorophore, effectively reversing termination. Examples of modified nucleotides are also described in U.S. Patent Nos. 7,427,673 and 7,057,026.

[0180] Additional specific SBS systems and methods that can be utilized in conjunction with the methods and systems described herein are described in U.S. Patent Application Publication Nos. 2007 / 0166705, 2006 / 0188901, 2006 / 0240439, 2006 / 0281109, 2012 / 0270305, and 2013 / 0260372, U.S. Patent No. 7,057,026, PCT International Publication No. WO 05 / 065814, U.S. Patent Application Publication No. 2005 / 0100900, and PCT International Publication Nos. WO 06 / 064199 and 07 / 010,251.

[0181] Some embodiments may employ detection of four different nucleotides using fewer than four different labels. For example, SBS may be performed using methods and systems described in the incorporated materials of US Patent Application Publication No. 2013 / 0079232. As a first example, pairs of nucleotide types may be detected at the same wavelength, but may be distinguished based on a difference in intensity between one member of the pair and the other, or on a change (e.g., due to chemical, photochemical, or physical modification) in one member of the pair that induces the appearance or disappearance of an apparent signal when compared to the signal detected in the other member of the pair. As a second example, three of the four different nucleotide types may be detected under certain conditions, but the fourth nucleotide type may lack a detectable label under those conditions or may be minimally detected under those conditions (e.g., minimal detection due to background fluorescence). Incorporation of the first three nucleotide types into a nucleic acid may be determined based on the presence of their respective signals, and incorporation of the fourth nucleotide type into a nucleic acid may be determined based on the absence or minimal detection of a signal. As a third example, one nucleotide type can include label(s) that are detected in two different channels, while the other nucleotide type is only detected in one channel. The three exemplary configurations described above are not considered mutually exclusive and can be used in various combinations.An exemplary embodiment combining all three examples is a fluorescence-based SBS method that uses a first nucleotide type that is detected in a first channel (e.g., dATP having a label that is detected in the first channel when excited by a first excitation wavelength), a second nucleotide type that is detected in a second channel (e.g., dCTP having a label that is detected in the second channel when excited by a second excitation wavelength), a third nucleotide type that is detected in both the first and second channels (e.g., dTTP having at least one label that is detected in both channels when excited by the first and / or second excitation wavelengths), and a fourth nucleotide type that is not detected in either channel or minimally lacks a detectable label (e.g., dGTP having no label).

[0182] Additionally, as described in the incorporated materials of U.S. Patent Application Publication No. 2013 / 0079232, a single channel can be used to obtain sequencing data. In such so-called one-dye sequencing approaches, a first nucleotide type is labeled but the label is removed after the first image is generated, and a second nucleotide type is labeled only after the first image is generated. A third nucleotide type retains its label in both the first and second images, and a fourth nucleotide type remains unlabeled in both images.

[0183] Some embodiments may use sequencing by ligation techniques. Such techniques incorporate oligonucleotides using DNA ligase to identify the incorporation of such oligonucleotides. The oligonucleotides typically have different labels that correlate with the identity of a particular nucleotide in the sequence to which the oligonucleotide hybridizes. As with other SBS methods, an array of nucleic acid features may be treated with labeled sequencing reagents, and then images may be acquired. Each image will display nucleic acid features that incorporate a particular type of label. Different features will be present or absent in different images due to the different sequence content of each feature, but the relative positions of the features will remain unchanged in the images. Images obtained from ligation-based sequencing methods may be stored, processed, and analyzed as described herein. Exemplary SBS systems and methods that can be utilized with the methods and systems described herein are described in U.S. Patent Nos. 6,969,488, 6,172,218, and 6,306,597.

[0184] Some embodiments can use nanopore sequencing (Deamer, DW & Akeson, M. "Nanopores and nucleic acids: prospects for ultrarapid sequencing." Trends Biotechnol. 18, 147-151 (2000); Deamer, D. and D. Branton, "Characterization of nucleic acids by nanopore analysis", Acc. Chem. Res. 35:817-825 (2002); Li, J., M. Gershow, D. Stein, E. Brandin and JA Golovchenko, "DNA molecules and configurations in a solid-state nanopore microscope" Nat. Mater. 2:611-615 (2003)). In such embodiments, the indexed fragments pass through a nanopore. The nanopore can be a synthetic pore or a biological membrane protein such as α-hemolysin. As the indexed fragments pass through the nanopore, each base pair can be identified by measuring the change in electrical conductivity of the pore. (U.S. Pat. No. 7,001,792; Soni, GV &Meller, "A. Progress toward ultrafast DNA sequencing using solid-state nanopores." Clin. Chem. 53, 1996-2001(2007); Healy, K. "Nanopore-based single-molecule DNA analysis." Nanomed. 2, 459-481(2007); Cockroft, SL, Chu, J., Amorin, M. &Ghadiri, MR "A single-molecule nanopore device detects DNA polymerase activity with single-nucleotide resolution." J. Am. Chem. Soc. 130, 818-820(2008)).Data obtained from nanopore sequencing can be stored, processed, and analyzed as described herein. In particular, the data can be processed as images according to the exemplary processing of optical and other images described herein.

[0185] Some embodiments can use methods that include real-time monitoring of DNA polymerase activity.Nucleotide incorporation can be detected through fluorescence resonance energy transfer (FRET) interactions between fluorophore-bearing polymerase and γ-phosphate-labeled nucleotides, as described, for example, in U.S. Patent Nos. 7,329,492 and 7,211,414, or nucleotide incorporation can be detected using fluorescent nucleotide analogs and modified polymerases, as described, for example, in U.S. Patent No. 7,405,281 and U.S. Patent Application Publication No. 2008 / 0108082, with zero-mode waveguides, as described, for example, in U.S. Patent No. 7,315,019. Illumination can be restricted to a zeptoliter-scale volume around the surface-tethered polymerase so that incorporation of fluorescently labeled nucleotides can be observed with low background (Levene, MJ et al., "Zero-mode waveguides for single-molecule analysis at high concentrations." Science 299, 682-686 (2003); Lundquist, PM et al., "Parallel confocal detection of single molecules in real time." Opt. Lett. 33, 1026-1028 (2008); Korlach, J. et al., "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nano structures." Proc. Natl. Acad. Sci. USA 105, 1176-1181 (2008)). Images obtained from the above methods can be stored, processed, and analyzed as described herein.

[0186] Some SBS embodiments include detection of protons released upon incorporation of nucleotide into extension product.For example, sequencing based on detection of released protons can use electric detectors and related technology available from Ion Torrent (a Life Technologies subsidiary of Guilford, Connecticut), or the sequencing methods and systems described in US Patent Application Publication Nos. 2009 / 0026082; 2009 / 0127589; 2010 / 0137143; and 2010 / 0282617.The method described herein for amplifying target nucleic acid using kinetic exclusion can be easily applied to the substrate used for detecting protons.More specifically, the method described herein can be used to produce a clonal population of amplicons used for detecting protons.

[0187] The SBS method described above can be advantageously carried out in a multiplex format, such that multiple different indexed fragments are manipulated simultaneously. In certain embodiments, the different indexed fragments can be processed in a common reaction vessel or on the surface of a particular substrate. This allows for convenient delivery of sequencing reagents, removal of unreacted reagents, and detection of incorporation events in a multiplexed manner. In embodiments using surface-bound target nucleic acids, the indexed fragments can be in an array format. In an array format, the indexed fragments can be bound to the surface, typically in a spatially distinguishable manner. The indexed fragments can be bound by direct covalent binding, attachment to beads or other particles, or binding to a polymerase or other molecule attached to the surface. The array can include a single copy of the indexed fragment at each site (also called a feature), or multiple copies with the same sequence can be present at each site or feature. As described in more detail herein, multiple copies can be generated by amplification methods such as bridge amplification or emulsion PCR.

[0188] The methods described herein can be used to fabricate, for example, at least about 10 features / cm2 , 100 features / cm 2 , 500 features / cm 2 , 1,000 features / cm 2 , 5,000 features / cm 2 , 10,000 features / cm 2 , 50,000 features / cm 2 , 100,000 features / cm 2 , 1,000,000 features / cm 2 , 5,000,000 features / cm 2 Arrays having features of any of a variety of densities, including 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 3000, 4000, 5000,

[0189] The advantage of the method described herein is that multiple cm 2The advantage of the present disclosure is that it allows for rapid and efficient detection of nucleic acids in parallel. Thus, the present disclosure provides an integrated system that can prepare and detect nucleic acids using techniques known in the art, such as those specifically illustrated herein. Thus, the integrated system of the present disclosure can include fluidic components that can deliver amplification and / or sequencing reagents to one or more immobilized indexed fragments, including components such as pumps, valves, reservoirs, and fluid lines. A flow cell can be configured and / or used in an integrated system for detection of target nucleic acids. Exemplary flow cells are described, for example, in U.S. Patent Application Publication No. 2010 / 0111768 and U.S. Patent Application No. 13 / 273,666. Illustratively, for a flow cell, one or more of the fluidic components of the integrated system can be used for amplification and detection methods. Illustratively, for a nucleic acid sequencing embodiment, one or more of the fluidic components of the integrated system can be used for delivery of sequencing reagents in the amplification methods described herein and sequencing methods such as those illustrated above. Alternatively, the integrated system can include separate fluidic systems for performing the amplification method and for performing the detection method. Examples of integrated sequencing systems that can generate amplified nucleic acids and also determine the sequence of the nucleic acid include, but are not limited to, the MiSeq™ platform (Illumina, Inc., San Diego, Calif.) and the device described in U.S. Patent Application No. 13 / 273,666.

[0190] Compositions are also provided herein.During the implementation of the methods described herein, various compositions can be generated.For example, compositions can be generated that contain indexed nucleic acid fragments that are derived from newly synthesized RNA.In one embodiment, newly synthesized RNA is labeled.Also provided is a multi-well plate, the wells of the multi-well plate contain indexed nucleic acid fragments.

[0191] Kits are also provided herein. In one embodiment, the kit is for preparing a sequencing library in which newly synthesized RNA is labeled. In one embodiment, the kit comprises a nucleotide label as described herein. In another embodiment, the kit comprises one or more primers for annealing to the RNA, at least one primer for targeted amplification of one or more predefined nucleic acids. In a further embodiment, the kit comprises components for adding at least three indexes to the nucleic acid. The kit can also include other components useful for generating a sequencing library. For example, the kit can include at least one enzyme that mediates ligation, primer extension, or amplification to process the RNA molecule to include an index. The kit can include a nucleic acid with an index sequence. The kit can also include other components useful for adding an index to a nucleic acid, such as a transposome complex. The kit can also include one or more primers for annealing to the RNA. The primers can be for generating the whole transcriptome (e.g., primers that include poly-T sequences) or for targeted amplification of one or more predefined nucleic acids.

[0192] The components of the kit are typically in suitable packaging material in an amount sufficient for at least one assay or use. In some cases, other components, such as buffers and solutions, may be included. Typically, instructions for use of the packaged components are also included. As used herein, the phrase "packaging material" refers to one or more physical structures used to contain the contents of the kit. The packaging material is generally constructed in a conventional manner to provide a sterile, contaminant-free environment. The packaging material may be labeled to indicate that the components can be used to generate a sequencing library. Additionally, the packaging material includes instructions showing how to use the materials in the kit. As used herein, the term "package" refers to a container, such as glass, plastic, paper, foil, etc., capable of holding the components of the kit within certain limits. "Instructions for use" typically include specific language describing at least one assay method parameter, such as reagent concentrations or relative amounts of reagents and sample to be mixed, maintenance period of the reagent / sample mixture, temperature, buffer conditions, etc.

[0193] Exemplary embodiments Embodiment 1. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells to a first plurality of compartments, wherein each compartment comprises a subset of the nuclei or cells; (b) labeling newly synthesized RNA in the cells or in a subset of nuclei obtained from said cells; (c) processing the RNA molecules of each subset of nuclei or cells to generate indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to the first compartment to the RNA nucleic acids present in each subset of nuclei or cells to result in indexed DNA nucleic acids present in the indexed nuclei or cells, and said processing comprises ligation, primer extension, hybridization, or amplification; and (d) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells. The method includes:

[0194] Aspect 2. The processing comprises: contacting the subset with a reverse transcriptase and a primer that anneals to the RNA nucleic acid, thereby generating a double-stranded DNA nucleic acid comprising said primer and the corresponding DNA nucleotide sequence of the template RNA molecule. 2. The method of embodiment 1, comprising:

[0195] Embodiment 3. The method of embodiment 1 or 2, wherein the primer comprises a poly-T nucleotide sequence that anneals to an mRNA poly(A) tail.

[0196] Embodiment 4. The method of any one of embodiments 1-3, wherein said processing further comprises contacting the subset with a second primer, said second primer comprising a sequence that anneals to a predetermined DNA nucleic acid.

[0197] Embodiment 5. The method of any one of embodiments 1 to 4, wherein said second primer comprises an index unique to the compartment.

[0198] Embodiment 6. The method of any one of embodiments 1 to 5, wherein the primer comprises a sequence that anneals to a predetermined RNA nucleic acid.

[0199] Embodiment 7. The method of any one of embodiments 1 to 6, wherein said method comprises primers in different sections that anneal to different nucleotides of the same predetermined RNA nucleic acid.

[0200]

[0023] Embodiment 8. The method of any one of embodiments 1-7, wherein the primer comprises a template switch primer.

[0201] Embodiment 9. The method of any one of embodiments 1 to 8, wherein said processing of adding an index sequence unique to the first section comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to said RNA nucleic acid to obtain a DNA nucleic acid, and then adding an index sequence unique to the first section to said DNA nucleic acid.

[0202] Embodiment 10. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells to a plurality of first compartments, each compartment comprising a subset of the nuclei or cells; (b) contacting each subset with a reverse transcriptase and a primer that anneals to a given RNA nucleic acid, thereby generating a double-stranded DNA nucleic acid comprising said primer and the corresponding DNA nucleotide sequence of the template RNA nucleic acid; (c) processing the DNA molecules of each subset of nuclei or cells to generate indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to the first compartment to the DNA nucleic acid present in each subset of nuclei or cells to obtain indexed nucleic acids present in the indexed nuclei or cells, said processing comprising ligation, primer extension, hybridization, or amplification; and (d) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells. The method includes:

[0203] Embodiment 11. The method of embodiment 10, wherein said primer comprises an index sequence unique to said first section.

[0204] Embodiment 12. The method of embodiment 10 or 11, further comprising labeling newly synthesized RNA in said subset of cells or nuclei obtained from said cells prior to said contacting.

[0205]

[0023] Embodiment 13. The method of any one of embodiments 10 to 12, wherein the processing of adding an index sequence unique to said first section comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to said nucleic acid, and then adding an index sequence unique to said first section to said nucleic acid.

[0206] Aspect 14. The method of any one of aspects 1 to 13, wherein said predetermined RNA nucleic acid is mRNA.

[0207] Embodiment 15. The method of any one of embodiments 1 to 14, wherein the pre-existing RNA nucleic acid and the newly synthesized RNA nucleic acid are labeled with the same index in the same compartment.

[0208] Embodiment 16. The method of any one of embodiments 1 to 15, wherein said labeling comprises incubating a plurality of nuclei or cells in a composition comprising a nucleotide label, wherein said nucleotide label is incorporated into newly synthesized RNA.

[0209] Embodiment 17. The method of any one of embodiments 1 to 16, wherein the nucleotide label comprises a nucleotide analog, a hapten-labeled nucleotide, a mutagenic nucleotide, or a nucleotide that can be modified by chemical reaction.

[0210] Embodiment 18. The method of any one of embodiments 1 to 17, wherein two or more nucleotide labels are incorporated into the newly synthesized RNA.

[0211] Embodiment 19. The method of any one of embodiments 1 to 18, wherein the ratio of one or more of said nucleotide labels is different for different compartments or time points.

[0212] Embodiment 20. The method of any one of embodiments 1 to 19, further comprising exposing the nuclei or the subset of cells to a predetermined condition prior to said labeling.

[0213]

[0023] Embodiment 21. The method of any one of embodiments 1-20, wherein said predetermined condition comprises exposure to an agent.

[0214]

[0023] Embodiment 22. The method of any one of embodiments 1-21, wherein the agent comprises a protein, a non-ribosomal protein, a polyketide, an organic molecule, an inorganic molecule, an RNA or RNAi molecule, a carbohydrate, a glycoprotein, a nucleic acid, or a combination thereof.

[0215]

[0023] Embodiment 23. The method of any one of embodiments 1-22, wherein the agent comprises a therapeutic agent.

[0216]

[0036] Embodiment 24. The method of any one of embodiments 1-23, wherein said predetermined conditions of two or more compartments are different.

[0217] Embodiment 25. The method of any one of embodiments 1-24, wherein said exposing and said labeling occur simultaneously or said exposing occurs prior to said labeling.

[0218] Aspect 26. distributing a subset of the pooled indexed nuclei or cells into a second plurality of compartments and generating dual-indexed nuclei or cells comprising dual-indexed nucleic acid fragments by adding a second index sequence to the indexed nucleic acid present in the subset of nuclei or cells, wherein said adding comprises ligation, primer extension, hybridization, amplification, or transposition; and Combining dual-indexed nuclei or cells to produce pooled dual-indexed nuclei or cells The method of any one of embodiments 1-25, further comprising:

[0219] Aspect 27. distributing a subset of the pooled dual-indexed nuclei or cells into a third plurality of compartments and adding a third index sequence to the indexed nucleic acids present in the subset of nuclei or cells to generate triple-indexed nuclei or cells comprising triple-indexed nucleic acid fragments, wherein said adding comprises ligation, hybridization, primer extension, amplification, or transposition; Combining triple-indexed nuclei or cells to produce pooled triple-indexed nuclei or cells The method of any one of embodiments 1-26, further comprising:

[0220] Embodiment 28. The method of any one of embodiments 1 to 27, wherein the dispensing comprises dilution.

[0221] Embodiment 29. The method of any one of embodiments 1 to 27, wherein the distributing comprises sorting.

[0222]

[0023] Embodiment 30. The method of any one of embodiments 1 to 29, wherein said adding comprises contacting the subset with hairpin ligation duplexes under conditions suitable for ligation of said hairpin ligation duplexes to ends of a nucleic acid fragment comprising one or two index sequences.

[0223]

[0023] Embodiment 31. The method of any one of embodiments 1 to 30, wherein said adding comprises contacting a nucleic acid fragment comprising one or more index sequences with a transposome complex, said transposome complex within the compartment comprising a transposase and a universal sequence, and said contacting further comprises conditions suitable for fragmentation of the nucleic acid fragment and incorporation of the universal sequence into the nucleic acid fragment.

[0224]

[0023] Embodiment 32. The method of any one of embodiments 1 to 31, wherein said adding comprises ligation of an index sequence unique to the first compartment, and further comprising adding a second index sequence to generate a dual-indexed nucleus or cell comprising a dual-indexed nucleic acid fragment, wherein said adding comprises a transposition.

[0225]

[0023] Embodiment 33. The method of any one of embodiments 1 to 32, wherein said adding comprises ligation of an index sequence unique to the second compartment and further comprises adding a third index sequence to generate a triple-indexed nucleus or cell comprising the triple-indexed nucleic acid fragment, wherein said adding comprises a transposition.

[0226] Embodiment 34. The method of any one of embodiments 1 to 33, wherein the compartment comprises a well or a droplet.

[0227] Embodiment 35. The method of any one of embodiments 1-34, wherein the compartments of said first plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

[0228] Embodiment 36. The method of any one of embodiments 1-35, wherein the compartments of said second plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

[0229]

[0023] Embodiment 37. The method of any one of embodiments 1-36, wherein the compartments of said third plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

[0230] Embodiment 38. The method of any one of embodiments 1 to 37, further comprising generating a sequencing library from a plurality of nuclei or cells by obtaining indexed nucleic acids from pooled indexed nuclei or cells.

[0231] Embodiment 39. The method of any one of embodiments 1 to 38, further comprising generating a sequencing library from a plurality of nuclei or cells by obtaining dual-indexed nucleic acids from pooled dual-indexed nuclei or cells.

[0232] Embodiment 40. The method of any one of embodiments 1 to 39, further comprising generating a sequencing library from a plurality of nuclei or cells by obtaining triple-indexed nucleic acids from pooled triple-indexed nuclei or cells.

[0233] Aspect 41. providing a surface comprising a plurality of amplification sites, wherein said amplification sites comprise at least two populations of bound single-stranded capture oligonucleotides having free 3' ends; and contacting said surface containing amplification sites with nucleic acid fragments containing one, two, or three index sequences under conditions suitable to produce a plurality of amplification sites comprising a clonal population of amplicons from individual fragments each containing a plurality of indexes; The method of any one of embodiments 1-40, further comprising:

[0234]

[0023] Embodiment 42. The method of any one of embodiments 1 to 41, wherein adding said partition-specific index sequence comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to said nucleic acid, and then adding said partition-specific index sequence to said nucleic acid.

[0235] Embodiment 43. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells to a first plurality of compartments, wherein each compartment comprises a subset of the nuclei or cells; (b) contacting each subset with a reverse transcriptase and a primer to generate a double-stranded DNA nucleic acid comprising said primer and the corresponding DNA nucleotide sequence of the template RNA nucleic acid; (c) processing the DNA molecules in each subset of nuclei or cells to generate indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to the first compartment to DNA nucleic acids present in each subset of nuclei or cells to obtain indexed nucleic acids present in the indexed nuclei or cells, said processing comprising ligation, primer extension, hybridization, amplification, or transposition; (d) combining said indexed nuclei or cells to produce pooled indexed nuclei or cells; (e) distributing the pooled indexed nuclei or cells into a second plurality of compartments, each compartment comprising a subset of nuclei or cells; (f) processing the DNA molecules in each subset of nuclei or cells to generate dual-indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to the second compartment to the DNA nucleic acids present in each subset of nuclei or cells to obtain dual-indexed nucleic acids present in the indexed nuclei or cells, said processing comprising ligation, primer extension, hybridization, amplification, or transposition; (g) combining the dual-indexed nuclei or cells to produce pooled dual-indexed nuclei or cells; (h) distributing the pooled dual-indexed nuclei or cells into a third plurality of compartments, each compartment comprising a subset of nuclei or cells; (i) processing DNA molecules of each subset of nuclei or cells to generate triple-indexed nuclei or cells, wherein the processing comprises adding an index sequence unique to a third compartment to DNA nucleic acids present in each subset of nuclei or cells to generate triple-indexed nucleic acids present in the indexed nuclei or cells, the processing comprising ligation, primer extension, hybridization, amplification, or transposition; and (j) combining the triple-indexed nuclei or cells to produce pooled triple-indexed nuclei or cells. The method includes:

[0236] Embodiment 44. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells; (b) contacting the plurality of nuclei or cells with a reverse transcriptase and a primer, thereby generating a double-stranded DNA nucleic acid comprising the primer and a corresponding DNA nucleotide sequence of a template RNA nucleic acid; (c) distributing the nuclei or cells into a first plurality of compartments, each compartment comprising a subset of the nuclei or cells; (d) processing the DNA molecules in each subset of nuclei or cells to generate indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to the first compartment to DNA nucleic acids present in each subset of nuclei or cells to generate indexed nucleic acids present in the indexed nuclei or cells, said processing comprising ligation, primer extension, hybridization, amplification, or transposition; (e) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells; (f) distributing the pooled indexed nuclei or cells into a second plurality of compartments, each compartment comprising a subset of nuclei or cells; (g) processing the DNA molecules in each subset of nuclei or cells to generate dual-indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to the second compartment to the DNA nucleic acids present in each subset of nuclei or cells to obtain dual-indexed nucleic acids present in the indexed nuclei or cells, said processing comprising ligation, primer extension, hybridization, amplification, or transposition; (h) combining said dual-indexed nuclei or cells to produce pooled dual-indexed nuclei or cells; (i) distributing the pooled dual-indexed nuclei or cells into a third plurality of compartments, each compartment comprising a subset of nuclei or cells; (j) processing the DNA molecules of each subset of nuclei or cells to generate triple-indexed nuclei or cells, wherein said processing comprises adding an index sequence unique to a third compartment to the DNA nucleic acid present in the subset of nuclei or cells to obtain triple-indexed nucleic acids present in the indexed nuclei or cells, said processing comprising ligation, primer extension, hybridization, amplification, or transposition; and (k) combining the triple-indexed nuclei or cells to produce pooled triple-indexed nuclei or cells. A method comprising:

[0237] Embodiment 45. The method of any one of embodiments 43 or 44, wherein the primer anneals to an RNA nucleic acid to generate a double-stranded DNA nucleic acid comprising the primer and the corresponding DNA nucleotide sequence of the template RNA molecule.

[0238] Embodiment 46. The method of any one of embodiments 43 to 45, wherein the primer comprises a poly-T nucleotide sequence that anneals to an mRNA poly(A) tail.

[0239]

[0036] Embodiment 47. The method of any one of embodiments 43-46, wherein said contacting further comprises contacting the subset with a second primer, said second primer comprising a sequence that anneals to a predetermined DNA nucleic acid.

[0240] Embodiment 48. The method of any one of embodiments 43 to 47, wherein said second primer comprises an index unique to the compartment.

[0241] Embodiment 49. The method of any one of embodiments 43 to 45, wherein the primer comprises a sequence that anneals to a predetermined RNA nucleic acid.

[0242]

[0036] Embodiment 50. The method of any one of embodiments 43 to 49, wherein said RNA nucleic acid of interest is mRNA.

[0243]

[0023] Embodiment 51. The method of any one of embodiments 43 to 50, wherein the primer comprises a template switch primer.

[0244] Embodiment 52. The method of any one of embodiments 43 to 51, wherein the processing of adding one or more of the index sequences specific to the first partition, the second partition, or the third partition comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to the nucleic acid, and then adding an index sequence specific to the first partition to the DNA nucleic acid.

[0245] Embodiment 53. The method of any one of embodiments 43 to 52, wherein said primer comprises an index sequence that is unique to said first section.

[0246] Embodiment 54. The method of any one of embodiments 43 to 53, further comprising labeling newly synthesized RNA in the cells or a subset of nuclei obtained from said cells prior to said contacting.

[0247] Embodiment 55. The method of any one of embodiments 43 to 54, wherein the pre-existing RNA nucleic acid and the newly synthesized RNA nucleic acid are labeled with the same index in the same compartment.

[0248] Embodiment 56. The method of any one of embodiments 43 to 55, wherein said labeling comprises incubating a plurality of nuclei or cells in a composition comprising a nucleotide label, wherein said nucleotide label is incorporated into newly synthesized RNA.

[0249] Embodiment 57. The method of any one of embodiments 43 to 56, wherein the nucleotide label comprises a nucleotide analog, a hapten-labeled nucleotide, a mutagenic nucleotide, or a nucleotide that can be modified by chemical reaction.

[0250] Embodiment 58. The method of any one of embodiments 43 to 57, wherein two or more nucleotide labels are incorporated into the newly synthesized RNA.

[0251] Embodiment 59. The method of any one of embodiments 43 to 58, wherein the ratio of one or more said nucleotide labels is different for different compartments or time points.

[0252] Embodiment 60. The method of any one of embodiments 43 to 59, further comprising exposing the nuclei or subset of cells of said compartment to a predetermined condition prior to said labeling.

[0253]

[0023] Embodiment 61. The method of any one of embodiments 43-60, wherein the predetermined condition comprises exposure to an agent.

[0254]

[0023] Embodiment 62. The method of any one of embodiments 43-61, wherein the agent comprises a protein, a non-ribosomal protein, a polyketide, an organic molecule, an inorganic molecule, an RNA or RNAi molecule, a carbohydrate, a glycoprotein, a nucleic acid, or a combination thereof.

[0255]

[0023] Embodiment 63. The method of any one of embodiments 43 to 62, wherein the agent comprises a therapeutic agent.

[0256]

[0036] Embodiment 64. The method of any one of embodiments 43 to 63, wherein the predetermined conditions of two or more compartments are different.

[0257] Embodiment 65. The method of any one of embodiments 43-64, wherein said exposing and said labeling occur simultaneously or said exposing occurs prior to said labeling.

[0258]

[0036] Embodiment 66. The method of any one of embodiments 43 to 65, wherein the one or more dispensings comprise dilution.

[0259]

[0036] Embodiment 67. The method of any one of embodiments 43-65, wherein the one or more dispensings include sorting.

[0260] Embodiment 68. The method according to any one of embodiments 43 to 67, wherein the addition of one or more of the index sequences unique to the first section, the second section or the third section comprises contacting the subset with a hairpin ligation duplex under conditions suitable for ligation of said hairpin ligation duplex to the ends of the nucleic acid fragment.

[0261] Embodiment 69. The method of any one of embodiments 43 to 68, wherein adding one or more of the index sequences unique to the first compartment, the second compartment or the third compartment comprises contacting the nucleic acid fragment with a transposome complex, wherein said transposome complex in the compartment comprises a transposase and a universal sequence, and wherein said contacting further comprises conditions suitable for fragmentation of the nucleic acid fragment and incorporation of the nucleotide sequence into the nucleic acid fragment.

[0262] Embodiment 70. The method of any one of embodiments 43 to 69, wherein the addition of the index specific to the first or second partition comprises ligation, and the addition of the index sequence specific to the subsequent partition comprises transposition.

[0263]

[0036] Embodiment 71. The method of any one of embodiments 43 to 70, wherein the compartment comprises a well or a droplet.

[0264]

[0036] Embodiment 72. The method of any one of embodiments 43 to 71, wherein the compartments of said first plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

[0265] Embodiment 73. The method of any one of embodiments 43 to 72, wherein the compartments of said second plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

[0266]

[0036] Embodiment 74. The method of any one of embodiments 43 to 73, wherein the compartments of said third plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

[0267]

[0036] Embodiment 75. The method of any one of embodiments 43-74, further comprising generating a sequencing library from said plurality of nuclei or cells by obtaining triple-indexed nucleic acids from said pooled triple-indexed nuclei or cells.

[0268] Aspect 76. providing a surface comprising a plurality of amplification sites, wherein said amplification sites comprise at least two populations of bound single-stranded capture oligonucleotides having free 3' ends; and contacting said surface containing the amplification sites with triple-indexed nucleic acid fragments under conditions suitable to generate a plurality of amplification sites each containing a clonal population of amplicons from an individual fragment containing a plurality of indexes; The method of any one of embodiments 43 to 76, further comprising:

[0269] Embodiment 77. A method for preparing a sequencing library comprising nucleic acids from a plurality of single cells, comprising: (a) providing nuclei from multiple cells; (b) distributing a subset of the nuclei into a first plurality of compartments and contacting each subset with a reverse transcriptase and a primer, wherein the primer in each compartment comprises a first index sequence that is distinct from the first index sequences of the other compartments, thereby generating indexed nuclei that comprise indexed nucleic acid fragments; (c) combining said indexed nuclei to generate pooled indexed nuclei; (d) distributing a subset of the pooled indexed nuclei into a second plurality of compartments and contacting each subset with a hairpin ligation duplex under conditions suitable for ligation of the hairpin ligation duplex to an end of an indexed nucleic acid fragment comprising a first index sequence, thereby generating dual-indexed nuclei comprising dual-indexed nucleic acid fragments, wherein the hairpin ligation duplex comprises a second index sequence that is different from the second index sequences of the other compartments; (e) combining the dual-indexed nuclei to generate pooled dual-indexed nuclei; (f) distributing a subset of said pooled dual-indexed nuclei into a third plurality of compartments and subjecting said dual-indexed nucleic acid fragments to conditions for second strand synthesis; (g) contacting the dual-indexed nucleic acid fragment with a transposome complex, wherein the transposome complex in each compartment comprises a transposase and a universal sequence, and wherein the contacting comprises conditions suitable for fragmentation of the dual-indexed nucleic acid fragment and incorporation of the universal sequence into the dual-indexed nucleic acid fragment to generate a dual-indexed nucleic acid fragment comprising the first and second indexes at one end and the universal sequence at the other end; (h) incorporating a third index sequence into the dual-indexed nucleic acid fragments of each section to generate triple-indexed fragments; and (i) generating a sequencing library comprising transcriptome nucleic acids from a plurality of single cells by combining the triple index fragments; The method includes:

[0270] Embodiment 78. The method of embodiment 77, wherein the primer comprises a poly-T sequence that anneals to an mRNA poly(A) tail.

[0271] Embodiment 79. The method of embodiments 77-78, wherein said primers of each section comprise a sequence that anneals to a given mRNA.

[0272] Embodiment 80. The method of any one of embodiments 77 to 79, wherein said method comprises primers of different sections annealing to different nucleotides of the same predetermined mRNA.

[0273] Embodiment 81. A method of preparing a transcriptome sequencing library comprising nucleic acids from a plurality of single cells, comprising: (a) providing pooled nuclei from multiple cells; (b) contacting the pooled nuclei with a reverse transcriptase and a primer that comprises an oligo dT sequence that anneals to an mRNA poly(A) tail to generate pooled nuclei that comprise a nucleic acid fragment; (c) distributing a subset of the pooled nuclei into a plurality of compartments and contacting each subset with a hairpin ligation duplex under conditions suitable for ligation of the hairpin ligation duplex to an end of a nucleic acid fragment to generate indexed nuclei comprising an indexed nucleic acid fragment, wherein the hairpin ligation duplex comprises an index sequence that is distinct from the index sequences of other compartments; (d) combining said indexed nuclei to generate pooled indexed nuclei; (e) distributing a subset of the pooled indexed nuclei into a second plurality of compartments and subjecting the indexed nucleic acid fragments to conditions for second strand synthesis; (f) contacting said indexed nucleic acid fragments with a transposome complex, wherein the transposome complex of each compartment comprises a transposase and a universal sequence, and wherein said contacting comprises conditions suitable for fragmentation of the indexed nucleic acid fragments and incorporation of the universal sequence into the indexed nucleic acid fragments to generate indexed nucleic acid fragments comprising said index at one end and said universal sequence at the other end; (g) incorporating a second index sequence into the indexed nucleic acid fragment of each section to generate dual-indexed fragments; (j) generating a sequencing library comprising transcriptome nucleic acids from a plurality of single cells by combining the dual index fragments. The method includes:

[0274] Embodiment 82. A method for isolating nuclei comprising: (a) Rapid freezing of tissue in liquid nitrogen; (b) reducing the size of said tissue to obtain a processed tissue; and (c) extracting nuclei from said processed tissue by incubation in a buffer that promotes cell lysis and preserves nuclear integrity in the absence of one or more exogenous enzymes. The method includes:

[0275] Embodiment 83. The method of embodiment 82, wherein the reducing comprises mincing the tissue, applying a blunt force to the tissue, or a combination thereof.

[0276] (d) exposing the extracted nuclei to a cross-linking agent to obtain fixed nuclei; and (e) washing the fixed nuclei; 84. The method of embodiment 82 or 83, further comprising:

[0277] Embodiment 85. A kit for use in preparing a sequencing library, the kit comprising at least one enzyme that mediates nucleotide labeling and ligation, primer extension, or amplification.

[0278] Embodiment 86. A kit for use in preparing a sequencing library, the kit comprising a primer that anneals to a nucleic acid of interest and at least one enzyme that mediates ligation, primer extension, or amplification. EXAMPLES

[0279] The present disclosure is illustrated by the following examples, with the understanding that the specific examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the disclosure set forth herein.

[0280] Example 1 Dynamic transcriptional landscape of mammalian organogenesis at single-cell resolution During mammalian organogenesis, cells of the three germ layers transform into embryos that contain most of the major internal and external organs. Key regulators of developmental abnormalities can be studied during this critical period, but current technologies lack the throughput and resolution to obtain a complete picture of the molecular state and trajectory of a rapidly diversifying and expanding number of cell types. We set out to investigate the transcriptional dynamics of mouse development during organogenesis at single-cell resolution. Using an improved single-cell combinatorial indexing-based protocol ('sci-RNA-seq3'), we profiled 2 million cells derived from 61 mouse embryos staged between 9.5 and 13.5 days of gestation (E9.5 to E13.5; 10–15 replicates per time point). We identify hundreds of expanding, contracting and transient cell types, many of which have only been detected by the depth of cell coverage obtained here, and we define corresponding sets of cell type-specific marker genes, some of which we demonstrate by whole mount in situ hybridization. We investigate the dynamics of proliferation and gene expression over time within cell types, including focused analysis of the apical ectodermal ridge, limb mesenchyme and skeletal muscle. Using novel algorithms, we identify the major single-cell developmental trajectories of mouse organogenesis and, within these, find examples of distinct pathways leading to the same endpoint: divergence and convergence. These data comprise a fundamental resource for mammalian developmental biology and are made available in a way that facilitates continued annotation by the research community.

[0281] Introduction Mammalian organogenesis is a remarkable process. Within a short period of time, cells of the three germ layers transform into a proper embryo containing most of its major internal and external organs. Although very early human embryos can be cultured and studied in vitro,1 access to material corresponding to later stages of human embryonic development is limited. As a result, most studies of mammalian organogenesis rely on model organisms, particularly the mouse.

[0282] Compared to humans, mice develop rapidly, taking only 21 days from fertilization to the birth of offspring. Implantation of the mouse blastocyst (32-64 cells) occurs on embryonic day 4 (E4.0). This is followed by gastrulation and formation of the primary germ layers (E6.5-E7.5; 660-15K cells)2,3. During this period, the primitive streak forms, leading to the allocation of the different lineages of the embryo in an anterior to posterior order4. At the early somite stage (E8.0-E8.5), the embryo transitions from gastrulation to early organogenesis associated with neural plate and heart tube formation (60K-90K cells). Classical organogenesis begins at E9.5. Over the next 4 days (E9.5-E13.5), the mouse embryo expands from hundreds of thousands of cells to more than 10 million cells while simultaneously developing its sensory, gastrointestinal and respiratory organs, its spinal cord, skeletal system, and hematopoietic system. Not surprisingly, this critical period of mouse development has been intensively studied: indeed, most of the key regulators of developmental abnormalities can be studied during this period5,6.

[0283] Traditional paradigms for studying mouse organogenesis involve focusing on individual organ systems at restricted stages of development and combining gene knockout studies with phenotyping by anatomical morphology, in situ hybridization, immunohistochemistry7,8, or more recently, transcriptomic or epigenomic profiling.9 Although such focused studies have provided fundamental insights into mammalian development, the underlying technologies lack the throughput and resolution to obtain a complete picture of the dynamic molecular processes ongoing in diverse and rapidly expanding populations and subpopulations of cells during organogenesis.

[0284] "Shotgun profiling" of the molecular content of single cells represents a promising avenue to address these shortcomings and further advance our understanding of mammalian development. For example, the application of single-cell RNA-seq methods has recently revealed a large heterogeneity in neurons and cardiomyocytes during mouse development10,11. Although two single-cell transcriptional atlases for the mouse have been recently published and represent important resources for the field12,13, they are almost exclusively restricted to adult organs and do not attempt to characterize the emergence and temporal dynamics of mammalian cell types during development.

[0285] Single-cell combinatorial indexing ("sci-") is a methodological framework that uses split-pool barcoding methods to uniquely label the nucleic acid content of large numbers of single cells or single nuclei14-21. We recently developed a "sci-" protocol for transcriptomes ("sci-RNA-seq") and applied it to generate 50-fold "shotgun cell coverage" of the nematode Caenorhabditis elegans at the L2 stage19. Although the throughput of the "sci-" method increases exponentially with the number of indexing rounds, this potential has yet to be fully realized due to other factors such as cell loss rates and limited reaction efficiency at some stages19,21. To address this, we developed and extensively optimized three-level sci-RNA-seq (sci-RNA-seq3), resulting in a workflow capable of profiling more than one million cells per experiment. As previously described 19 , multiple samples (e.g., replicates, time points) can be barcoded and processed simultaneously during the first round of indexing.

[0286] Here we set out to investigate the transcriptional dynamics of mouse development during organogenesis at single-cell resolution using sci-RNA-seq3. In one experiment, we profiled over 2 million single cells derived from 61 mouse embryos (10 to 15 replicates at each time point) between E9.5 and E13.5. From these data, we identify 38 major cell types, and over 600 more granular cell types (herein termed "subtypes" to distinguish them from the 38 major cell types). Overall, we discover thousands of new candidate marker genes for cell types and subtypes, and validate representatives by whole-mount in situ hybridization. We quantify proliferation and gene expression dynamics in expanding and transient cell types during mid-gestation, including focused analysis of the apical ectodermal ridge, limb mesenchyme, and skeletal muscle. Using novel algorithms, we define the major single-cell developmental trajectories of mouse organogenesis and discover among these examples of distinct pathways to the same endpoint: divergence and convergence. All data are made freely available in a manner that facilitates continued annotation by the research community.

[0287] result Profiling 2 million cells from 61 mouse embryos across five developmental stages using sci-RNA-seq3

[0288] To increase the throughput of sci-RNA-seq, over 1,000 experimental conditions were investigated. Compared to the original description of the method, 19 The main improvements introduced by sci-RNA-seq3 (Figure 4A, Methods) are: (i) we developed a new nuclear extraction and fixation strategy, in which nuclei are directly extracted from fresh tissues without any enzymatic treatment. After nuclear extraction, nuclei can be fixed in 4% paraformaldehyde and stored in liquid nitrogen until further processing. (ii) We have developed a novel method to improve the accuracy of our previous three-level indexing description. 19In comparison, we switched from indexed Tn5 tagmentation to indexed hairpin ligation. (iii) Some individual reactions, e.g., reverse transcription, have been further optimized for efficiency. (iv) The FACS sorting step has been omitted, and sonication and filtration steps have been added to minimize nuclear clumping. The library preparation step of sci-RNA-seq3 can be completed by one person in one week, greatly exceeding the "per experiment" throughput of alternative sc-RNA-seq protocols (Figure 4B).

[0289] We collected C57BL / 6 mouse embryos between E9.5 and E13.5, including 10 to 15 embryos from at least three independent litters per stage, and flash-frozen them in liquid nitrogen. Subsequently, we isolated nuclei from 61 individual whole embryos and performed sci-RNA-seq3 (Figure 4A). Nuclei from each embryo were placed in different wells during the first round of indexing, so that the RNA-seq profiles of individual nuclei could be linked to the embryos from which they originated (Figure 5A). As an internal control, we also spiked a mixture of HEK293T and NIH / 3T3 cells into two wells during the first round of indexing. After completion of the sci-RNA-seq3 protocol, the resulting library was sequenced in a single NovaSeq run, yielding 11 billion reads (Figure 5B).

[0290] From this single experiment, we recovered 2,072,011 single-cell transcriptomes (>200 unique molecular identifier or UMI counts), including 2,058,652 cells from 61 mouse embryos and 13,359 cells from HEK293T or NIH / 3T3 cells. Encouragingly, HEK293T and NIH / 3T3 cell transcriptomes overwhelmingly mapped to genomes of one species or the other, with 420 collisions (3%) (Figure 4C). At a sequencing depth of 23,207 reads per cell, we observed a median of 3,676 UMIs per HEK293T cell and 5,163 UMIs per NIH / 3T3 cell, with 3.9% and 2.9% of reads per cell mapping to the wrong species, respectively (Figure 5C-D). Previously collected datasets 19 We compared the original sci-RNA-seq protocol with sci-RNA-seq3 by downsampling to equivalent sequencing depth per HEK293T or NIH / 3T3 cell. The sci-RNA-seq3 protocol showed a 40-fold increase in throughput but comparable efficiency in terms of the number of UMIs detected per cell (Figure 5E). Furthermore, aggregate transcriptomes of HEK293T single-cell profiles derived from sci-RNA-seq3 and sci-RNA-seq were highly correlated (Pearson: 0.98, Figure 5F).

[0291] We mapped 2,058,652 embryo-derived cells to 61 individual embryos based on their first-round barcodes (median 35,272 cells per embryo; Figure 4D). The number of cells recovered from each embryo correlated well with the number of first-round wells assigned to it (Spearman: 0.75, Figure 6A). At a relatively shallow sequencing depth (~5,000 reads per cell), we identified a median of 519 genes (671 UMIs) per cell (Figure 4E). This is comparable to other scRNA-seq studies in which diverse cell types have been differentiated and annotated, despite using less than one-third the raw sequencing reads per cell. 19,21,22Late embryos (E12.5 and E13.5) had somewhat lower UMI counts per cell, suggesting a decrease in mRNA content per nucleus during development (Figure 6E).

[0292] Based on rough estimates of cell numbers per embryo at each time point (Methods), summing 10-15 total replicates per time point, we estimate that the "shotgun cell coverage" of mouse embryos would be 0.8x at E9.5 (200K cells per embryo; 152K profiled here), 0.3x at E10.5 (1.1M cells; 378K profiled), 0.2x at E11.5 (2M cells; 616K profiled), 0.08x at E12.5 (6M cells; 475K profiled), and 0.03x at E13.5 (13M cells; 437K profiled). Thus, while still not "oversampling", the number of cells we are profiling at each stage represents a significant percentage of the cellular content of individual mouse embryos (3-80%).

[0293] As a check on data quality, we aggregated the single-cell transcriptomes of each individual to generate 61 "pseudo-bulk profiles" of mouse embryos. By counting the number of UMIs that mapped to Xist transcripts (expressed only in females) or to Y chromosome transcripts, mouse embryos were readily separated into male (x=31) and female (n=30) groups (Figure 4F) in a manner balanced with respect to male vs. female copy numbers at each stage (Figure 6F).

[0294] As a further quality check, we subjected the "pseudobulk" transcriptomes of 61 embryos to t-stochastic neighbor embedding (t-SNE), which ensured that the five clustered groups were perfectly matched to developmental stages (Figure 7A). We also performed a Monocle analysis based on the top 1,000 differentially expressed genes across all time points. 23We used Sigma to order mouse embryos along a "pseudotime" trajectory, and the resulting order is also consistent with expectations (Figure 4G). Notably, there are two notable gaps in the embryo-level pseudotime trajectory, one between E9.5 and E10.5 and the other between E11.5 and E12.5, suggesting dramatic changes in the global transcriptome during these periods. We assigned pseudotimes to each embryo, potentially reflecting a more fine-grained assessment of developmental stages (Figure 7B). For example, E10.5 embryos positioned early and late in the developmental pseudotime were morphologically distinct (Figure 7C).

[0295] We also investigated global transcriptome changes during development. 12,236 genes were differentially expressed across different developmental stages (data not shown); some of the most dynamic genes are plotted in Figure 4H. As expected, we observe increased expression of adult hemoglobin genes such as Hbb-bt and Hbb-bs, and decreased expression of embryonic hemoglobin genes such as Hbb-bh1 and Hbb-x. Cntn4 24 , Neurod2 25 and Neurod6 26 Genes with known roles in neural differentiation, such as Slc35f4, Prtg and Trim30a, show increased expression at later stages. However, many highly dynamic genes, such as Slc35f4, Prtg and Trim30a, have not been characterized so far. Regardless, our assumption - and indeed the motivation for collecting single-cell data - is that the dynamics of "whole embryo" gene expression are driven primarily by dramatic changes in the relative proportions of different cell types, rather than by changes within single cell types.

[0296] Identification and annotation of major cell types and subtypes present during mouse organogenesis To identify major cell types, we subjected 2,058,652 single-cell transcriptomes (i.e., all embryos from all time points) to Louvain clustering, identifying 40 distinct groups and performing t-SNE visualization (Figure 8A). Encouragingly, we observe clear differences between cells derived from different time points (Figure 9A), whereas cells derived from replicate embryos at the same time point are similarly distributed (Figure 10). Based on the gene sets unique to each of these 40 clusters, we manually curated cell type assignments by comparison to published marker genes (data not shown). For 37 clusters, we were able to reliably assign them to exactly one literature-defined cell type, whereas two clusters both corresponded to a definitive erythroid lineage. One cluster had an unusually high UMI count but no strongly cluster-specific genes, suggesting that this may be a technical artifact of cell doublets. Merging the definitive erythroid lineage clusters and discarding the putative doublet clusters resulted in 38 major cell types (Figure 8A). For many clusters, highly specific marker genes simplified cell type identification (Figure 8B, Figure 9B-Figure 9C, data not shown). For example, cluster 6 (epithelial cells) expressed the well-characterized marker genes Epcam and Trp63. 27、28 Cluster 29 (hepatocytes) specifically expressed Afp and Alb. 12 Smaller clusters could be easily annotated, including those corresponding to highly specialized cell types. For example, transcripts highly expressed during retinal development, such as Tyr and Trpm1, were enriched in cluster 36, strongly suggesting that these are melanocytes. 29,30 Cluster 37 was enriched for transcripts expressed exclusively in the developing lens. For the clusters corresponding to embryonic mesenchyme and connective tissues, cell type discrimination was more difficult due to the paucity of highly specific marker genes available in the current literature.

[0297] Of the 26,183 genes, 17,789 genes (68%) were differentially expressed in the 38 major cell types (FDR 5%) (Figure 9B, data not shown). Among these, we identified 2,863 cell type-specific markers, the majority of which to the best of our knowledge have not been previously associated with their respective cell types (average of 75 markers per cluster; Figure 8B, Figure 9C). As an example of how these data can help define new, developmental and cell type-specific markers of gene expression, consider Sonic Hedgehog (Shh), which has been shown to play a key role during the development of many organ systems, including limbs, brain, thalamus, spinal cord and midline structures of the lungs. 31 The present inventors have identified 16 genes, all of which are known to be expressed in cells of the developing notochord and floor plate. 32~34 We detected the highest expression of Shh in cluster 30 (notochord; data not shown), together with Ntn1, Slit1, and Spon1. However, genes Tox2, Stxbp6, Schip1, and Frmd4b, which have not previously been reported as markers of the notochord, were also highly specific to cluster 30.

[0298] As expected, we observed a striking change in the proportion of cell types during organogenesis. Most of the 38 major cell types expanded exponentially, while some were transient and eventually disappeared at E13.5 (Figure 11A-B). For example, the primitive erythroid lineage derived from the yolk sac, represented by cluster 26, was characterized by Hbb-bh1 expression, and the definitive erythroid lineage derived from the fetal liver was marked by Hbb-bs expression in cluster 22 (data not shown). At E9.5, we detected cells corresponding mainly to the primitive erythroid lineage (Figure 8A). Over the next 5 days, the definitive erythroid lineage became the major cell type in the fetal circulation and eventually became the exclusive erythroid lineage by E13.5 (Figure 8A). The corresponding genetic markers showed similar kinetics (Figure 11C).

[0299] The median number of 38 major cell types identified here was 47,073 cells, with the largest cluster containing 144,648 cells (connective tissue progenitor cells; 7.0% of the entire data set) and the smallest cluster containing only 1,000 cells (monocytes / granulocytes; 0.05% of the entire data set). Because cell type heterogeneity was readily apparent in many of these 38 clusters, we employed an iterative strategy in which we repeated the Leuven clustering on each major cell type to identify subclusters (Figures S12-S13). After subclusters dominated by one or two embryos were removed and highly similar subclusters were merged (Methods), a total of 655 subclusters were identified (herein referred to as "subtypes" to distinguish them from the 38 major cell types; Figures S12-S13). Of note, the sensitivity of detecting cell types and subtypes in this study was a direct function of the large number of cells profiled. For example, repeating Louvain clustering on 2.5% of our data (50,000 cells) identified only a subset of cell types and subtypes (Figure 14).

[0300] The 655 subtypes were comprised of a median of 1,869 cells, ranging from 51 cells (notochordal cell subtype) to 65,894 cells (connective tissue progenitor cell subtype) (Figure 15A).

[0301] Nearly all subtypes (99%) were composed of multiple embryo contributions, with no single embryo dominating (Figure 15B-C). Supporting the view that these subtypes constitute bona fide transcriptional programs distinct from related subtypes, we identified a median of 55 specific markers per subtype (Figure 15D; subtype-specific markers are defined by their specificity within the corresponding major cell type, not across the entire dataset). Even more than the 38 major cell types, individual subtypes exhibited variable dynamics between E9.5 and E13.5. The majority of subtypes (64%) showed an increase in estimated cell number, 12% a decrease, and 24% showed a more complex pattern (Figure 16A-B). Interestingly, we could easily separate embryos of different developmental stages based solely on the proportion of cells assigned to each subtype (Figure 16C).

[0302] Characterization of gene expression trajectories during limb apical ectodermal ridge (AER) development As an example of what can be achieved with detailed subtype annotation and exploration, we focused on epithelium (cluster 6), specifically the apical ectodermal ridge (subcluster 6.25). Based on subtype-specific marker genes, we annotated 29 subtypes of epithelium (cluster 6; Figure S17A; Figure S18A, data not shown). For example, epithelial cells of subtype 6.10 were marked by Oc90, a gene expressed exclusively in the epithelium of the otic vesicle, whereas 35 Subtype 6.25 epithelial cells showed increased expression of the well-characterized marker genes Fgf8, Msx2 and Rspo2, which are specific to the apical ectodermal ridge (AER), a highly specialized epithelium involved in digit development. 36For all epithelial subtypes, we identified genes not previously known as markers. For example, the AER was also distinguished by expression of Fndc3a, Adamts3, Slc16a10, Snap91, and Pou6f2. Whole-mount in situ hybridization (WISH) of Fgf8 (known marker) and Fndc3a (novel marker) confirmed that both genes were expressed in the distal-most tip of the limb bud, which represents the AER at E10.5 (Figures 17B-E).

[0303] Next, we investigated the dynamics of cell proliferation and gene expression during AER development. We identified a total of 1,237 AER cells, which represents only 0.06% of the entire dataset, with nearly all embryos contributing (45 of 61 with more than 5 AER cells profiled). Although AER cells are detected at all time points, we observed that they peak in terms of cell percentage per embryo at E9.5 and then decline (Figure 17F), which is consistent with previous reports. 37 and consistent with our in situ demonstration (Figure 17C). To characterize the dynamics of gene expression within the AER during development, we performed pseudotime series analysis of AER cells based on the top 500 differentially expressed genes in the developmental stages, generating a simple early-to-late trajectory (Figure 17G). 710 protein-coding genes were differentially expressed (FDR 5%) along the developmental pseudotime (data not shown). For example, Fgf9, known to exhibit AER-specific expression in limb buds, 38 , showed delayed activation kinetics compared to Fgf8 and Fndc3a (Figure S17H). Significantly activated genes may play important roles in the differentiation of AER cells. For example, activated genes include Rspo2, which is known to be important for the maintenance of the AER and growth and pattern formation in limb development. 39 (Figure 17H).

[0304] We also identified genes whose expression was significantly decreased in AER cells between E9.5 and E13.5 (169 genes with an FDR of 1%; Figure 19A). These included Ki67 (Mki67) and insulin-like growth factor 2 (Igf2), both of which have roles in promoting cell proliferation. 40,41 (FIG. S4H). Indeed, pathway-level analysis of genes significantly decreased during this developmental window, consistent with AER-induced proliferation arrest, highlights terms related to cell cycle progression and glucose metabolism, as well as transcription factors associated with pluripotency (Isl1, Pou5f1, Nanog) (FIGS. S5B-C).

[0305] Characterizing cell fate trajectories during limb mesenchyme development We then decided to investigate the developmental trajectories that cell types go through during this critical period of mammalian development, including transitions between cell types and subtypes. Most contemporary algorithms for pseudochronic trajectory reconstruction have two major limitations. First, they assume that cells exist on a single continuous manifold, i.e., there are no discontinuities between subsets of cells. However, because early embryos are derived from E9.5, our dataset is unlikely to contain cells that correspond to at least some ancestral states. Second, they assume that the underlying trajectory is a tree whose branching points correspond to fate decisions. However, it is known that some tissues contain transcriptionally distinct lineages, i.e., transcriptionally indistinguishable cells resulting from the convergence of trajectories separated by one or several branching events.

[0306] To address these limitations, we developed the Monocle package 42We developed a novel algorithm, embedded in Monocle 3, to decompose multiple disjoint trajectories while allowing both divergence and convergence within the trajectories. Monocle 3 starts by projecting cells into a low-dimensional space that encodes their transcriptional state using Uniform Manifold Approximation and Projection (UMAP). Monocle 3 then uses Louvain clustering to detect communities of mutually similar cells and approximate graph abstraction (AGA) algorithms. 44 We then merge adjacent communities using a statistical test introduced in. Importantly, these procedures allow the maintenance of multiple disjoint cell communities. The final stage of Monocle 3 aims to decompose the paths that individual cells can take during development, identifying places of divergence and convergence, i.e., trajectories, within the sets of cells that make up each community. We previously described a procedure called "L1-graph" that embeds a "principal graph" within the projection of the RNA-seq profile of a single cell, such that every cell is near some point on the graph. 45 Although the L1-graph was able to learn trajectories with closed loops and branches, it only ran on datasets containing a few hundred cells. To allow the algorithm to handle thousands or even millions of cells, we implemented two extensions. First, we run it on hundreds of centroids of the data, rather than on the cells themselves. Second, we constrain the linear programming method of the algorithm to respect the bounds between disjoint trajectories defined by the AGA test.

[0307] We first sought to apply this new algorithm to a single major cell type, cluster 25. 26,559 cells in cluster 25 are annotated as limb bud mesenchyme based on Hoxd13, Fgf10, and Lmx1b expression (data not shown). Visualization of cell trajectories in this cluster with Monocle3 reveals a dramatic expansion of limb mesenchyme cells over the developmental period, with the main major outgrowth occurring between E10.5 and E12.5 (Figure 20A). Gene expression is never static during this expansion, with levels of 4,763 protein-coding genes changing substantially (1% FDR; data not shown). The early stages of limb mesenchyme development are marked by the expression of Tbx15. 46 , and Gpc3 47 The later stages were characterized by several predicted genes, such as Msx1 48 , Epha4 49 and Dach1 50 The dynamic expression of genes is characterized by a number of distinct morphological and physiological roles (Figure 21A), although the majority of the dynamically expressed genes are novel. Transcription factors that were significantly upregulated during limb mesenchyme development included those involved in chondrocyte differentiation (e.g., Sox9 51 and Yap1 52 ), muscle differentiation (e.g., Tead4 53 ), and wound healing and limb regeneration (e.g., Smarcd1 54 ) were included (Figure 21B).

[0308] Interestingly, forelimb and hindlimb cells were not easily separated by unsupervised clustering ( Figure 21C ) or trajectory analysis ( Figure 22A ), but could be distinguished by mutually exclusive expression of Tbx5 in the forelimb (2,085 cells, 7.9% of all limb mesenchymal cells) and Pitx1 in the hindlimb (1,885 cells, 7.1% of all limb mesenchymal cells), with only 22 cells expressing both markers (0.08% of all limb mesenchymal cells versus the expected value of approximately 0.6% if expressed independently; Figure 20B ). 55In this way, 285 genes were differentially expressed between cells allocated to the forelimb and hindlimb (Figure 20C and data not shown). 56 Genes were upregulated in hindlimb cells as expected, but novel markers were also identified: for example, we observed that Epha3 and Hs3st3b1 were enriched five-fold in the forelimb, and Pcdh17 and Igf1 were enriched three-fold in the hindlimb.

[0309] Although developmental time is the primary axis of variation in Monocle3 limb mesenchymal trajectories (Figure 20A), there are clearly additional structures, at least in part, that appear to correspond to two major spatial axes of limb development: the proximal-distal axis (the primary direction of large elongations) and the anterior-posterior axis (corresponding to the 5 digits). 55 For example, Sox6 and Sox9 (proximal) 57、58 , Hoxd13 and Tfap2b (distal) 36 , Pax9 and Alx4 (anterior), and Shh and Hand2 (posterior) were differentially distributed on the Monocle 3 locus (Figure 20D; Figure 22B). Whole-mount in situ hybridization of Hoxd13 (a known distal marker) and Cpa2 (a novel marker whose distribution on the Monocle 3 locus resembled that of known distal markers) confirmed that both genes were expressed in the distal limb mesenchyme between E10.5 and E13.5 (Figure 20F-Figure 20H). Application of Moran's test to detect spatial autocorrelation to the limb mesenchyme trajectory revealed 1,191 significantly differential genes (FDR 1%, Moran's I>10). These genes clustered into eight expression patterns, some of which matched the distribution of markers on the proximal-distal and anterior-posterior axes (Figure 23, data not shown).

[0310] A summary of our results for AER and limb mesenchymal trajectories is shown in Figure 20I. Although limb development is defined by a relatively simple trajectory, our analysis demonstrates how this single-cell atlas of mouse organogenesis can be used to characterize the spatiotemporal dynamics of gene expression in specific systems.

[0311] Delineation and characterization of key cell lineages in mouse organogenesis Next, we sought to identify the major developmental lineages and cell trajectories across the entire dataset. Monocle3 organized the 100,000 sampled high-quality cells (UMI>400) into eight well-separated lineages (Figure 24A, Figure 25A). Nearly all of the 38 major cell types fall almost exclusively into one of these eight groups (Figure 24B). The exceptions are three of the four smallest clusters, monocytes / granulocytes (36 cells), lens (125 cells), and megakaryocytes (287 cells), likely due to their low numbers. The two most complex structures are apparently the mesenchymal trajectory, which includes all mesenchymal and muscle cell types (Figure 24A and Figure 25A, left), and the neural tube / notochord trajectory, which includes notochord, neural tube, primitive and developing nervous system and glial cell types (Figure 24A and Figure 25A, right). The first neural crest trajectory ("neural crest 1") contains melanocyte and Schwann cell precursors, while the second neural crest trajectory ("neural crest 2") is composed of sensory neurons. The hematopoietic trajectory includes megakaryocytes, erythrocytes and lymphocytes, while the remaining three trajectories (hepatic, endothelial and epithelial) each correspond to a single major cell type. Although the estimated number of cells per embryo in each of these lineages increases exponentially from E9.5 to E13.5, their proportions remain relatively stable (from 0.3% at E9.5 to 2.8% at E13.5), with the exception of hepatocytes, which expand their contribution almost ten-fold during that developmental window (Figure 25B-C).

[0312] UMAP projects cells of the same type to a defined region, but unlike t-SNE, it places related cell types near each other. For example, early mesenchymal cells appeared to radiate from a defined region to muscle cells, limb mesenchyme, chondrocytes / osteoblasts, and connective tissue (Figure 24A, left). Similarly, cell types seen at later developmental time points, such as glutamatergic neurons, are separated from early central neural precursors (e.g., radial glia) by a "bridge" of neural progenitor cells (Figure 24A, right). On the other hand, discontinuities (e.g., between the eight major lineages) likely reflect a lack of representation of intermediate or ancestral states among these groups, resulting in our study being restricted to E9.5–E13.5.

[0313] Similar to recurrent subclustering, when each of the eight major lineages was subjected to trajectory analysis as described above individually, the mesenchymal trajectories and neural tube / notochord trajectories were reorganized as described above (Figures 26-27, top row), while the major lineages (epithelial, endothelial, etc.) showed multiple discontinuous sublineages, potentially revealing detailed trajectories of subtypes (Figures 26-27, remaining rows). For example, when we annotated the epithelial trajectory with 29 subtypes (Figure 17A), we observed several distinct subtrajectories, each emanating from a focal concentration of E9.5-derived cells, a subset underlying the epithelial subtypes (Figures 24C, 28). For example, epithelial cells of the apical ectodermal ridge (Figure 17G) formed a linear subtrajectory of cells from E9.5 to E13.5, well separated from other epithelial subtrajectories (Figure 24C, bottom center).

[0314] Reconstructing cell trajectories during skeletal myogenesis Considerable further work is required to fully elucidate the relationships of cell types and subtypes that make up the trajectories depicted in Figure 24, especially the more complex trajectories. As a representative example of what may be possible, we sought to investigate in more detail the developing musculature, which is composed of different mesodermal lineages that form before the onset of organogenesis. For example, for the extraocular muscles the prechordal mesoderm contributes, while others in the face and jaw are generated by the pharyngeal mesoderm. Skeletal myogenesis is driven by a core set of myogenic regulatory factors (MRFs) that are activated by a distinct set of upstream genes. 59 For example, Pax3 activates Myod1 in trunk muscles, but in the head, Pax3 is dispensable and MRFs are activated by Pitx2 and Tbx1. 60~62 Myod1 or Myf5 activate myogenin, driving the expression of numerous genes required for contractile skeletal muscle. We hypothesized that, when viewed at the whole-embryonic scale, the myogenic locus is characterized by multiple entry points that feed cells into a common pathway that corresponds to the activation of a core gene expression program shared in myotubes.

[0315] To test this hypothesis, we separated myocytes and their putative "progenitor" cells from the mesenchymal trajectory by quantifying the fraction of cells at each principal graph node that were initially classified as myocytes (cluster 13). We collected all "multiple myocyte" nodes and then used the edges of the principal graph to expand this set of nodes to a wider "neighborhood" of cells (Figure 29A). We then re-ran Monocle3 on this subset of cells to construct a myogenesis-specific trajectory. This trajectory was characterized by multiple focal concentrations of cells from E9.5, with cells from later stages distributed across several trajectories that radiated outward (Figure 29B), and Pax3 and Pax7, which mark skeletal muscle progenitors, were expressed in cells distributed throughout a broad swath of the principal graph (Figure 29C). Two parallel line segments emanated from this region of the graph where cells expressed Myf5 or Myod. Both pathways feed into a common region occupied by cells expressing Myog or Myh3, markers of muscle cells and myotubes, respectively. An additional pathway, traversed by E9.5-derived cells expressing Lhx2, Tbx1, and Pitx2, but very low levels of Pax3, feeds into a trajectory just upstream of the Myf5 and Myod1 segments that may correspond to pharyngeal mesoderm. Thus, the dynamics of MRFs and their upstream activators across the trajectories were consistent with the view that different mesodermal lineages use distinct factors to converge on a core program of muscle genes (Figure 29D).

[0316] Consider In this study, we seek to characterize mammalian development by profiling the transcriptome of single cells at the scale of the whole mouse embryo, focusing on a period corresponding to classical organogenesis. By profiling over 2,000,000 cells from 61 individual embryos in a single experiment using sci-RNA-seq3, we also provide a technical framework for small-scale laboratories to generate single-cell RNA-seq datasets with unprecedented throughput. To resolve divergences, convergences, and discontinuities in developmental trajectories, we present Monocle 3, a novel algorithm for trajectory inference that scales to millions of cells.

[0317] In mid-gestation mouse embryos, we identify 38 major cell types and over 600 subtypes. Each of these types and subtypes is characterized by the expression of a set of marker genes, the majority of which are novel, representative of which we validate by whole-mount in situ hybridization. Illustrating the utility of deep shotgun cell coverage to characterize rare cell types, we highlight markers and dynamically expressed genes in the apical ectodermal ridge (AER), a specialized epithelium with a key role in digit development but which represents only 0.06% of the cells profiled here. The 38 major cell types are broadly resolved into eight trajectories, including mesenchymal, neural tube / notochord, hematopoietic, hepatic, endothelial, epithelial, and two neural crest trajectories. The discontinuity between these eight trajectories may be a result of the lack of representation of ancestral or intermediate states in the dataset starting from E9.5. Limb mesenchymal trajectory analysis reveals correlates of developmental heterogeneity corresponding to both time and multiple spatial axes. Focusing on a subset of mesenchymal trajectories corresponding to muscle cells and their progenitors, we identify multiple sub-trajectories that feed into a common endpoint corresponding to myotubes. This example of "convergence" of expression programs contrasts with the branching structure assumed by most algorithms for developmental trajectory estimation.

[0318] Our study has several limitations that need to be considered. First, like other single-cell atlases, individual cell transcriptome data are scattered throughout. However, previous studies have shown that transcriptional programs can be readily distinguished within single-cell transcriptome datasets at surprisingly shallow sequencing depths. 63 Our ability to define 655 transcriptionally distinct subtypes with a median of 671 UMI per cell is consistent with this view, and by aggregating transcriptomes with each cell type or subtype, we can construct representative expression profiles. Second, we are reasonably confident in most cell type assignments made here, which should still be considered preliminary. A key challenge is that mid-gestational mouse development (E9.5–E13.5) has never before been studied at either single-cell resolution or whole-organism scale. Existing single-cell transcriptional atlases profile individual organs in the adult mouse or at late embryonic stages. 12、13 Although we have made significant progress so far, a comprehensive annotation of these 655 cell subtypes is an ongoing project, and we expect that community input and domain expertise will be leveraged to reach a stable consensus. To that end, we have created a wiki (available on the World Wide Web at atlas.gs.washington.edu / mouse-rna / ) to facilitate annotation by us and the community. The specific page for each subtype includes a downloadable matrix of the cells that compose it, a list of marker genes specific for that subtype, and a description of the dynamics of that subtype in the developmental window examined here.

[0319] A long-standing goal of the field, perhaps ultimately from a technical point of view, seems to be to create a comprehensive, spatiotemporally resolved molecular atlas of mammalian development at single-cell resolution. Towards this end, focusing on the mouse has several advantages, including its small size, accessibility to early developmental time points, inbred genetic background, and genetic manipulability. By profiling a large number of cells corresponding to a significant percentage of the cellular content of individual mouse embryos (3–80% “shotgun cell coverage” per stage), these data will constitute a powerful resource for the developmental biology field and may also help further the development of computational methods to resolve and interpret cell types or developmental trajectories. Going forward, further studies will be conducted on the transcriptome, additional molecular phenotypes, and the developmental biology of mammalian embryos. 64 , History of lineage 65 We anticipate that integrated measures of retinal and spatial information will further shape a holistic view of mammalian development.

[0320] In conclusion, we note that our single-cell atlas of wild-type mouse development represents a first step towards understanding pleiotropic developmental disorders at an organismal scale and will also aid in the detailed investigation of the subtle roles of genes and regulatory sequences in developmental processes. For example, approximately 35% of gene knockouts in mice are lethal, 5 However, many knockouts, especially those of conserved regulatory sequences, do not show any abnormalities in traditional phenotypic classifications. 66 We predict that organism-scale sc-RNA-seq will empower reverse genetics, potentially enabling the discovery of previously overlooked phenotypes, for example those with subtle defects in molecular programs or the relative proportions of specific cell types. 67 .

[0321] method embryo dissection C57BL / 6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and plug mating was set up. The day of plugging was considered as embryonic day (E) 0.5. Dissection was performed as previously described. 69, all embryos were immediately flash frozen in liquid nitrogen. All animal procedures followed institutional, state, and federal regulations (IACUC protocol 4378-01).

[0322] Whole-mount in situ hybridization mRNA expression in E9.5–E11.5 mouse embryos was assessed by whole-mount in situ hybridization (WISH) using digoxigenin-labeled antisense riboprobes transcribed from cloned gene-specific probes (PCR DIG Probe Synthesis Kit, Roche). Whole embryos were fixed overnight in 4% PFA / PBS. Embryos were washed in PBST (0.1% Tween), dehydrated stepwise in 25%, 50%, and 75% methanol / PBST, and finally stored in 100% methanol at -20°C. The WISH protocol was as follows: day 1) Embryos were rehydrated on ice with reverse methanol / PBST steps, washed in PBST, and dehydrated in 6% H 2 O 2The embryos were then bleached in 10 μg / ml proteinase K / PBST for 1 h and washed in PBST. The embryos were then treated with 10 μg / ml proteinase K / PBST for 3 min, incubated in glycine / PBST, washed in PBST, and finally re-fixed in 4% PFA / PBS, 0.2% glutaraldehyde, 0.1% Tween 20 for 20 min. After a further washing step with PBST, the embryos were incubated in L1 buffer (50% deionized formamide in DEPC, 5xSSC, 1% SDS, 0.1% Tween 20; pH 4.5) at 68 °C for 10 min. The embryos were then incubated in hybridization buffer 1 (L1 with 0.1% tRNA and 0.05% heparin) at 68 °C for 2 h. Embryos were then incubated overnight at 68 °C in hybridization buffer 2 (hybridization buffer 1 containing 0.1% tRNA and 0.05% heparin and 1:500 DIG probe). Day 2) Removal of unbound probe was performed by a series of washing steps with L1, L2 (50% deionized formamide, 2xSSC pH 4.5, 0.1% Tween 20 in DEPC; pH 4.5) and L3 (2x SSC pH 4.5, 0.1% Tween 20 in DEPC; pH 4.5) for 3x30 min each at 68 °C. Embryos were then incubated overnight at 68 °C in RNase solution (0.1 M NaCl, 0.01 M Tris pH 7.5, 0.2% Tween 20, H 2 After treatment with 100 μg / ml RNase A in 1000 for 1 h, embryos were washed with TBST 1 (140 mM NaCl, 2.7 mM KCl, 25 mM Tris-HCl, 1% Tween 20; pH 7.5). Embryos were then blocked in blocking solution (TBST 1 with 2% calf serum and 0.2% BSA) for 2 h at RT, followed by incubation in blocking solution containing 1:5000 anti-digoxigenin AP at 4 °C. Day 3) Removal of unbound antibodies was performed in a series of washing steps with TBST 2 (TBST with 0.1% Tween 20, and 0.05% levamisole / tetramisole) for 8 × 30 min at RT, followed by overnight at 4 °C. Day 4) Embryos were stained in alkaline phosphate buffer (0.02 M NaCl, 0.05 M MgCl ) at RT. 2, 0.1% Tween 20, 0.1M Tris-HCl, and 0.05% levamisole / tetramisole, H 2 The embryos were incubated for 20 min at 37 °C for 1 h at 4 °C for 1 h at 4 °C for 1 h at 4 °C for 2 ...

[0323] mammalian cell culture All mammalian cells were cultured at 37°C with 5% CO2 and maintained in high glucose DMEM for HEK293T and NIH / 3T3 cells (Gibco Catalog No. 11965) supplemented with both 10% FBS and 1X Pen / Strep (Gibco Catalog No. 15140122; 100U / ml penicillin, 100μg / ml streptomycin). Cells were trypsinized with 0.25% typsin-EDTA (Gibco Catalog No. 25200-056) and split 1:10 three times a week.

[0324] Extraction and fixation of mouse embryo nuclei To reduce batch effects, mouse embryos from different developmental stages were processed together. Each mouse embryo was lysed in 1 mL of ice-cold cell lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 0.1% IGEPAL CA-630, 70The nuclei were minced into small pieces with a blade in 100% PBS (also modified to contain 1% SUPERase In and 1% BSA) and transferred onto the top of a 40um cell strainer (Falcon). The tissue was homogenized with the rubber tip of a syringe plunger (5ml, BD) in 4ml of cell lysis buffer. The filtered nuclei were then transferred to a new 15ml tube (Falcon), pelleted by centrifugation at 500xg for 5 minutes, and washed once with 1ml of cell lysis buffer. Nuclei were fixed in 4ml of ice-cold 4% paraformaldehyde (EMS) for 15 minutes on ice. After fixation, nuclei were washed twice with 1ml of nuclei wash buffer (cell lysis buffer without IGEPAL) and resuspended in 500ul of nuclei wash buffer. The sample was split into two tubes, 250ul in each tube, and flash frozen in liquid nitrogen.

[0325] As a quality control, HEK293T and NIH / 3T3 cells were trypsinized, spun down at 300xg for 5 min (4°C), and washed once with 1X PBS. Equal cell numbers of HEK293T and NIH / 3T3 cells were combined and lysed using 1 mL of ice-cold cell lysis buffer, followed by the same fixation and storage conditions as for mouse embryos.

[0326] sci-RNA-seq3 library preparation and sequencing Thawed nuclei were permeabilized with 0.2% tritonX-100 (in nuclei wash buffer) for 3 min on ice and briefly sonicated (Diagenode, 12 s in low power mode) to reduce nuclear clumping. Nuclei were then washed once with nuclei wash buffer and filtered through a 1 ml Flowmi cell strainer (Flowmi). Filtered nuclei were spun down at 500xg for 5 min and resuspended in nuclei wash buffer.

[0327] Nuclei from each mouse embryo were then distributed into several individual wells in four 96-well plates. The link between the well ID and the mouse embryo was recorded for downstream data processing. For each well, 80,000 nuclei (16 μL) were mixed with 8 μL of 25M fixed oligo-dT primer (5'- / 5Phos / CAGAGCNNNNNNNN[10bp barcode]TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3' (SEQ ID NO: 1), where "N" is any base; IDT) and 2 μL of 10 mM dNTP mix (Thermo), denatured at 55°C for 5 min, and immediately placed on ice. Then, 14 μL of first-strand reaction mix containing 8 μL of 5X Superscript IV First-Strand Buffer (Invitrogen), 2 μL of 100 mM DTT (Invitrogen), 2 μL of SuperScript IV reverse transcriptase (200 U / μL, Invitrogen), and 2 μL of RNaseOUT recombinant ribonuclease inhibitor (Invitrogen) was added to each well. Reverse transcription was performed by incubating the plate through a gradient of temperatures (4° C. for 2 min, 10° C. for 2 min, 20° C. for 2 min, 30° C. for 2 min, 40° C. for 2 min, 50° C. for 2 min, and 55° C. for 10 min).

[0328] After the RT reaction, 60 μL nuclei dilution buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 1% BSA) was added to each well. Nuclei from all wells were pooled together and spun down at 500×g for 10 min. Nuclei were then resuspended in nuclei wash buffer and redistributed into another four 96-well plates containing, in each well, 4 μL T4 ligation buffer (NEB), 2 μL T4 DNA ligase (NEB), 4 μL betaine solution (5M, Sigma-Aldrich), 6 μL nuclei in nuclei wash buffer, 8 μL barcoded ligation adapter (100 uM, 5'-GCTCTG[9 bp or 10 bp barcode A] / ideoxyU / ACGACGCTCTTCCGATCT[reverse complement of barcode A]-3') (SEQ ID NO: 2) and 16 μL 40% PEG 8000 (Sigma-Aldrich). The ligation reaction was carried out at 16°C for 3 hours.

[0329] After the RT reaction, 60 μL nuclei dilution buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 1% BSA) was added to each well. Nuclei from all wells were pooled together and spun at 600xg for 10 min. Nuclei were washed once with nuclei wash buffer, filtered twice through a 1 ml Flowmi cell strainer (Flowmi), counted and redistributed into eight 96-well plates, each well containing 2,500 nuclei in 5 μL nuclei wash buffer and 5 μL elution buffer (Qiagen). Then, 1.33 μl of mRNA second strand synthesis buffer (NEB) and 0.66 μl of mRNA second strand synthesis enzyme (NEB) were added to each well and second strand synthesis was carried out for 180 min at 16 °C.

[0330] For tagmentation, each well was mixed with 11 μL of Nextera TD buffer (Illumina) and 1 L of i7-only TDE1 enzyme (62.5 nM, Illumina) and incubated at 55 °C for 5 min to perform tagmentation. The reaction was then stopped by adding 24 μL of DNA binding buffer (Zymo) per well and incubating at room temperature for 5 min. Each well was then purified using 1.5xAMPure XP beads (Beckman Coulter). For the elution step, each well was added with 8 μL nuclease-free water, 1 μL 10X USER buffer (NEB), 1 μL USER enzyme (NEB) and incubated at 37 °C for 15 min. Another 6.5 μL elution buffer was added to each well. The AMPure XP beads were removed with a magnetic stand and the eluted products were transferred to a new 96-well plate.

[0331] For PCR amplification, each well (16 µL product) was mixed with 2 µL of 10 µM indexed P5 primer (5'-AATGATACGGCGACCACCGAGATCTACAC[i5]ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3'; IDT) (SEQ ID NO: 3), 2 µL of 10 µM P7 primer (5'-CAAGCAGAAGACGGCATACGAGAT[i7]GTCTCGTGGGCTCGG-3'; IDT) (SEQ ID NO: 4), and 20 µL of NEBNext High-Fidelity 2X PCR Master Mix (NEB). Amplification was performed using the following program: 72 °C for 5 min, 98 °C for 30 s, 12 to 14 cycles (98 °C for 10 s, 66 °C for 30 s, 72 °C for 1 min) and a final 72 °C for 5 min.

[0332] After PCR, samples were pooled and purified using 0.8 volumes of AMPure XP beads. Library concentrations were determined by Qubit (Invitrogen), and the libraries were visualized by electrophoresis on a 6% TBE-PAGE gel. All libraries were sequenced on one NovaSeq platform (Illumina) (read 1:34 cycles, read 2:52 cycles, index 1:10 cycles, index 2:10 cycles).

[0333] Sequencing read processing Base calls were converted to fastq format using Illumina's bcl2fastq and the maximum likelihood demultiplexing package deML with default settings. 71 The downstream sequence processing and single-cell digital expression matrix generation were performed as described in sci-RNA-seq, except that the mapped reads were split into constituent cell indexes by combining the RT index with the hairpin adapter index, i.e., by demultiplexing reads using both the RT index and ligation (ED<2, including insertions and deletions) indexes. 19 Briefly, demultiplexed reads were filtered based on RT index and ligation index (ED<2, including insertions and deletions) and adapters were clipped using trim_galore / 0.4.1 with default settings. STAR / v 2.5.2b with default settings and gene annotations. 72The trimmed reads were mapped to the mouse reference genome (mm10) for mouse embryonic nuclei, or to the chimeric reference genomes of human hg19 and mouse mm10 for HEK293T and NIH / 3T3 mixed nuclei using GENCODE V19 for human, GENCODE VM11 for mouse. Unique mapping reads were extracted and duplicates were removed using unique molecular identifier (UMI) sequences, reverse transcription (RT) index, hairpin ligation adapter index and read 2 end coordinates (i.e., identical UMI, RT index, ligation adapter index and tagmentation site were considered as duplicates). Finally, the mapped reads were split into constituent cell indexes by further demultiplexing the reads using RT index and ligation hairpin (ED<2, including insertions and deletions). For mixed species experiments, the percentage of unique mapping reads in the genome of each species was calculated. Cells with more than 85% of UMIs assigned to one species were considered species-specific cells, and the remaining cells were classified as mixed cells or "conflicts". To generate digital expression matrices, we used the Python HTseq package 73 We used qRT-PCR to calculate the number of strand-specific UMIs for each cell that map to exonic and intronic regions of each gene. For multiple mapping reads, the read was assigned to the nearest gene, except when the intersecting gene was within 100 bp of the end of the nearest gene, in which case the read was discarded. For most analyses, we included both intronic and exonic UMIs for the predicted strand in the single-cell expression matrix for each gene.

[0334] Mouse whole embryo analysis After the single-cell gene count matrix was generated, each cell was assigned to its original mouse embryo based on its RT barcode. Reads mapping to each embryo were aggregated to generate a "bulk RNA-seq" for each embryo. For embryo sex separation, we counted reads that mapped to the female-specific non-coding RNA (Xist) gene or the chr Y gene (except for the gene Erdr1, which is located on both chr X and chr Y). Embryos were easily separated into female populations (more reads mapped to the Xist gene than to the chr Y gene) and male populations (more reads mapped to the chr Y gene than to the Xist gene).

[0335] Pseudo-time series analysis of whole mouse embryos using Monocle 2 74 Briefly, aggregated gene expression matrices were constructed as described above. 74 The differentialGeneTest function of Monocle2 was used to identify genes that were differentially expressed across different developmental conditions. The top 2,000 genes with the lowest q-values ​​were used to identify genes that were differentially expressed across different developmental conditions. 74 Pseudotime trajectories were constructed using Each embryo was assigned a pseudotime value based on its position along the trajectory tree.

[0336] Cell clustering, t-SNE visualization and marker gene identification A digital gene expression matrix was constructed from the raw sequencing data described above. Cells with UMIs below 200 were discarded. 74 and the Python package scanpy 75 Downstream analysis was performed using scanpy. Briefly, prior to clustering and dimensionality reduction, gene counts that mapped to sex chromosomes were removed. The preprocessing step was performed using scanpy. 75 In the “zheng17 recipe” function (n_top__genes=2,000), Zheng et al. 22The dimensionality of the data was reduced first by PCA (30 components), then t-SNE, followed by Louvain clustering (resolution = 1.5) performed on the 30 principal components. 40 clusters were identified. We then sampled 1,000 cells from each cluster and ran the Monocle2 74 We identified genes that were differentially expressed between the different clusters using the DifferentialGeneTest function in . Genes specific to each cluster were identified previously as 76 Clusters were assigned to known cell types based on cluster-specific markers (Table 1). One cluster had an unusually high UMI count, but the cluster-specific genes were not robust, suggesting that this was a technical artifact of cell doublets and may therefore be removed. Another two clusters both appear to correspond to a definitive erythroid lineage and are merged. A common expression profile for each cell type was determined by 76 To identify cell type-specific gene markers, we selected genes that were differentially expressed in different cell types (5% FDR, likelihood ratio test) and had the highest expression in each cell type with at least a two-fold increase compared to the other cell type with the second highest expression.

[0337] [Table 1] [Table 2] [Table 3]

[0338] For subcluster identification, we selected high-quality cells (UMI>400) in each major cell type and applied PCA, t-SNE, and Louvain clustering as well as common cluster analysis. Highly biased subclusters were excluded if most cells (>50%) of a cluster were from a single embryo. Highly similar subclusters were merged if the aggregated transcriptomes were highly correlated (Pearson correlation coefficient>0.95) and two clusters were close to each other in t-SNE space. Differentially expressed genes across subclusters were identified for each major cell type as described above.

[0339] For estimation of cell numbers of each cell type (or subcell type), we first calculated the percentage of each cell type in individual embryos and then multiplied that percentage by the estimated total cell number in each embryo (E9.5: 200,000; E10.5: 1,100,000; E11.5: 2,600,000; E12.5: 6,100,000; E13.5: 13,000,000).

[0340] To identify sex-specific cell types (or sub-cell types), we first calculated the number of cells in each cell type (sub-cell type) in males and females across the five developmental stages. The cell type-specific ratios between males and females were compared with the ratio of overall cell numbers between males and females at each developmental stage. We then applied a binomial test in R to identify cell types or sub-cell types that were significantly different between males and females in each cell type (x and n are the number of female cells and total cells in each cell type from each developmental stage, and p is the female cell ratio at each developmental stage). The p-values ​​were converted to q-values ​​adjusted by the Benjamini & Hochberg method using the p.adjust function in R.

[0341] Pseudotemporal analysis of the AER and limb mesenchyme A pseudo-time series analysis of AER cells, forelimbs, or hindlimb (hidnlimb) was performed using Monocle 2 74 In short, Monocle2 74Differentially expressed genes across the five developmental stages were identified using the DifferentialGeneTest function in Monocle 2. The top 500 genes with the lowest q-values ​​were used to perform a quantification run. 74 Pseudotime trajectories were constructed using Monocle2, with UMI counts per cell used as a covariate in tree construction. Each cell was assigned a pseudotime value based on its position along the trajectory tree. 74 The plot_genes_in_pseudotim function in generated smoothed gene marker expression changes along pseudotime. Cells in the trajectory were plotted as 77 In brief, cells were first grouped at similar positions in pseudotime by k-means clustering along the pseudotime axis (k=10). These clusters were subdivided into groups containing at least 50 but not more than 100 cells. We then aggregated the transcriptome profiles of cells within each group. Gene expression along pseudotime was calculated as 77 was calculated with the same approach as in . Briefly, genes that passed the significance test (5% FDR) across different treatment conditions were selected and natural splines were used to fit gene expression along pseudotime with mean_number_genes as a covariate. The lowest expression was subtracted from the gene expression for each gene and divided by the highest expression. Genes showing maximum expression within the first 20% of pseudotime were labeled as activated genes. Genes showing maximum expression in the last 20% of pseudotime were labeled as repressed genes. Other genes were labeled as transient genes. EnrichR package 78 Using this method, enriched reactome terms (Reactome_2016) and transcription factors (ChEA_2016) were identified.

[0342] Trajectory inference with Monocle 3 The Monocle 3 workflow consists of three core steps to organize cells into potentially discontinuous trajectories, followed by optional statistical tests to find genes whose expression changes across those trajectories. Monocle 3 also includes visualization tools to help explore the trajectories in three dimensions.

[0343] Dimensionality Reduction by Uniform Manifold Approximation and Projection (UMAP) Monocle 3 first projects the data into a low-dimensional space, which facilitates learning a primal graph that describes how cells transition between transcriptome states. Monocle 3 does this with UMAP, a recently proposed algorithm based on Riemannian geometry and algebraic topology, which aids in dimensionality reduction and data visualization. 79 Its visualization quality is competitive with the popular t-SNE (t-Stochastic Neighbor Embedding) method, which is widely used in single-cell transcriptomics. However, where t-SNE mainly aims to place highly similar cells in the same region of a low-dimensional space, UMAP also preserves long-range distance relationships. Also, the UMAP algorithm itself is more efficient (UMAP's algorithmic complexity is 10 times that of t-SNE).

number

number

[0344] The computational efficiency of UMAP dramatically accelerated the analysis of mouse embryo data. It was found that UMAP finished the analysis of a 2 million cell dataset in 3 hours, whereas t-SNE took longer than 10 hours on 10 cores (multi-core bh-t-SNE was used). Several implementation details lead to the effectiveness of UMAP. Both UMAP and t-SNE algorithms involve two main stages: first, an intermediate structure from the high dimensional space (usually the upper PCA reduced space) is constructed, and then a low dimensional embedding is found to represent that intermediate structure. In the second stage, the data is embedded into the low dimensional space using a stochastic grid descent method, where the loss function is different in both methods. While t-SNE requires a loss function for global regularization, UMAP uses a different objective function that avoids the need for that. This stage allows UMAP to scale essentially linearly with the number of data samples. In Monocle 3, we interact with Leland McInnes and John Healy's UMAP python implementation (available on the world-wide web atgithub.com / lmcinnes / umap) through the reticulate package (available on the world-wide web atcran.r-project.org / web / packages / reticulate / index.html).

[0345] Division of cells into discontinuous trajectories Recently, Wolf and colleagues proposed the idea of ​​organizing single-cell transcriptome data into "abstract partitioning graphs" (AGAs) that associate clusters of cells that may be developmentally related to each other. Briefly, their algorithm builds a k-nearest neighbor graph of cells and then analyzes them using traditional methods to analyze CyTOF or single-cell RNA-seq data. 80 Similarly, we identify "communities" of cells via the Louvain algorithm. Then, AGA builds a graph whose vertices are Louvain communities. If the cells of each community are neighbors of the kNN graph, then we can model them as a simple binomial model. 81Two vertices are linked by an edge in the AGA graph more frequently than would be expected. A similar method was also recently developed and applied to the analysis of zebrafish and Xenopus cell atlas datasets. 82、83 .

[0346] Monocle 3 draws from these ideas by first constructing a kNN graph for cells in the UMAP space, then grouping them into Louvain communities and testing each pair of communities for a significant number of links between each cell. Communities with more links than expected under the null hypothesis of pseudo-linkage (FDR < 10%) remain connected in the AGA graph, while links that fail this test are disconnected. The resulting AGA graph has one or more components, each of which is carried forward to the next stage (the L1-graph) as a separate group of cells that will be organized into trajectories. The AGA algorithm essentially stops at this stage and presents the AGA graph as a kind of coarse-grained trajectory for each community, reflecting the different states that a cell can adopt as it develops. In contrast, as we will explain in the next section, Monocle 3 uses the AGA graph to restrict the space of primal graphs that can form the final trajectory. That is, Monocle 3 uses the coarse-grained AGA graph to learn the coarse-grained trajectories.

[0347] Monocle 3's implementation of the above procedure scales to millions of cells. Briefly, we use the clustering_louvain function from the igraph package to perform community detection. Wolf et al.'s core AGA computation is then computed via a series of sparse matrix operations. Let X be a (sparse) matrix representing the community membership of cells. Each column of X represents a Louvain community, and each row of X corresponds to a particular cell. Cells

number

number

number

number

number

number

number

number

number

number

[0348] Learning the Principal Graph Monocle 3 learns a primal graph that exists in the same low-dimensional space as the data, and represents the possible paths that cells can take as they develop. Monocle 3 uses an L1 graph algorithm 84 We learn the primal graph using an enhanced implementation of L1-graph. Mao et al. reported two versions of the L1-graph approach. 84First ("Algorithm 1"), we perform the optimization over all individual data points in the dataset. Previously, we have shown that L1 graphs can be applied to single-cell RNA-seq data, but tend to learn very noisy graphs that are not robust to downsampling, and this approach does not scale effectively to datasets larger than a few hundred cells. 85 did not consider "Algorithm 2," which uses a K-means clustering algorithm to first select a set of "landmark" data points. The algorithm then optimizes over this very small sample of data. Monocle 3 uses this approach, which is robust when applied to cells in the UMAP space and can be scaled to millions of cells with some important modifications.

[0349] Our implementation of the L1-graph has several important features that support the analysis of large datasets and the robust recovery of the primal graph. First, we learn an L1 graph in the (by default 3-dimensional) UMAP space. We use K-medioid clustering to select landmark cells to accelerate the optimization. The number of landmark cells selected impacts the running time of the algorithm and the quality of the solution: too many landmarks leads to an infeasible linear programming problem. Therefore, by setting K to three times the number of Louvain communities found among cells, we determine the number of landmarks in a data-dependent manner, which indeed leads to a fast and stable solution.

[0350] The second major optimization of the L1 graph is to impose constraints on the “feasible” space of all possible graphs W considered in the optimization. Mao et al. considered all possible edges between landmark data points. However, even with only a few thousand landmark cells, the linear programming problem can quickly become infeasible because the number of variables is a function of the number of edges in the graph. In Monocle3, we only allow edges into the feasible space that are in a minimum spanning tree (MST) built on the landmark points or in a kNN graph (by default, k=3) built on vertices with odd degrees in the MST. Finally, we exclude edges that link cells in different connected components of the AGA graph constructed as described in the previous section.

[0351] Identifying genes with locus-dependent expression To identify genes whose expression changes over developmental trajectories, we borrow a statistical test commonly used in the analysis of spatial data: Moran's I statistic, which is a measure of multidirectional and multidimensional spatial autocorrelation. This statistic is particularly suited to the analysis of large single-cell RNA-seq datasets, as it encodes spatial relationships between data points via a nearest-neighbor graph.

[0352] Moran's I test 86 is defined as

number

number

number

number

number

number

number

number

number

number

number

number

number

[0353] To identify the nearest neighbors used to construct the weight matrix W, we first build a k (default is 25) nearest neighbor graph (kNN) for every cell in the UMAP space. We also project each cell to its nearest node in the primal graph. We then remove all edges from the kNN graph that connect cells that are projected to the primal graph node and do not share edges.

[0354] In Monocle 3, we implemented the manifoldTest function to identify variant-associated genes that rely on a modified version of a routine in the spdep package to perform Moran's I tests.

[0355] REFERENCES 1. Fogarty, NMEet al.Genome editing reveals a role for OCT4 in human embryogenesis. Nature 550, 67-73 (2017). 2. Kojima, Y., Tam, OH & Tam, PPL Timing of developmental events in the early mouse embryo. Semin. Cell Dev. Biol.34, 65-75 (2014). 3. Tam, PPL & Loebel, DAF Gene function in mouse embryogenesis:get set for gastrulation. Nat.Rev. Genet.8, 368-381 (2007). 4. Rivera-Perez, JA & Hadjantonakis, A.-K. The Dynamics of Morphogenesis in the Early Mouse Embryo. Cold Spring Harb. Perspect. Biol.7, a015867 (2014). 5. Dickinson, MEet al.High-throughput discovery of novel developmental phenotypes. Nature 537, 508-514 (2016). 6. Meehan, T. F. et al.Disease model discovery from 3,328 gene knockouts by The International Mouse Phenotyping Consortium. Nat.Genet.49, 1231-1238 (2017). 7. Shyer, A.E., Huycke, T. R., Lee, C., Mahadevan, L. & Tabin, C.J.Bending gradients:how the intestinal stem cell gets its home. Cell 161, 569-580 (2015). 8. Uygur, A.et al.Scaling Pattern to Variations in Size during Development of the Vertebrate Neural Tube. Dev. Cell 37, 127-135 (2016). 9. Gorkin, D.et al.Systematic mapping of chromatin state landscapes during mouse development. (2017). doi:10.1101 / 166652 10. Mayer, C.et al.Developmental diversification of cortical inhibitory interneurons. Nature 555, 457-462 (2018). 11. Lescroart, F. et al.Defining the earliest step of cardiovascular lineage segregation by single-cell RNA-seq. Science (2018). doi:10.1126 / science.aao4174 12. Han, X. et al.Mapping the Mouse Cell Atlas by Microwell-Seq. Cell 172, 1091-1107.e17 (2018). 13. The Tabula Muris Consortium, Quake, S.R., Wyss-Coray, T. & Darmanis, S.Transcriptomic characterization of 20 organs and tissues from mouse at single cell resolution creates a Tabula Muris. (2017). doi:10.1101 / 237446 14. Amini, S.et al.Haplotype-resolved whole-genome sequencing by contiguity-preserving transposition and combinatorial indexing. Nat.Genet.46, 1343-1349 (2014). 15. Adey, A.et al.In vitro, long-range sequence information for de novo genome assembly via transposase contiguity. Genome Res.24, 2041-2049 (2014). 16. Cusanovich, D.A.et al.Multiplex single cell profiling of chromatin accessibility by combinatorial cellular indexing. Science 348, 910-914 (2015). 17. Vitak, S.A.et al.Sequencing thousands of single-cell genomes with combinatorial indexing. Nat.Methods 14, 302-308 (2017). 18. Ramani, V.et al.Massively multiplex single-cell Hi-C.Nat.Methods 14, 263-266 (2017). 19. Cao, J.et al.Comprehensive single-cell transcriptional profiling of a multicellular organism. Science 357, 661-667 (2017). 20. Mulqueen, R.M.et al.Scalable and efficient single-cell DNA methylation sequencing by combinatorial indexing. (2017). Doi:10.1101 / 157230 21. Rosenberg, A.B. et al.Single-cell profiling of the developing mouse brain and spinal cord with split-pool barcoding. Science (2018). doi:10.1126 / science.aam8999 22. Zheng, G.X. Y. et al.Massively parallel digital transcriptional profiling of single cells. Nat.Commun. 8, 14049 (2017). 23. Qiu, X. et al.Reversed graph embedding resolves complex single-cell developmental trajectories. (2017). doi:10.1101 / 110668 24. Fernandez, T. et al.Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. Am.J.Hum. Genet.74, 1286-1293 (2004). 25. Olson, J.M.et al.NeuroD2 is necessary for development and survival of central nervous system neurons. Dev. Biol.234, 174-187 (2001). 26. Uittenbogaard, M., Baxter, K.K. & Chiaramello, A.NeuroD6 Genomic Signature Bridging Neuronal Differentiation to Survival via the Molecular Chaperone Network. J.Neurosci. Res.88, 33 (2010). 27. Yang, A.et al.p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714-718 (1999). 28. McQualter, J.L., Yuen, K., Williams, B. & Bertoncello, I. Evidence of an epithelial stem / progenitor cell hierarchy in the adult mouse lung. Proc.Natl.Acad.Sci.U. S.A.107, 1414-1419 (2010). 29. Cichorek, M., Wachulska, M., Stasiewicz, A. & Tyminska, A.Skin melanocytes:biology and development. Advances in Dermatology and Allergology 1, 30-41 (2013). 30. Tomihari, M., Hwang, S.-H., Chung, J.-S., Cruz, P.D., Jr. & Ariizumi, K.Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte / keratinocyte adhesion in a RGD-dependent fashion. Exp. Dermatol. 18, 586-595 (2009). 31. Varjosalo, M. & Taipale, J.Hedgehog:functions and mechanisms. Genes Dev. 22, 2454-2472 (2008). 32. Straehle, U., Lam, C.S., Ertzer, R. & Rastegar, S.Vertebrate floor-plate specification:variations on common themes. Trends Genet.20, 155-162 (2004). 33. Holmes, G.P.et al.Distinct but overlapping expression patterns of two vertebrate slit homologs implies functional roles in CNS development and organogenesis. Mech. Dev. 79, 57-72 (1998). 34. Akle, V.et al.F-spondin / spon1b expression patterns in developing and adult zebrafish. PLoS One 7, e37593 (2012). 35. Hartman, B. H., Durruthy-Durruthy, R., Laske, R.D., Losorelli, S. & Heller, S.Identification and characterization of mouse otic sensory lineage genes. Front. Cell. Neurosci. 9, 79 (2015). 36. Petit, F., Sears, K.E. & Ahituv, N. Limb development:a paradigm of gene regulation. Nat.Rev. Genet.18, 245-258 (2017). 37. Guo, Q., Loomis, C. & Joyner, A.L. Fate map of mouse ventral limb ectoderm and the apical ectodermal ridge. Dev. Biol.264, 166-178 (2003). 38. Lewandoski M, E.al. Fgf8 signalling from the AER is essential for normal limb development. - PubMed - NCBI. Available at:https: / / www.ncbi.nlm.nih.gov / pubmed / 11101846. (Accessed:22nd April 2018) 39. Aoki M, E.al. R-spondin2 expression in the apical ectodermal ridge is essential for outgrowth and patterning in mouse limb development. - PubMed - NCBI. Available at:https: / / www.ncbi.nlm.nih.gov / pubmed / 18067586. (Accessed:22nd April 2018) 40. Gerdes, J., Schwab, U., Lemke, H. & Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int.J.Cancer 31, 13-20 (1983). 41. Bergman, D., Halje, M., Nordin, M. & Engstroem, W.Insulin-like growth factor 2 in development and disease:a mini-review. Gerontology 59, 240-249 (2013). 42. Trapnell, C.et al.The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat.Biotechnol.32, 381-386 (2014). 43. McInnes, L. & Healy, J.UMAP:Uniform Manifold Approximation and Projection for Dimension Reduction. (2018). 44. Alexander Wolf, F. et al.Graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. bioRxiv 208819 (2017). doi:10.1101 / 208819 45. Qiu, X. et al.Reversed graph embedding resolves complex single-cell trajectories. Nat.Methods 14, 979-982 (2017). 46. Singh, M.K.et al.The T-box transcription factor Tbx15 is required for skeletal development. Mech. Dev. 122, 131-144 (2005). 47. Paine-Saunders, S., Viviano, B. L., Zupicich, J., Skarnes, W.C. & Saunders, S.glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev. Biol.225, 179-187 (2000). 48. Hara, K. & Ide, H. Msx1 expressing mesoderm is important for the apical ectodermal ridge (AER)-signal transfer in chick limb development. Dev. Growth Differ. 39, 705-714 (1997). 49. Lupianez, D.G.et al.Disruptions of Topological Chromatin Domains Cause Pathogenic Rewiring of Gene-Enhancer Interactions. Cell 161, 1012-1025 (2015). 50. Davis, R.J.et al.Dach1 mutant mice bear no gross abnormalities in eye, limb, and brain development and exhibit postnatal lethality. Mol.Cell. Biol.21, 1484-1490 (2001). 51. Akiyama, H., Chaboissier, M.-C., Martin, J.F., Schedl, A. & de Crombrugghe, B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 16, 2813-2828 (2002). 52. Deng, Y. et al.Yap1 Regulates Multiple Steps of Chondrocyte Differentiation during Skeletal Development and Bone Repair. Cell Rep. 14, 2224-2237 (2016). 53. Joshi, S.et al.TEAD transcription factors are required for normal primary myoblast differentiation in vitro and muscle regeneration in vivo. PLoS Genet.13, e1006600 (2017). 54. Knapp, D.et al.Comparative transcriptional profiling of the axolotl limb identifies a tripartite regeneration-specific gene program. PLoS One 8, e61352 (2013). 55. Zeller, R., Lopez-Rios, J. & Zuniga, A.Vertebrate limb bud development:moving towards integrative analysis of organogenesis. Nat.Rev. Genet.10, 845-858 (2009). 56. Nishimoto, S., Minguillon, C., Wood, S. & Logan, M.P.O. A combination of activation and repression by a colinear Hox code controls forelimb-restricted expression of Tbx5 and reveals Hox protein specificity. PLoS Genet.10, e1004245 (2014). 57. Vargesson, N., Luria, V., Messina, I., Erskine, L. & Laufer, E.Expression patterns of Slit and Robo family members during vertebrate limb development. Mech. Dev. 106, 175-180 (2001). 58. Chimal-Monroy, J.et al.Analysis of the molecular cascade responsible for mesodermal limb chondrogenesis:Sox genes and BMP signaling. Dev. Biol.257, 292-301 (2003). 59. Braun, T. & Gautel, M.Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat.Rev. Mol.Cell Biol.12, 349-361 (2011). 60. Tajbakhsh, S., Rocancourt, D., Cossu, G. & Buckingham, M.Redefining the genetic hierarchies controlling skeletal myogenesis:Pax-3 and Myf-5 act upstream of MyoD.Cell 89, 127-138 (1997). 61. Harel, I. et al.Distinct origins and genetic programs of head muscle satellite cells. Dev. Cell 16, 822-832 (2009). 62. Sambasivan, R.et al.Distinct regulatory cascades govern extraocular and pharyngeal arch muscle progenitor cell fates. Dev. Cell 16, 810-821 (2009). 63. Heimberg, G., Bhatnagar, R., El-Samad, H. & Thomson, M.Low Dimensionality in Gene Expression Data Enables the Accurate Extraction of Transcriptional Programs from Shallow Sequencing. Cell Syst 2, 239-250 (2016). 64. Cusanovich, D.A.et al.The cis-regulatory dynamics of embryonic development at single cell resolution. (2017). doi:10.1101 / 166066 65. McKenna, A.et al.Whole-organism lineage tracing by combinatorial and cumulative genome editing. Science 353, aaf7907 (2016). 66. Osterwalder, M.et al.Enhancer redundancy provides phenotypic robustness in mammalian development. Nature 554, 239-243 (2018). 67. Dickel, D.E.et al.Ultraconserved Enhancers Are Required for Normal Development. Cell 172, 491-499.e15 (2018). 68. Li, D.et al.Formation of proximal and anterior limb skeleton requires early function of Irx3 and Irx5 and is negatively regulated by Shh signaling. Dev. Cell 29, 233-240 (2014). 69. Kraft, K.et al.Deletions, Inversions, Duplications:Engineering of Structural Variants using CRISPR / Cas in Mice. Cell Rep. (2015). doi:10.1016 / j.celrep.2015.01.016 70. Buenrostro, J.D., Giresi, P.G., Zaba, L. C., Chang, H. Y. & Greenleaf, W.J.Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat.Methods 10, 1213-1218 (2013). 71. Renaud, G., Stenzel, U., Maricic, T., Wiebe, V. & Kelso, J.deML:robust demultiplexing of Illumina sequences using a likelihood-based approach. Bioinformatics 31, 770-772 (2015). 72. Dobin, A.et al.STAR:ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013). 73. Anders, S., Pyl, P.T. & Huber, W.HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics btu638 (2014). 74. Qiu, X. et al.Reversed graph embedding resolves complex single-cell developmental trajectories. (2017). doi:10.1101 / 110668 75. Wolf, F. A., Angerer, P. & Theis, F. J.SCANPY:large-scale single-cell gene expression data analysis. Genome Biol.19, 15 (2018). 76. Cao, J.et al.Comprehensive single-cell transcriptional profiling of a multicellular organism. Science 357, 661-667 (2017). 77. Pliner, H. et al.Chromatin accessibility dynamics of myogenesis at single cell resolution. (2017). doi:10.1101 / 155473 78. Kuleshov, M.V.et al.Enrichr:a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res.44, W90-7 (2016). 79. McInnes, L. & Healy, J.UMAP:Uniform Manifold Approximation and Projection for Dimension Reduction. (2018). 80. Levine, J.H. et al.Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell 162, 184-197 (2015). 81. Wolf, F. A.et al.Graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. (2017). doi:10.1101 / 208819 82. Wagner, DEet al.Single-cell mapping of gene expression landscapes and lineage in the zebrafish embryo. Science eaar4362 (2018). 83. Briggs, JAet al.The dynamics of gene expression in vertebrate embryogenesis at single-cell resolution. Science eaar5780 (2018). 84. Mao, Q., Wang, L., Tsang, I. & Sun, Y. Principal Graph and Structure Learning Based on Reversed Graph Embedding. IEEE Trans. Pattern Anal. Mach. Intel. (2016). doi:10.1109 / TPAMI.2016.2635657 85. Qiu, X. et al.Reversed graph embedding resolves complex single-cell trajectories. Nat.Methods 14, 979-982 (2017). 86. Moran, PAPNotes on continuous stochastic phenomena. Biometrika 37, 17-23 (1950).

[0356] Example 2 A new method for extracting and fixing tissue nuclei (sc-RNA-seq) Reagents: BSA (Molecular Biology Grade, NEB, #B9000S); SuperRnase Inhibitor (Thermo, #AM2696); EMS 157-4-100 4% Paraformaldehyde (Formaldehyde) Aqueous Solution, EM Grade, 100 mL (Amazon).

[0357] Buffer. Nuclear buffer (stored at 4°C): 10mM Tris-HCl, pH7.4, 10mM NaCl, 3mM MgCl 2 . 10% IGEPAL CA-630 (store at 4°C). Nuclei Wash Buffer (make fresh each time): 980ul Nuclei Buffer with 10ul BSA and 10ul SuperRnaseIn, mix well and store on ice. Nuclei Lysis Buffer (make fresh each time): Nuclei Wash Buffer with 0.1% IGEPAL CA-630.

[0358] Direct nuclear extraction from tissue The tissue was minced into small pieces with a blade in 1 mL of ice-cold cell lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 0.1% IGEPAL CA-630, 1% SUPERase In, and 1% BSA) and transferred onto the top of a 40 um cell strainer (Falcon).

[0359] The tissue was homogenized with the rubber tip of a syringe plunger (5 ml, BD) in 4 ml of cell lysis buffer.

[0360] The filtered nuclei were then transferred to a new 15 ml tube (Falcon), pelleted by centrifugation at 500×g for 5 min, and washed once with 1 ml of cell lysis buffer.

[0361] nuclear immobilization Nuclei were fixed in 4 ml of ice-cold 4% paraformaldehyde (EMS) for 15 min on ice.

[0362] After fixation, nuclei were washed twice with 1 ml of nuclei wash buffer (cell lysis buffer without IGEPAL) and resuspended in 500 ul of nuclei wash buffer.

[0363] The samples were divided into several portions and flash frozen in liquid nitrogen. The frozen samples can be shipped on dry ice.

[0364] Example 3 Characterization of single-cell state transition dynamics with Sci-Fate The beauty of development lies in the generation of diverse cellular states in a tightly orchestrated temporal order. Despite the proliferation of single-cell genomic techniques, quantitatively determining cellular state transition dynamics remains challenging. Here we introduce sci-fate, a combinatorial indexing-based high-throughput assay for profiling both the whole and newly synthesized transcriptomes in each of thousands of single cells. As a proof of concept, we applied sci-fate to a model system of cortisol response and characterized across more than 6,000 single-cell state transition events, consistent with known cell cycle dynamics upon glucocorticoid receptor activation. From the analysis, we showed that the direction and probability of cellular state transitions are regulated by the landscape of inter-state distances and state instability. This method and computational approach can be readily applied to other biological systems to quantitatively characterize cellular state dynamics and decipher the internal mechanisms of ...

Claims

1. 1. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells to a first plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (b) labeling newly synthesized RNA in the cell or a subset of nuclei obtained from said cell; (c) processing the RNA molecules of each subset of nuclei or cells to generate indexed nuclei or cells; wherein said processing adds an index sequence unique to the first compartment to RNA nucleic acids present in each subset of nuclei or cells to result in indexed DNA nucleic acids present in the indexed nuclei or cells; The processing includes ligation, primer extension, hybridization, or amplification; and (d) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells. A method comprising:

2. The processing comprises: contacting the subset with a reverse transcriptase and a primer that anneals to the RNA nucleic acid, thereby generating a double-stranded DNA nucleic acid comprising said primer and the corresponding DNA nucleotide sequence of the template RNA molecule. The method of claim 1 , comprising:

3. 3. The method of claim 2, wherein the primer comprises a poly-T nucleotide sequence that anneals to an mRNA poly(A) tail.

4. 4. The method of claim 3, wherein said processing further comprises contacting the subset with a second primer, said second primer comprising a sequence that anneals to a predetermined DNA nucleic acid.

5. The method of claim 4, wherein the second primer comprises an index unique to the section.

6. The method of claim 2 , wherein the primer comprises a sequence that anneals to a predetermined RNA nucleic acid.

7. 7. The method of claim 6, wherein the method comprises primers in different sections that anneal to different nucleotides of the same given RNA nucleic acid.

8. The method of claim 2 , wherein the primer comprises a template switch primer.

9. 2. The method of claim 1, wherein the processing of adding an index sequence unique to the first section comprises a two-step process of obtaining a DNA nucleic acid by adding a nucleotide sequence containing a universal sequence to the RNA nucleic acid, and then adding an index sequence unique to the first section to the DNA nucleic acid.

10. 1. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells to a first plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (b) contacting each subset with a reverse transcriptase and a primer that anneals to a given RNA nucleic acid, thereby generating a double-stranded DNA nucleic acid comprising said primer and the corresponding DNA nucleotide sequence of the template RNA nucleic acid; (c) processing the DNA molecules of each subset of nuclei or cells to generate indexed nuclei or cells; wherein the processing comprises adding an index sequence unique to the first compartment to DNA nucleic acids present in each subset of nuclei or cells to obtain indexed nucleic acids present in the indexed nuclei or cells, the processing comprising ligation, primer extension, hybridization, or amplification; and (d) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells. A method comprising:

11. The method of claim 10, wherein the primer comprises an index sequence that is unique to the first section.

12. The method of claim 10, further comprising labeling newly synthesized RNA in said subset of cells or nuclei obtained from said cells prior to said contacting.

13. 11. The method of claim 10, wherein the processing of adding an index sequence unique to the first section comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to the nucleic acid, and then adding an index sequence unique to the first section to the nucleic acid.

14. The method of claim 6 or 10, wherein the selected RNA nucleic acid is mRNA.

15. The method of claim 1 or 12, wherein the pre-existing RNA nucleic acid and the newly synthesized RNA nucleic acid are labeled with the same index in the same compartment.

16. 13. The method of claim 1 or 12, wherein the labeling comprises incubating a plurality of nuclei or cells in a composition comprising a nucleotide label, wherein the nucleotide label is incorporated into the newly synthesized RNA.

17. 17. The method of claim 16, wherein the nucleotide label comprises a nucleotide analog, a hapten-labeled nucleotide, a mutagenic nucleotide, or a nucleotide that can be modified by chemical reaction.

18. 17. The method of claim 16, wherein two or more nucleotide labels are incorporated into the newly synthesized RNA.

19. 20. The method of claim 18, wherein the ratio of one or more of the nucleotide labels is different for different compartments or time points.

20. 13. The method of claim 1 or 12, further comprising exposing the nuclei or subset of cells to a predetermined condition prior to said labeling.

21. 21. The method of claim 20, wherein the predetermined condition comprises exposure to an agent.

22. 22. The method of claim 21, wherein the agent comprises a protein, a non-ribosomal protein, a polyketide, an organic molecule, an inorganic molecule, an RNA or RNAi molecule, a carbohydrate, a glycoprotein, a nucleic acid, or a combination thereof.

23. 22. The method of claim 21, wherein the agent comprises a therapeutic agent.

24. The method of claim 20, wherein the predetermined conditions in two or more compartments are different.

25. 21. The method of claim 20, wherein said exposing and said labeling occur simultaneously or said exposing occurs before said labeling.

26. distributing a subset of the pooled indexed nuclei or cells into a second plurality of compartments and adding a second index sequence to the indexed nucleic acid present in the subset of nuclei or cells to generate dual-indexed nuclei or cells comprising dual-indexed nucleic acid fragments, wherein said adding comprises ligation, primer extension, hybridization, amplification, or transposition; and combining said dual-indexed nuclei or cells to produce pooled dual-indexed nuclei or cells.

11. The method of claim 1 or 10, further comprising:

27. distributing a subset of the pooled dual-indexed nuclei or cells into a third plurality of compartments and adding a third index sequence to the indexed nucleic acids present in the subset of nuclei or cells to generate triple-indexed nuclei or cells comprising triple-indexed nucleic acid fragments, wherein said adding comprises ligation, hybridization, primer extension, amplification, or transposition; combining said triple-indexed nuclei or cells to produce pooled triple-indexed nuclei or cells.

27. The method of claim 26, further comprising:

28. 28. The method of claim 26 or 27, wherein dispensing comprises dilution.

29. 28. The method of claim 26 or 27, wherein distributing comprises sorting.

30. 28. The method of claim 26 or 27, wherein said appending comprises contacting the subset with a hairpin ligation duplex under conditions suitable for ligation of the hairpin ligation duplex to an end of a nucleic acid fragment comprising one or two index sequences.

31. 28. The method of claim 26 or 27, wherein the attaching comprises contacting a nucleic acid fragment comprising one or more index sequences with a transposome complex, the transposome complex in the compartment comprising a transposase and a universal sequence, and the contacting further comprises conditions suitable for fragmentation of the nucleic acid fragment and incorporation of the universal sequence into the nucleic acid fragment.

32. 11. The method of claim 1 or 10, wherein said adding comprises ligating an index sequence unique to said first compartment and further comprises adding a second index sequence to generate a dual-indexed nucleus or cell comprising a dual-indexed nucleic acid fragment, wherein said adding comprises a transposition.

33. 27. The method of claim 26, wherein said adding comprises ligating an index sequence unique to said second compartment and further comprises adding a third index sequence to create a triple-indexed nucleus or cell comprising a triple-indexed nucleic acid fragment, wherein said adding comprises a transposition.

34. 28. The method of claim 1, 26 or 27, wherein the compartment comprises a well or a droplet.

35. 28. The method of claim 1, 26 or 27, wherein the compartments of the first plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

36. 27. The method of claim 26, wherein the compartments of the second plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

37. 28. The method of claim 27, wherein the compartments of the third plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

38. 11. The method of claim 1 or 10, further comprising generating a sequencing library from a plurality of nuclei or cells by obtaining indexed nucleic acids from pooled indexed nuclei or cells.

39. 27. The method of claim 26, further comprising generating a sequencing library from said plurality of nuclei or cells by obtaining said dual-indexed nucleic acids from said pooled dual-indexed nuclei or cells.

40. 28. The method of claim 27, further comprising generating a sequencing library from said plurality of nuclei or cells by obtaining said triple-indexed nucleic acids from said pooled triple-indexed nuclei or cells.

41. providing a surface comprising a plurality of amplification sites; provided that the amplification site comprises at least two populations of linked single-stranded capture oligonucleotides having free 3' ends; and contacting the surface containing said amplification sites with nucleic acid fragments containing one, two or three index sequences under conditions suitable to produce a plurality of amplification sites comprising a clonal population of amplicons from individual fragments each containing a plurality of indexes; 34. The method of any one of claims 1 to 33, further comprising:

42. 28. The method of claim 26 or 27, wherein adding an index sequence unique to the partition comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to the nucleic acid and then adding an index sequence unique to the partition to the nucleic acid.

43. 1. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells to a first plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (b) contacting each subset with a reverse transcriptase and a primer to generate a double-stranded DNA nucleic acid comprising the primer and the corresponding DNA nucleotide sequence of the template RNA nucleic acid; (c) processing the DNA molecules in each subset of nuclei or cells to generate indexed nuclei or cells; wherein said processing comprises adding an index sequence unique to the first compartment to DNA nucleic acids present in each subset of nuclei or cells to obtain indexed nucleic acids present in the indexed nuclei or cells; The processing includes ligation, primer extension, hybridization, amplification, or translocation; and (d) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells; (e) distributing the pooled indexed nuclei or cells into a second plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (f) processing the DNA molecules in each subset of nuclei or cells to generate dual-indexed nuclei or cells; wherein said processing comprises adding an index sequence unique to the second compartment to DNA nucleic acids present in each subset of nuclei or cells to obtain dual-indexed nucleic acids present in the indexed nuclei or cells; The processing includes ligation, primer extension, hybridization, amplification, or translocation; and (g) combining the dual-indexed nuclei or cells to produce pooled dual-indexed nuclei or cells; (h) distributing the pooled dual-indexed nuclei or cells into a third plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (i) processing DNA molecules from each subset of nuclei or cells to generate triple-indexed nuclei or cells; wherein said processing comprises adding an index sequence unique to a third compartment to DNA nucleic acids present in each subset of nuclei or cells, thereby generating triple-indexed nucleic acids present in the indexed nuclei or cells; The processing includes ligation, primer extension, hybridization, amplification, or translocation; and (j) combining the triple-indexed nuclei or cells to produce pooled triple-indexed nuclei or cells. A method comprising:

44. 1. A method for preparing a sequencing library comprising nucleic acids from a plurality of single nuclei or single cells, comprising: (a) providing a plurality of nuclei or cells; (b) contacting the plurality of nuclei or cells with a reverse transcriptase and a primer to generate a double-stranded DNA nucleic acid comprising the primer and a corresponding DNA nucleotide sequence of a template RNA nucleic acid; (c) distributing the nuclei or cells into a first plurality of compartments; provided that each compartment contains a subset of nuclei or cells; (d) processing the DNA molecules in each subset of nuclei or cells to generate indexed nuclei or cells; wherein said processing comprises adding an index sequence unique to the first compartment to DNA nucleic acids present in each subset of nuclei or cells, thereby generating indexed nucleic acids present in indexed nuclei or cells; The processing includes ligation, primer extension, hybridization, amplification, or translocation; and (e) combining the indexed nuclei or cells to produce pooled indexed nuclei or cells; (f) distributing the pooled indexed nuclei or cells into a second plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (g) processing the DNA molecules in each subset of nuclei or cells to generate dual-indexed nuclei or cells; wherein said processing adds an index sequence unique to the second compartment to DNA nucleic acids present in each subset of nuclei or cells to provide dual-indexed nucleic acids present in the indexed nuclei or cells; The processing comprises ligation, primer extension, hybridization, amplification, or translocation; (h) combining the dual-indexed nuclei or cells to produce pooled dual-indexed nuclei or cells; (i) distributing the pooled dual-indexed nuclei or cells into a third plurality of compartments; wherein each compartment comprises a subset of nuclei or cells; (j) processing the DNA molecules of each subset of nuclei or cells to generate triple-indexed nuclei or cells; wherein said processing comprises adding an index sequence unique to a third compartment to DNA nucleic acids present in a subset of nuclei or cells to obtain triple-indexed nucleic acids present in the indexed nuclei or cells; The processing includes ligation, primer extension, hybridization, amplification, or translocation; and (k) combining the triple-indexed nuclei or cells to produce pooled triple-indexed nuclei or cells. A method comprising:

45. 45. The method of claim 43 or 44, wherein the primer anneals to an RNA nucleic acid to generate a double-stranded DNA nucleic acid comprising the primer and the corresponding DNA nucleotide sequence of the template RNA molecule.

46. 46. ​​The method of claim 45, wherein the primer comprises a poly-T nucleotide sequence that anneals to an mRNA poly(A) tail.

47. 47. The method of claim 46, wherein said contacting further comprises contacting the subset with a second primer, said second primer comprising a sequence that anneals to a predetermined DNA nucleic acid.

48. 48. The method of claim 47, wherein the second primer comprises an index unique to the section.

49. 46. ​​The method of claim 45, wherein the primer comprises a sequence that anneals to a predetermined RNA nucleic acid.

50. 50. The method of claim 49, wherein the selected RNA nucleic acid is mRNA.

51. 45. The method of claim 43 or 44, wherein the primer comprises a template switch primer.

52. 45. The method of claim 43 or 44, wherein the processing of adding one or more of the index sequences unique to the first partition, the second partition, or the third partition comprises a two-step process of adding a nucleotide sequence comprising a universal sequence to the nucleic acid, and then adding an index sequence unique to the first partition to the DNA nucleic acid.

53. 45. The method of claim 43 or 44, wherein the primer comprises an index sequence that is unique to the first section.

54. 45. The method of claim 43 or 44, further comprising labeling newly synthesized RNA in the cells or a subset of nuclei obtained from said cells prior to said contacting.

55. 55. The method of claim 54, wherein the existing RNA nucleic acid and the newly synthesized RNA nucleic acid are labeled at the same index in the same compartment.

56. 55. The method of claim 54, wherein said labeling comprises incubating a plurality of nuclei or cells in a composition comprising a nucleotide label, wherein said nucleotide label is incorporated into newly synthesized RNA.

57. 55. The method of claim 54, wherein the nucleotide label comprises a nucleotide analog, a hapten-labeled nucleotide, a mutagenic nucleotide, or a nucleotide that can be modified by chemical reaction.

58. 55. The method of claim 54, wherein two or more nucleotide labels are incorporated into the newly synthesized RNA.

59. 59. The method of Claim 58, wherein the ratio of one or more of the nucleotide labels is different for different compartments or time points.

60. 55. The method of claim 54, further comprising exposing the nuclei or subset of cells of said compartment to a predetermined condition prior to said labeling.

61. 61. The method of claim 60, wherein the predetermined condition comprises exposure to an agent.

62. 62. The method of claim 61, wherein the agent comprises a protein, a non-ribosomal protein, a polyketide, an organic molecule, an inorganic molecule, an RNA or RNAi molecule, a carbohydrate, a glycoprotein, a nucleic acid, or a combination thereof.

63. 62. The method of claim 61 , wherein the agent comprises a therapeutic agent.

64. 61. The method of claim 60, wherein the predetermined conditions in two or more compartments are different.

65. 61. The method of claim 60, wherein said exposing and said labeling occur simultaneously or said exposing occurs prior to said labeling.

66. 45. The method of claim 43 or 44, wherein one or more dispensings comprise dilution.

67. 45. The method of claim 43 or 44, wherein one or more of the dispensings comprises sorting.

68. 45. The method of claim 43 or 44, wherein adding one or more of the unique index sequences to the first section, the second section or the third section comprises contacting a subset with a hairpin ligation duplex under conditions suitable for ligation of the hairpin ligation duplex to the ends of the nucleic acid fragment.

69. 45. The method of claim 43 or 44, wherein adding one or more of the index sequences unique to the first compartment, the second compartment or the third compartment comprises contacting the nucleic acid fragment with a transposome complex, wherein the transposome complex in the compartment comprises a transposase and a universal sequence, and wherein the contacting further comprises conditions suitable for fragmentation of the nucleic acid fragment and incorporation of the nucleotide sequence into the nucleic acid fragment.

70. 45. The method of claim 43 or 44, wherein adding a unique index to the first or second section comprises ligation, and adding a unique index sequence to a subsequent section comprises transposition.

71. 45. The method of claim 43 or 44, wherein the compartment comprises a well or a droplet.

72. 45. The method of claim 43 or 44, wherein the compartments of the first plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

73. 45. The method of claim 43 or 44, wherein the compartments of the second plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

74. 45. The method of claim 43 or 44, wherein the compartments of the third plurality of compartments comprise between 50 and 100,000,000 nuclei or cells.

75. 45. The method of claim 43 or 44, further comprising generating a sequencing library from said plurality of nuclei or cells by obtaining triple-indexed nucleic acids from said pooled triple-indexed nuclei or cells.

76. providing a surface comprising a plurality of amplification sites; wherein the amplification site comprises at least two populations of bound single-stranded capture oligonucleotides having free 3' ends; and contacting said surface containing the amplification sites with triple-indexed nucleic acid fragments under conditions suitable to generate a plurality of amplification sites each containing a clonal population of amplicons from an individual fragment containing a plurality of indexes; 45. The method of claim 43 or 44, further comprising:

77. 1. A method for preparing a sequencing library comprising nucleic acids from a plurality of single cells, comprising: (a) providing nuclei from multiple cells; (b) distributing a subset of the nuclei into a first plurality of compartments and contacting each subset with a reverse transcriptase and a primer; wherein the primers of each section contain a first index sequence that is different from the first index sequences of the other sections, thereby generating indexed nuclei that contain indexed nucleic acid fragments; (c) combining the indexed nuclei to generate pooled indexed nuclei; (d) distributing a subset of said pooled indexed nuclei into a second plurality of compartments and contacting each subset with a hairpin ligation duplex under conditions suitable for ligation of said hairpin ligation duplex to an end of an indexed nucleic acid fragment comprising a first index sequence, thereby generating dual-indexed nuclei comprising dual-indexed nucleic acid fragments; wherein said hairpin ligation duplex comprises a second indexing sequence that is different from the second indexing sequences of other sections; (e) combining the dual-indexed nuclei to generate pooled dual-indexed nuclei; (f) distributing a subset of said pooled dual-indexed nuclei into a third plurality of compartments and subjecting said dual-indexed nucleic acid fragments to conditions for second strand synthesis; (g) contacting the dual-indexed nucleic acid fragment with a transposome complex; wherein said transposome complex in each compartment comprises a transposase and a universal sequence, and said contacting comprises conditions suitable for fragmentation of the dual-indexed nucleic acid fragment and incorporation of the universal sequence into the dual-indexed nucleic acid fragment to generate a dual-indexed nucleic acid fragment comprising a first and second index at one end and a universal sequence at the other end; (i) incorporating a third index sequence into said dual-indexed nucleic acid fragments of each section to generate triple-indexed fragments; (j) generating a sequencing library comprising transcriptome nucleic acids from a plurality of single cells by combining the triple index fragments. A method comprising:

78. 78. The method of claim 77, wherein the primer comprises a poly-T sequence that anneals to an mRNA poly(A) tail.

79. 78. The method of claim 77, wherein the primers of each section comprise a sequence that anneals to a given mRNA.

80. 80. The method of claim 79, wherein the method comprises primers in different sections that anneal to different nucleotides of the same given mRNA.

81. 1. A method for preparing a transcriptome sequencing library comprising nucleic acids from a plurality of single cells, comprising: (a) providing pooled nuclei from multiple cells; (b) contacting the pooled nuclei with a reverse transcriptase and a primer that comprises an oligo dT sequence that anneals to an mRNA poly(A) tail to generate pooled nuclei that comprise a nucleic acid fragment; (c) distributing a subset of the pooled nuclei into a plurality of compartments and contacting each subset with a hairpin ligation duplex under conditions suitable for ligation of the hairpin ligation duplex to the ends of the nucleic acid fragments to generate indexed nuclei comprising the indexed nucleic acid fragments; wherein the hairpin ligation duplex comprises an index sequence that is different from the index sequences of other sections; (d) combining the indexed nuclei to generate pooled indexed nuclei; (e) distributing a subset of the pooled indexed nuclei into a second plurality of compartments and subjecting the indexed nucleic acid fragments to conditions for second strand synthesis; (f) contacting the indexed nucleic acid fragment with a transposome complex; wherein said transposome complex in each compartment comprises a transposase and a universal sequence, and said contacting comprises conditions suitable for fragmentation of indexed nucleic acid fragments and incorporation of a universal sequence into the indexed nucleic acid fragments to generate indexed nucleic acid fragments comprising said index at one end and said universal sequence at the other end; (i) incorporating a second index sequence into the indexed nucleic acid fragment of each section to generate a dual-index fragment; and (j) generating a sequencing library comprising transcriptome nucleic acids from a plurality of single cells by combining the dual index fragments. A method comprising:

82. 1. A method for isolating nuclei comprising: (a) Rapid freezing of tissue in liquid nitrogen; (b) reducing the size of the tissue to obtain a processed tissue; and (c) extracting nuclei from said processed tissue by incubation in a buffer that promotes cell lysis and preserves nuclear integrity in the absence of one or more exogenous enzymes. A method comprising:

83. 83. The method of claim 82, wherein the reducing comprises mincing the tissue, applying a blunt force to the tissue, or a combination thereof.

84. (d) exposing the extracted nuclei to a cross-linking agent to obtain fixed nuclei; and (e) washing the fixed nuclei; 83. The method of claim 82, further comprising:

85. 60. A kit for use in preparing a sequencing library, comprising a nucleotide label according to claim 16 or 56 and at least one enzyme that mediates ligation, primer extension, or amplification.

86. 13. A kit for use in preparing a sequencing library, comprising a primer according to claim 4, 6 or 10 that anneals to a nucleic acid of interest and at least one enzyme that mediates ligation, primer extension or amplification.

Images